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A B S T R A C T
Background
Bladder pain syndrome (BPS), which includes the condition of interstitial cystitis, is a poorly understood clinical condition for which
patients present with varying symptoms. Management of BPS is challenging for both patients and practitioners. At present, there is no
universally accepted diagnosis and diverse causes have been proposed. This is reflected in wide-ranging treatment options, used alone
or in combination, with limited evidence. A network meta-analysis (NMA) simultaneously comparing multiple treatments may help to
determine the best treatment options for patients with BPS.
Objectives
To conduct a network meta-analysis to assess the eFects of interventions for treating people with symptoms of bladder pain syndrome
(BPS).
Search methods
We searched the Cochrane Incontinence Specialised Register, which contains trials identified from the Cochrane Central Register of
Controlled Trials (CENTRAL, in the Cochrane Library), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov,
the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and handsearched journals and conference
proceedings (searched 11 May 2018) and the reference lists of relevant articles. We conducted a further search on 5 June 2019, which
yielded four small studies that were screened for eligibility but were not incorporated into the review.
Selection criteria
We included randomised controlled trials (RCTs) and quasi-RCTs of interventions for treating adults with BPS. All types of interventions
(including conservative, pharmacological and surgical) were eligible.
Data collection and analysis
We assessed the risk of bias of included studies using Cochrane's 'Risk of bias' tool. Primary outcomes were the number of people cured
or improved, pain, frequency and nocturia. For each outcome, random-eFects NMA models were fitted using WinBUGS 1.4. We monitored
median odds ratios (ORs) for binary outcomes and mean diFerences (MDs) for continuous outcomes with 95% credible intervals (Crls). We
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compared results of the NMA with direct evidence from pairwise meta-analysis of head-to-head trials. We used the CINeMA tool to assess
the certainty of evidence for selected treatment categories.
Main results
We included 81 RCTs involving 4674 people with a median of 38 participants (range 10 to 369) per RCT. Most trials compared treatment
against control; few trials compared two active treatments. There were 65 diFerent active treatments, and some comparisons were
informed by direct evidence from only one trial. To simplify, treatments were grouped into 31 treatment categories by mode of action.
Most studies were judged to have unclear or high risk of bias for most domains, particularly for selection and detection bias. Overall, the
NMA suggested that six (proportion cured/improved), one (pain), one (frequency) and zero (nocturia) treatment categories were eFective
compared with control, but there was great uncertainty around estimates of eFect.
Due to the large number of intervention comparisons in this review, we focus on three interventions: antidepressants, pentosan polysulfate
(PPS) and neuromuscular blockade. We selected these interventions on the basis that they are given 'strong recommendations' in the EAU
Guidelines for management of BPS (EAU Guidelines 2019).
We found very low-certainty evidence suggesting that antidepressants were associated with greater likelihood of cure or improvement
compared with control (OR 5.91, 95% CrI 1.12 to 37.56), but it was uncertain whether they reduced pain (MD -1.27, 95% CrI -3.25 to 0.71;
low-certainty evidence), daytime frequency (MD -2.41, 95% CrI -6.85 to 2.05; very low-certainty evidence) or nocturia (MD 0.01, 95% CrI
-2.53 to 2.50; very low-certainty evidence).
There was no evidence that PPS had improved cure/improvement rates (OR 0.14, 95% CrI 0.40 to 3.35; very low-certainty evidence) or
reduced pain (MD 0.42, 95% CrI -1.04 to 1.91; low-certainty evidence), frequency (MD -0.37, 95% CrI -5.00 to 3.44; very low-certainty
evidence) or nocturia (MD -1.20, 95% CrI -3.62 to 1.28; very low-certainty evidence).
There was evidence that neuromuscular blockade resulted in greater cure or improvement (OR 5.80, 95% CrI 2.08 to 18.30) but no evidence
that it improved pain (MD -0.33, 95% CrI -1.71 to 1.03), frequency (MD -0.91, 95% CrI -3.24, 1.29) or nocturia (MD -0.04, 95% CrI -1.35 to 1.27).
The certainty of this evidence was always very low.
Authors' conclusions
We are uncertain whether some treatments may be eFective in treating patients with BPS because the certainty of evidence was generally
low or very low. Data were available for a relatively large number of trials, but most had small sample sizes and eFects of treatments oLen
could not be estimated with precision. An NMA was successfully conducted, but limited numbers of small trials for each treatment category
hampered our ability to fully exploit the advantages of this analysis. Larger, more focused trials are needed to improve the current evidence
base.
P L A I N   L A N G U A G E   S U M M A R Y
Treatments for people with bladder pain syndrome
What is bladder pain syndrome?
Bladder pain syndrome (BPS; also called painful bladder syndrome or interstitial cystitis) is a long-term painful condition that aFects
the bladder. ‘Syndrome’ refers to a collection of symptoms. In BPS, these symptoms include: intense pain in the pelvis (felt below the
bellybutton); sudden strong urges to urinate; needing to urinate more oLen than usual; and waking up several times during the night to
urinate.
BPS is more common in women. We do not know what causes it or how to cure it. Symptoms sometimes come and go in phases. BPS can
significantly aFect lifestyle, work, emotional health and relationships.
Treatments for BPS
Lifestyle changes are usually tried first, then medicines and supportive therapies. Surgery may be needed as a last resort.
Medicines used include pentosan polysulfate sodium – which may help to restore the inner surface of the bladder – anti-inflammatories,
antidepressants and antihistamines. Medicines that block the connection between nerves and muscles can be injected into the bladder
muscle to try to relax it (‘neuromuscular blockade’). Supportive therapies and treatments include behavioural therapy, physiotherapy,
bladder re-training, psychological therapy and transcutaneous electrical nerve stimulation (TENS).
Review question
In this Cochrane Review, we wanted to find out which treatments work best to treat BPS.
What did we do?
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We searched for studies that looked at any type of treatment for BPS. We looked for randomised controlled studies, in which the treatment
people receive is randomly decided, because these studies usually give the most reliable evidence about treatments.
Search date
We included evidence published up to 11 May 2018. We conducted a further search on 5 June 2019, which yielded four small studies that
were screened for eligibility but were not incorporated into the review.
What we found
We found 81 studies involving 4674 people with BPS. The biggest study included 369 people, and the smallest study included 10 people.
Most studies lasted around three months; only six studies lasted 12 months or longer. Twenty-four studies were funded by pharmaceutical
companies.
We found 65 treatments for BPS, which we grouped into 31 categories based on how the treatments worked. In most studies, a treatment
for BPS was compared with a placebo (or dummy) treatment. We compared all treatments with each other using a mathematical method
called network meta-analysis.
What are the results of our review?
ALer 12 months, antidepressants or neuromuscular blockade (and some other treatments) may improve symptoms of BPS more than
placebo, but we are not certain about this result. We did not find enough evidence to know if pentosan polysulfate sodium improves
symptoms.
We are uncertain whether 12 months of treatment with antidepressants, neuromuscular blockade or pentosan polysulfate sodium reduced
pain (as measured on a scale); the number of times people had to urinate during the day; or the number of times people had to get up
to urinate during the night.
Our confidence in the results
We are uncertain about our results because we did not find enough reliable evidence. Although we obtained results from 81 studies, most of
these studies were small and did not include enough people for us to be certain of their results. Some of the studies (30%) were conducted
by pharmaceutical companies, and this may have aFected how the studies were designed, conducted and reported. Our results may change
when results from more, and larger, studies become available.
Conclusions
We did not find enough reliable evidence about how well medicines, behavioural therapy, physiotherapy and neuromuscular blockade
worked to treat all, or any, of the symptoms of BPS.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Interventions for treating people with symptoms of bladder pain syndrome
Interventions for treating people with symptoms of bladder pain syndrome
Patient or population: people with bladder pain syndrome
Settings: hospital setting
Intervention: antidepressants, pentosan polysulfate (PPS), neuromuscular blockade
Comparison: control treatment
Effects and 95% credible intervals (NMA) and confidence intervals (pairwise) in the effects. Main compara-






Risk with PPS** Risk with neuromuscular
blockade**
Comments












Follow-up: 12 months or
nearest time point available
to 12 months
Mean pain score in the in-
tervention groups was 1.27
lower (3.25 lower to 0.71
higher)
Mean pain score in the in-
tervention groups was 0.42
higher (1.04 lower to 1.91
higher)
Mean pain score in the inter-
vention groups was 0.33 low-
er (1.71 lower to 1.03 higher)
Pain score: mean
differences vs con-













Scale ranged from 0 to 10.
Less pain indicated by lower
values
MCID = 2.5 points
Follow-up: 12 months or
nearest time point available
to 12 months
Mean number of daytime
voids in the intervention
groups was
2.41 lower (6.85 lower to
2.05 higher)
Mean number of daytime
voids in the intervention
groups was
0.37 lower (5.00 lower to
3.44 higher)
Mean number of daytime
voids in the intervention
groups was
0.91 lower (3.24 lower to 1.29
higher)
Daytime frequen-
cy (number of day-
time voids): mean
differences vs con-













Lower scores indicate better
outcome
MCID = 2 points
Follow-up: 12 months or






























































































































































Mean number of nighttime
voids in the intervention
groups was
0.01 higher (2.53 lower to
2.50 higher)
Mean number of nighttime
voids in the intervention
groups was
1.20 lower (3.62 lower to
1.28 higher)
Mean number of nighttime
voids in the intervention
groups was


















Lower scores indicate better
outcome
MCID = 1 point
Follow-up: 12 months or
nearest time point available
to 12 months
* The risk in the control group (and its 95% confidence interval) is based on a meta-analysis of proportions from the studies included in this review for this group.
** Risks in the antidepressant, PPS and neuromuscular blockade groups (and their 95% credible interval) are based on the assumed risk in the control group and the rel-
ative effects of the interventions (and their 95% credible interval).
Note: In GRADE assessments, 'within-study bias' was determined using the following domains from the 'risk of bias' assessments: sequence generation, allocation conceal-
ment and blinding of outcome assessor. Studies were classified as 'low risk of bias' if all key domains were judged to be at low risk, 'unclear risk of bias' if one or more key
domains were judged to be at unclear risk, and 'high risk of bias' if one or more key domains were judged to be at high risk. We conducted GRADE assessments using the
CINeMA 2017 web application.
MCID: minimal clinically important difference; NMA: network meta-analysis; OR: odds ratio; PPS: pentosan polysulfate.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded due to within-study bias, heterogeneity and incoherence, based on 2 studies.
bDowngraded due to within-study bias and imprecision, based on 6 studies.
cDowngraded due to within-study bias and heterogeneity, based on 6 studies.
dDowngraded due to within-study bias and imprecision, based on 2 studies.
eDowngraded due to within-study bias and heterogeneity, based on 4 studies.
fDowngraded due to within-study bias, imprecision and heterogeneity, based on 1 study.
gDowngraded due to within-study bias, imprecision and heterogeneity, based on 5 studies.
hDowngraded due to within-study bias and imprecision, based on 1 study.
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B A C K G R O U N D
Description of the condition
Bladder pain syndrome (BPS), which includes the condition of
interstitial cystitis, is a chronic condition that most oLen aFects
women and is characterised by pain in the bladder and/or pelvis
and other urinary symptoms, such as urgency and frequency
(Hanno 2017). The causes of BPS remain poorly understood, and no
single causative trigger or validated diagnostic markers have been
identified. Thus, diagnosis primarily relies on reported symptoms
and the exclusion of any other identifiable causes (Hanno 2017).
During a major international meeting in 1987, and later in 1990, the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) developed diagnostic criteria for interstitial cystitis based
on objective cystoscopic and urodynamic evaluation (NIDDK 2017).
Such evaluation involves putting the patient under local or general
anaesthesia and catheterising the urinary bladder, and so is
associated with substantial risks and costs. The NIDDK criteria have
helped inform the selection of homogeneous patient populations
for research purposes but have proven too strict for use in routine
clinical practice (Hanno 1999). Consequently, the International
Continence Society (ICS) proposed a broader term - 'painful
bladder syndrome' (Abrams 2002). The European Society for Study
of Interstitial Cystitis/Bladder Pain Syndrome (ESSIC) used the
term, 'bladder pain syndrome (BPS)', defined as "chronic pelvic
pain, pressure or discomfort of greater than six months duration
perceived to be related to the urinary bladder accompanied by
at least one other urinary symptom like persistent urge to void
or urinary frequency. Confusable diseases as the cause of the
symptoms must be excluded" (van de Merwe 2008). This definition
was accepted by the International Consultation on Incontinence
in 2010 (Hanno 2010). As patients tend to refer to it as interstitial
cystitis, the name 'interstitial cystitis' may be used in parallel
with BPS (e.g. ‘IC/BPS’). In this Cochrane Review, we will refer to
the condition as BPS, although we will also consider some older
literature using the original terminology.
Lack of a universally accepted clinical diagnosis of BPS makes
epidemiological studies of the condition problematic. Prevalence
estimates vary widely depending on diagnostic criteria and how
prevalence estimates were derived (i.e. self-report, physician
diagnoses and/or symptom-based surveys). One estimate is that
BPS is experienced by 100 to 200 per 100,000 women, with a male
prevalence of 10% to 20% of the estimate for females (Hanno
2017), although it is accepted that BPS is more common than is
suggested by empirical studies (Hanno 2017). BPS may negatively
impact quality of life and the psychological state of people with
the condition, with some experiencing depression, anxiety, distress
and sexual dysfunction (Cox 2016).
Although not consistently present (particularly in non-ulcerative
BPS), the main pathological feature of BPS is inflammation of the
bladder. This leads to vasodilation, enhanced vascular permeability
and degradation of the mucosal glycosaminoglycan coating of the
urothelium. When inflammation is present, it can spread to deeper
tissues of the bladder, and, in some cases, Hunner’s lesions may
appear in the bladder wall. This is oLen referred to as ulcerative
BPS. It is thought that this abnormal inflammation of the bladder
underlies the symptoms of pain (Grover 2011; Logadottir 2014).
To date, no definitive consensus has been reached on how or why
BPS develops.
Description of the intervention
Treatment options for BPS are varied (Hanno 2017). Current clinical
guidelines emphasise that an individualised treatment plan is likely
to lead to better patient outcomes (Cox 2016). Usually, the initial
treatment of BPS comprises patient education and support, dietary
manipulation, stress reduction, non-prescription analgesics and
pelvic floor relaxation techniques. When the conservative approach
fails, or symptoms are severe and conservative management
is unlikely to succeed, pharmacological interventions including
analgesics, antidepressants, antibiotics and immune modulators
may be used orally or intravesically (directly into the bladder). As
a last approach, surgery, including botulinum toxin A injections or
removal of the bladder, may be considered (Hanno 2017). Some
evidence indicates that BPS with Hunner's lesions may have a
diFerent clinical response to certain treatment as compared with
non-lesion disease; however, this has not yet been formalised
(Hanno 2017).
How the intervention might work
Conservative interventions including dietary and lifestyle changes,
behavioural modifications (e.g. patient education, bladder
retraining) and psychological therapies (e.g. stress management
techniques) can be beneficial in reducing the symptoms associated
with BPS. Women with BPS may also have pelvic floor dysfunction,
and physical therapy techniques such as pelvic floor muscle
training and soL tissue massage can be eFective in helping to relax
the pelvic floor muscles.
Pharmacological treatments address the many theories of
pathogenesis, including the following.
• Analgesics, such as non-steroidal anti-inflammatory drugs
(NSAIDs), target the main symptom of pain.
• Antidepressants are oLen used to manage pain in chronic
conditions, including BPS.
• Antibiotics are known to decrease the markers of bladder
inflammation, thus reducing pain.
• Immune modulators, such as bacillus Calmette-Guerin (BCG),
are believed to work immunologically, on the basis of an
autoimmune cause for interstitial cystitis.
• Steroids are known to have an anti-inflammatory eFect.
Surgery should be considered only when all other treatments have
failed (Hanno 2017). People should be informed of all aspects of
surgery and should understand the consequences and potential
side eFects of these interventions. Surgical interventions can work
in the following ways.
• Botulinum toxin A injections inhibit the release of chemical
transmitters from nerve fibres and the urothelium.
• A total cystectomy (removal of the bladder) can be performed for
extreme cases. This approach also requires subsequent urinary
diversion to expel urine from the body.
Some therapies for treating BPS are emerging. These include:
• hyperbaric oxygen, which involves breathing pure oxygen in a
pressurised chamber;
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• monoclonal antibodies, which inhibit nerve growth factors and
act as potential analgesics;
• cannabinoids, which could help relieve the symptoms of BPS;
and
• intravesical liposomes, which could potentially protect against
inflammation.
The algorithm for diagnosis and treatment proposed at the Sixth
International Consultation on Incontinence in 2016 is presented in
Figure 1 (Hanno 2017).
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Figure 1.   Algorithm for diagnosis and treatment: 2016 International Consultation on Incontinence. Taken from
Hanno 2017, and reproduced with permission from Abrams 2017.
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Why it is important to do this review
BPS is a condition with an unknown cause. More information
is needed about the eFects and safety of available treatment
options and therapies. Currently, several small trials are assessing
a wide range of treatment options, but the number of large
trials comparing one treatment versus another is limited (there
is one existing Cochrane Review on intravesical treatments for
BPS (Dawson 2007)). A Cochrane Review increasing coverage to
all clinical interventions by any route of administration, including
both direct and indirect comparisons, will help to provide valuable
information to inform clinical practice. A systematic review using
network meta-analysis (NMA) is the most appropriate method in
this clinical context, as it can simultaneously incorporate evidence
for the eFectiveness of many diFerent treatments within a single
analysis.
O B J E C T I V E S
To conduct a network meta-analysis to assess the eFects of
interventions for treating people with symptoms of bladder pain
syndrome (BPS).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel-group and cross-over randomised controlled
trials (RCTs) and quasi-RCTs (e.g. alternate allocation) of
interventions for treating BPS.
Types of participants
Allowing for the many terminologies that have been used for
this condition, we included trials in which adults were specified
as having BPS, interstitial cystitis or painful bladder syndrome.
We accepted the classification of diagnoses as defined by trial
investigators, and we regarded as eligible a clinical diagnosis of BPS
that did or did not meet NIDDK criteria (NIDDK 2017). We excluded
studies of adults with urethral syndrome.
Types of interventions
We included trials of any intervention that aimed to cure or improve
symptoms of BPS, covering both emerging and more traditional
modes of treatment. All types of interventions were eligible,
including conservative, pharmacological and surgical therapies.
Conservative therapies include behavioural therapies (e.g. bladder
training), psychological therapies (e.g. stress management
techniques), complementary therapies (e.g. acupuncture) and
physical therapy (e.g. pelvic floor muscle training, non-invasive
electrical stimulation). We considered pharmacological treatments
regardless of their routes of administration (which are likely to
be oral, subcutaneous, intramuscular, intravenous or intravesical).
Examples of relevant interventions are shown in Table 1.
Valid comparators were placebo, no treatment and another
intervention.
We excluded trials:
• comparing two or more regimens of the same treatment (e.g.
varying doses of pentosan polysulfate); or
• comparing two or more treatments with the same mechanism
or mode of action (e.g. sacral nerve stimulation versus pudendal
nerve stimulation, both of which are neuromodulation).
Types of outcome measures
We used the following definitions of outcomes. If a particular
outcome was reported by using diFerent definitions across
diFerent studies, then, depending on the quantity of data available,
we decided either to restrict inclusion to the primary (or most
common) definition or to include multiple definitions selected
according to the hierarchies proposed below. In the event that a
study reported any other measure not included in our proposed list,
we added this measure to the bottom of the hierarchy and extracted
the data.
Primary outcomes
• Proportion of participants whose symptoms were cured or
improved: self-reported measures are preferred, such as the
Global Response Assessment. We used objective measures (e.g.
number of participants who experienced pain score reduction)
as a proxy if self-reported measures were unavailable. We used
the number cured if this was reported. If cure was not reported,
we used the number improved, as defined by trial investigators
• Pain score: we used the following hierarchy to select one
outcome measure per study: visual analogue scale (VAS);
numerical rating scale (NRS); McGill Pain Questionnaire (Melzack
1975; Melzack 1987); Short Form Health Survey (SF-36)/RAND-36
(if a score for the pain-specific item is available) (Hays 1993;
McHorney 1993; Ware 1992); and the number of participants
with pain reduction
• Daytime frequency (number of voids): we considered the
following terms to be equivalent to daytime frequency:
frequency; daily frequency; frequency per day; and daytime
frequency. We excluded 24-hour frequency
• Nocturia (number of nighttime voids)
Secondary outcomes
• Subjective symptom measures (combining frequency, nocturia
and pain): we used the following hierarchy to select one
outcome measure per study: O'Leary-Sant Interstitial Cystitis
Symptom Index (ICSI) (O'Leary 1997); Pelvic Pain and Urgency/
Frequency Questionnaire (PUF) (Parsons 2002); University of
Wisconsin Interstitial Cystitis Scale (UW-IC Scale) (Goin 1998);
and King's Health Questionnaire (KHQ), Part III (Kelleher 1997)
• Quality of life (including symptom bother): we used the
following hierarchy to select one outcome measure per study:
O'Leary-Sant Interstitial Cystitis Problem Index (ICPI) (O'Leary
1997); Pelvic Pain and Urgency/Frequency Questionnaire (PUF),
bother score (Parsons 2002); King's Health Questionnaire (KHQ)
(Kelleher 1997); Short Form Health Survey (SF)-36 and SF-12,
Mental component (McHorney 1993; Ware 1992; Ware 1996); and
SF-36 and SF-12, Physical component (McHorney 1993; Ware
1992; Ware 1996)
• Functional bladder capacity: this is defined using the following
terms for the purpose of this review: functional bladder capacity;
functional bladder volume; bladder capacity; maximum bladder
capacity; and maximum tolerable bladder capacity. We
excluded volume at first or strong desire to void, (mean)
voided volume, (maximum) cystometric bladder capacity and
urodynamic capacity
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• Adverse events: the category of adverse events was accepted as
reported by study authors
Timing of outcome assessment
The primary time point for outcome assessment is 12 months or the
nearest time point available to 12 months.
Main outcomes for 'Summary of findings' tables
We included the following outcomes in our 'Summary of findings'
table, in order of priority.
• Proportion of participants whose symptoms were cured or
improved.
• Pain score (VAS (0 to 10)).
• Daytime frequency.
• Nocturia.
We used minimal clinically important diFerence (MCID) to rate the
certainty of evidence for the primary outcomes in the 'Summary of
findings' table. As there is no agreed MCID in the literature for BPS,
we considered MCID to be as follows based on expert opinion: for
cure or improvement, risk reduction of 25% (odds ratio (OR) 0.8 to
1.25); for pain, 2.5 points; for daytime frequency, 2 points; and for
nocturia, 1 point.
Search methods for identification of studies
We did not impose any language or other limitations on any of the
searches described below.
Electronic searches
We performed searches that drew on the search strategy developed
for Cochrane Incontinence. We identified relevant trials from
the Cochrane Incontinence Specialised Register. For details of
the search methods used to build the Specialised Register,
please see the Group's webpages, where details of the Register's
development (from inception) and the most recent searches
performed to populate the Register can be found. To summarise,
the Register contains trials identified from the Cochrane Central
Register of Controlled Trials (CENTRAL), in the Cochrane Library;
MEDLINE; MEDLINE In-Process; MEDLINE Epub Ahead of Print;
ClinicalTrials.gov; WHO ICTRP; and the UK Clinical Research
Network Portfolio (now replaced by Be Part of Research), and from
handsearching of journals and conference proceedings. Many of the
trials in the Cochrane Incontinence Specialised Register are also
contained in CENTRAL.
The terms that we used to search the Cochrane Incontinence
Specialised Register are given in Appendix 1.
The most recent search of the Cochrane Incontinence Specialised
Register was fully incorporated into this review on 11 May 2018. A
further search was conducted on 5 June 2019, which was screened
for eligibility but was not incorporated into the review.
Searching other resources
We identified relevant studies from an existing Cochrane Review on
intravesical treatments for BPS (date of last search: 30 May 2006)
(Dawson 2007). We also screened the reference lists of the included
studies for other relevant trials.
Data collection and analysis
Selection of studies
One review author (SW) established the selection of studies from
the relevant Cochrane Review on intravesical treatments for BPS
(Dawson 2007), which a second review author (MI) checked. Two
review authors (JO and AF) independently screened the titles and
abstracts of all citations identified by the literature searches. The
same two review authors evaluated full-text copies of all potentially
relevant reports. We resolved any discrepancies or inconsistencies
by recourse to a third review author (SW, MI, NS or MB).
We obtained translations of eligible studies when resources
allowed, including any available translated information obtained
by Dawson 2007. If translations were not obtained, we added
these studies to Studies awaiting classification and discussed
the implications of any missing information under Overall
completeness and applicability of evidence.
Data extraction and management
We exported study characteristics and outcome data of individual
studies from the relevant Cochrane Review, and one review author
(MI or YAD) checked them against individual trial reports (Dawson
2007). From additional studies identified by updated literature
searches, one review author (MI or YAD) performed data extraction
using a pre-piloted data form, which another review author (MI or
YAD) checked. We resolved any discrepancies or inconsistencies by
recourse to a third review author (SW, NS or MB).
We collected information on study design and setting, participant
characteristics (including disease diagnosis), study eligibility
criteria, details of the intervention(s) given, outcomes assessed and
the source of study funding for each included study. When multiple
publications of the same study were identified, we extracted the
most complete data across all known publications.
For binary outcomes, we extracted the total number of participants
in each treatment arm and the number with the event. For
continuous outcomes, we extracted mean scores (i.e. mean scores
at follow-up or mean change scores from baseline) for each arm
along with standard deviation (SD) and the number of participants.
If both final scores and change scores were available, we used final
scores in the analysis.
Assessment of risk of bias in included studies
We used the original risk of bias assessments made by review
authors of the relevant Cochrane Review (Dawson 2007). In that
review, judgements were made for the following criteria.
• Adequacy of randomisation and description of allocated groups
before treatment and blinding to allocation.
• Adherence to prescribed treatment once allocated.
• Adequacy of follow-up and accounting for participants
excluded/withdrawing from trial.
• Analysis of participants based on allocated treatment group and
adequacy of presented data.
Each study was judged to be at ‘low', 'high' or 'unclear' risk of bias.
Two review authors (JO and AF) independently updated these
assessments using Cochrane's 'Risk of bias' tool (Higgins
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2011a), resolving any discrepancies by discussion. The updated
assessments addressed the following domains.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessor (detection bias).
• Incomplete outcome data (attrition bias).
• Free of selective reporting (reporting bias).
• Other sources of bias.
Assessment of two domains, detection bias and attrition bias,
was modified further and these domains were assessed on an
outcome-specific basis. One review author (MI) performed these
assessments, which were checked by another review author (SW).
For detection bias, we grouped outcomes into subjective and
objective outcomes. We defined the following as subjective
outcomes.





• Subjective symptom measures (combining frequency, nocturia
and pain).
• Quality of life (QoL) (including symptom bother).
• Adverse events.
We defined functional bladder capacity as an objective outcome.
For attrition bias, we assessed individual outcomes separately.
Measures of treatment e:ect
For binary outcomes, we used odds ratios (ORs) as the measure
of treatment eFect. For continuous outcomes, we used mean
diFerences (MDs) in final scores or in change scores.
We re-scaled visual analogue scale (VAS) pain scores so that zero
represented no pain and 10 maximum pain.
Unit of analysis issues
We included only patient randomised trials in this review, and the
unit of analysis was the individual participant.
For cross-over trials, we intended to use data from paired analyses
when available. In cross-over studies, when paired analyses were
not reported, we used data from the first trial period if these were
presented separately, as detailed in the Cochrane Handbook for
Systematic Reviews of Interventions, Section 16.4.5 (Higgins 2011b).
We excluded cross-over studies from the analysis if only data for the
first and second periods combined were available.
If two or more arms of a multi-arm trial belonged to the same
treatment category, we combined data using standard pooling
formulae (Higgins 2011b).
Dealing with missing data
We employed a number of approaches to calculate or estimate
SDs when these were not reported. The standard methods
described in the Cochrane Handbook for Systematic Reviews of
Interventions were preferred (Higgins 2011c). If standard errors
(SEs) were reported, we derived the SD using the appropriate
standard formula, as detailed in the Cochrane Handbook for
Systematic Reviews of Interventions, Section 7.7.3.2 (Higgins 2011b).
If necessary, we calculated SDs from a 90% or 95% confidence
interval (CI) for a mean diFerence or from the P value for a t-test
(Higgins 2011b), or we imputed the SD using the average of other
studies in the review.
Assessment of heterogeneity
We assessed the presence of statistical heterogeneity by visually
inspecting forest plots for pairwise meta-analyses and by
calculating the I2 statistic (Higgins 2003). I2 values above 50% were
considered to represent important heterogeneity. For network
meta-analyses, we also investigated consistency between direct
and indirect evidence (see Data synthesis).
Assessment of reporting biases
If there had been more than 10 trials per comparison in an outcome,
we had planned to examine funnel plots to assess reporting bias.
Data synthesis
We divided interventions into treatment categories, each of which
was further classified as a conservative, pharmacological or
surgical intervention. The total number of treatment categories
that could be included in each analysis depended on the number
of studies that provided usable data for the outcomes of interest. If
considered clinically appropriate (e.g. if treatment B is considered
a routine therapy or procedure), we 'cancelled' treatments (e.g.
a trial of A + B versus B become A versus control). If this was
not considered appropriate, we used a combination of therapies
as a single treatment category (e.g. "chondroitin sulfate plus
hyaluronic acid"). We combined diFerent doses of the same
treatment as a single category, provided this was considered
clinically appropriate.
We performed two approaches to meta-analysis. The primary
method was network meta-analysis, but we also conducted
standard pairwise meta-analyses and compared the results with
those from the network meta-analysis.
Network meta-analysis
Network meta-analysis is an analytical approach that allows a large
number of treatments to be evaluated within a single analysis, and
allows the eFect size between any two treatments to be estimated
using evidence from the entire network. If we found a large number
of treatment combinations, we planned to report only the eFects of
each active treatment versus control.
We followed the recommendations in the National Institute for
Health and Care Excellence Decision Support Unit Technical
Support Documents 2 (NICE DSU TSD 2) (Dias 2016). Network
meta-analysis models were fitted using WinBUGS 1.4 and were
used to conduct synthesis of trial data (Lunn 2000). We used a
binomial likelihood for binary outcomes and the normal likelihood
for continuous outcomes. We used random-eFects models due
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to expected heterogeneity between treatments and outcome
measures. Three chains were used and parameters were fitted
using vague normal prior distributions.
For binary outcomes, we used Programme 1(c) from the NICE DSU
TSD 2 (Dias 2016). We monitored ORs for all treatments in the
network against control and presented results using 95% credible
intervals (CrI). ORs greater than 1 were associated with a favourable
eFect of treatment versus control. We monitored only eFects of
active treatments versus control. Treatments were described as
eFective if 95% CrIs from the NMA did not contain 1 (binary
outcome) or 0 (continuous outcomes).
For continuous outcomes, the eFect size was the mean diFerence
(MD) between groups. We monitored only contrasts between active
treatments and control. For each outcome, high scores represent
poorer patient outcomes than lower scores. Therefore, eFect sizes
less than zero will mean that treatment is favoured over control.
We used a shared parameter model (Programme 8(a) from the NICE
DSU TSD 2) to simultaneously incorporate two data formats (Dias
2016).
• Final score arm-based data.
• Contrast-based diFerences in change from baseline.
For the network meta-analysis, there is an additional assumption
of transitivity, also known as consistency or coherence, which
assumes that included participants should be eligible to be
randomised to any treatment within the network. Violations of
this assumption can be investigated by examining the consistency
between direct and indirect evidence when there are closed loops
in the network that allow this. We intended to use the methods
described in the NICE DSU TSD 4 to compare closed loops within the
network (Dias 2014), and we used CINeMA soLware as the primary
way to examine direct and indirect evidence (CINeMA 2017).
We produced network diagrams for each outcome using the
networkplot command in Stata (Stata 2017). Lines between
treatment categories mean that direct evidence exists between a
pair of treatments. The thickness of the line is proportionate to the
number of included studies.
When data allowed, we planned to undertake network meta-
analyses for all outcomes specified in the review. For cross-over
trials that provided usable data, we used data from the first period
only if they did not provide information to approximate a paired
analysis.
Pairwise meta-analyses
We compared results of the network meta-analysis with direct
evidence from head-to-head trials using standard Cochrane
methods. For each outcome, we performed a separate pairwise
meta-analysis for each treatment category versus control. We
conducted meta-analyses using the metan command in Stata (Stata
2017). We did not conduct meta-analyses between pairs of active
treatments. The number of trials contributing to the pairwise
meta-analyses may be smaller than the number included in the
corresponding network meta-analysis because only trials with a
control group were included.
For binary outcomes, we pooled ORs for each treatment versus
control. We used the Mantel-Haenszel approach to meta-analysis
using random-eFects models in Stata as the primary analysis
(Stata 2017). For continuous outcomes, the eFect size was the
mean diFerence between treatment and control. As for network
meta-analyses, we used a mixture of change score and final
score data within the same analysis (see the Cochrane Handbook
for Systematic Reviews of Interventions, Section 9.4.5.2; Deeks
2011). We combined studies using the inverse variance weighted
approach and presented results using 95% confidence intervals
(CIs).
Subgroup analysis and investigation of heterogeneity
We did not conduct subgroup analyses.
Sensitivity analysis
We did not conduct sensitivity analyses.
Summarising findings and assessing certainty of the evidence
We assessed the overall certainty (quality) of evidence for the
primary outcomes using the GRADE approach (Guyatt 2008;
Guyatt 2011; Schünemann 2011). We applied the GRADE approach
modified for network meta-analysis (Salanti 2014), using the
CINeMA 2017 web application. We rated the certainty of each
outcome as ‘high’, ‘moderate’, ‘low’ or ‘very low’, taking into
account six criteria: within-study bias (study limitations), across-
studies bias (e.g. publication bias), indirectness, imprecision,
heterogeneity and incoherence (among direct, indirect and mixed
evidence).
Two review authors (MI and NS) worked together to conduct the
GRADE assessment, reaching consensus for how each outcome
should be rated. We followed the guidance provided in the latest
draL version of the Cochrane Handbook for Systematic Reviews of
Interventions, in the chapter on network meta-analysis, to develop
our own 'Summary of findings' table (Chaimani 2017).
Due to the large number of intervention comparisons in this
review, we present one 'Summary of findings' table with three
interventions: antidepressants (including amitriptyline), pentosan
polysulfate and neuromuscular blockade (injection of botulinum
toxin type A). We selected these interventions on the basis that
they are given 'strong recommendations' in the EAU Guidelines for
management of BPS (EAU Guidelines 2019).
R E S U L T S
Description of studies
Results of the search
The initial search of the list of included studies of an existing
Cochrane Review yielded 12 reports of nine studies that were
eligible for this current review (Dawson 2007).
The literature search produced 431 records in total, which were
screened. The full text of 160 articles was obtained for further
assessment, of which 129 reports of 81 studies were included
and the available data fully incorporated into this review. Sixteen
reports of 14 studies did not meet the eligibility criteria and were
excluded, the reasons for which are given in the Characteristics
of excluded studies table. Additionally, we identified 15 reports
of 13 ongoing studies; the details of these can be found in the
Characteristics of ongoing studies table.
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The further updated literature search (conducted on 5 June 2019)
identified 45 records, which were screened. Of these, 15 reports of
14 studies were eligible for inclusion in this review (five reports of
four new studies; three additional reports of three already included
studies; and seven study registrations of seven ongoing studies). All
four new studies were small (ranging from 15 to 42 participants)
(Aboyan 2018; Bosch 2018; Cervigni 2018; Oh-Oka 2017). Only
one of these studies covered one of the comparisons included in
our NMA (hyaluronic acid alone compared with hyaluronic acid
in combination with chondroitin sulphate) (Aboyan 2018). Due to
resource constraints, these were not fully incorporated into the
review, but brief details of each can be viewed in the Characteristics
of studies awaiting classification table.
The flow of literature through the assessment process is shown in
the PRISMA diagram (Figure 2).
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Figure 2.   PRISMA study flow diagram.
 
 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Figure 2.   (Continued)
 
Included studies
The 81 RCTs identified by the literature searches were published
between 1988 and 2017 (Carty 2017; Chuang 2017; Nomiya 2017;
Perez-Marrero 1988; Wang 2017a). Of these, 61 (75%) were available
as full-text publications (Bade 1997; Barbalias 2000; Bosch 2014;
Carrico 2008; Cartledge 2000; Carty 2017; Cervigni 2014; Chen
2005; Chen 2014; Chuang 2017; Davis 2008; De Ridder 2013; El-
Hefnawy 2015; Evans 2011; FitzGerald 2009; FitzGerald 2012; Foster
2010; Geirsson 1993; Gottsch 2011; Gulpinar 2015; Ham 2012; Hsieh
2012; Irani 2004; Kanter 2016; Korting 1999; Kuo 2009; Kuo 2016;
Lazzeri 1996; Lazzeri 2000; Leadership 201 Trial 2016; Lee 2014;
Lu 2015; Manning 2014; Matsumoto 2013; Mayer 2005; Mulholland
1990; Nguan 2005; Nickel 2009; Nickel 2010; Nickel 2012a; Nickel
2012b; Nickel 2015; Nickel 2016; O'Reilly 2004; Parsons 2012; Payne
2005; Payne 2014; Peeker 2000; Perez-Marrero 1988; Peters 1997;
Sairanen 2005; Sairanen 2009; Sant 2003; Souza 2012; Thilagarajah
2001; van Ophoven 2004; van Ophoven 2006; Wang 2017a; Warren
2000; Yang 2011; Zakaria 2016), and the remaining 20 (25%) were
available as conference abstracts only (Ahmadnia 2011; Dimitrakov
2001; Gulpinar 2013; Hanno 2015; Herati 2011; Ismail 2016; Kasyan
2012; Kim 2012; Kim 2015; Lee 2016; Mirkin 2012; Mirkin 2015;
Moldwin 2015; Nomiya 2017; Oliver 2013; Pinto 2016; Shirvan 2015;
Singh 2003; Taha 2007; Yassin 2011).
The Characteristics of included studies tables provide further
details of the included studies.
Design
Six of the identified studies were randomised cross-over trials
(Cartledge 2000; Geirsson 1993; Nguan 2005; Parsons 2012; Peeker
2000; Perez-Marrero 1988). The other 75 studies were parallel RCTs.
Sample size
The included studies enrolled a total of 4674 participants. A
majority of studies had a small sample size, but 34 studies (42%)
included 50 or more participants (Carty 2017; Cervigni 2014;
Chuang 2017; Evans 2011; FitzGerald 2012; Foster 2010; Gulpinar
2013; Hanno 2015; Hsieh 2012; Korting 1999; Kuo 2009; Kuo 2016;
Leadership 201 Trial 2016; Lee 2014; Lee 2016; Manning 2014; Mayer
2005; Mirkin 2015; Moldwin 2015; Mulholland 1990; Nickel 2009;
Nickel 2010; Nickel 2012a; Nickel 2012b; Nickel 2015; Nickel 2016;
O'Reilly 2004; Payne 2005; Sairanen 2005; Sairanen 2009; Sant 2003;
van Ophoven 2004; Warren 2000; Yang 2011). Sample sizes ranged
from 10 in Oliver 2013 to 369 in Nickel 2015, with a median size of 38.
Setting
Of the included studies, 29 studies (36%) were conducted in
several centres (multi-centre) (Cervigni 2014; Chen 2005; Chen
2014; Chuang 2017; De Ridder 2013; Evans 2011; FitzGerald 2009;
FitzGerald 2012; Foster 2010; Irani 2004; Kim 2015; Kuo 2016;
Leadership 201 Trial 2016; Manning 2014; Mayer 2005; Mulholland
1990; Nguan 2005; Nickel 2009; Nickel 2010; Nickel 2012a; Nickel
2012b; Nickel 2015; Parsons 2012; Payne 2005; Sairanen 2005; Sant
2003; Wang 2017a; Warren 2000; Yang 2011). Thirteen (16%) were
small-scale, single-centre trials (Bade 1997; Bosch 2014; Carrico
2008; Carty 2017; Davis 2008; El-Hefnawy 2015; Gottsch 2011; Lu
2015; Payne 2014; Perez-Marrero 1988; Peters 1997; Souza 2012; van
Ophoven 2004). Thirty-nine (48%) did not provide information on
the number of centres involved (Ahmadnia 2011; Barbalias 2000;
Cartledge 2000; Dimitrakov 2001; Geirsson 1993; Gulpinar 2013;
Gulpinar 2015; Ham 2012; Hanno 2015; Herati 2011; Hsieh 2012;
Ismail 2016; Kanter 2016; Kasyan 2012; Kim 2012; Korting 1999; Kuo
2009; Lazzeri 1996; Lazzeri 2000; Lee 2014; Lee 2016; Matsumoto
2013; Mirkin 2012; Mirkin 2015; Moldwin 2015; Nickel 2016; Nomiya
2017; O'Reilly 2004; Oliver 2013; Peeker 2000; Pinto 2016; Sairanen
2009; Shirvan 2015; Singh 2003; Taha 2007; Thilagarajah 2001; van
Ophoven 2006; Yassin 2011; Zakaria 2016).
Included studies were conducted in various countries. The USA
was the country where most studies were conducted (25 studies)
(Bosch 2014; Carrico 2008; Carty 2017; Davis 2008; Evans 2011;
FitzGerald 2009; FitzGerald 2012; Foster 2010; Gottsch 2011; Hanno
2015; Herati 2011; Kanter 2016; Korting 1999; Mayer 2005; Moldwin
2015; Mulholland 1990; Nickel 2012a; Oliver 2013; Parsons 2012;
Payne 2005; Payne 2014; Peeker 2000; Peters 1997; Sant 2003;
Warren 2000). Nineteen studies were conducted in 11 other
Western countries, including Canada (Chen 2005; Nguan 2005;
Perez-Marrero 1988); Australia (Manning 2014; O'Reilly 2004);
Belgium (De Ridder 2013); Finland (Sairanen 2005); Germany (van
Ophoven 2004; van Ophoven 2006); Greece (Barbalias 2000); Italy
(Cervigni 2014; Lazzeri 1996; Lazzeri 2000); Portugal (Pinto 2016);
Sweden (Geirsson 1993); the Netherlands (Bade 1997); and the UK
(Cartledge 2000; Singh 2003; Thilagarajah 2001). Eighteen studies
were conducted in six diFerent Asian countries, including China
(Chen 2014; Lu 2015); Japan (Matsumoto 2013; Nomiya 2017); Korea
(Ham 2012; Kim 2012; Kim 2015); Taiwan (Chuang 2017; Hsieh 2012;
Kuo 2009; Kuo 2016; Lee 2014; Lee 2016); Iran (Ahmadnia 2011; Irani
2004; Shirvan 2015); and Turkey (Gulpinar 2013; Gulpinar 2015).
Four studies were conducted in Egypt (El-Hefnawy 2015; Taha 2007;
Yassin 2011; Zakaria 2016); three in Iran (Ahmadnia 2011; Irani 2004;
Shirvan 2015); and one in Brazil (Souza 2012), and three studies
were conducted in Russia (Kasyan 2012; Mirkin 2012; Mirkin 2015).
Seven studies involved more than one country (Leadership 201 Trial
2016; Nickel 2009; Nickel 2010; Nickel 2012b; Nickel 2015; Wang
2017a; Yang 2011). For four studies, the country in which the study
was conducted is unclear (Dimitrakov 2001; Ismail 2016; Nickel
2016; Sairanen 2009).
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Participants
Participants enrolled in the included studies presented with various
clinical diagnoses including interstitial cystitis (IC); painful bladder
syndrome (PBS); bladder pain syndrome (BPS); painful bladder
disease (PBD); chronic urogenital pain (Carty 2017); severe bladder
pain (Lazzeri 1996); or hypersensitive disorder and severe pain
(Lazzeri 2000). One study included patients with IC/PBS, as well as
patients with chronic prostatitis (CP)/chronic pelvic pain syndrome
(CPPS) (not eligible for this evidence synthesis) (FitzGerald 2009).
Study participants were female in 29 studies and were
predominantly (> 75%) female in 34 studies (Bosch 2014; Cartledge
2000; Chen 2005; Chuang 2017; De Ridder 2013; Evans 2011; Foster
2010; Ismail 2016; Kuo 2016; Lazzeri 1996; Matsumoto 2013; Mayer
2005; Mulholland 1990; Nickel 2009; Nickel 2010; Nickel 2012b;
Nickel 2015; Nickel 2016; Nomiya 2017; Oliver 2013; Payne 2005;
Payne 2014; Peeker 2000; Perez-Marrero 1988; Sairanen 2005;
Sairanen 2009; Sant 2003; Souza 2012; Thilagarajah 2001; van
Ophoven 2004; Wang 2017a; Warren 2000; Yang 2011; Yassin 2011).
Two studies included slightly more women than men (51% to 63%)
(FitzGerald 2009; Lazzeri 2000), and one study included only men
(Zakaria 2016). The other 15 studies did not report participants'
gender.
The reported mean or median age of participants in each study
lay between 30 and 44 years in 12 studies (Carrico 2008; Cartledge
2000; Chen 2014; Davis 2008; El-Hefnawy 2015; FitzGerald 2009;
FitzGerald 2012; Foster 2010; Geirsson 1993; Lazzeri 2000; Mirkin
2012; Thilagarajah 2001); between 45 and 64 years in 45 studies
(Bade 1997; Barbalias 2000; Bosch 2014; Carty 2017; Cervigni 2014;
Chen 2005; Chuang 2017; Gottsch 2011; Gulpinar 2013; Gulpinar
2015; Ham 2012; Hsieh 2012; Irani 2004; Kanter 2016; Kim 2012; Kim
2015; Korting 1999; Kuo 2016; Lazzeri 1996; Leadership 201 Trial
2016; Lee 2014; Lu 2015; Manning 2014; Mayer 2005; Mulholland
1990; Nickel 2009; Nickel 2010; Nickel 2012a; Nickel 2012b; Nickel
2015; Nickel 2016; Payne 2005; Payne 2014; Peeker 2000; Perez-
Marrero 1988; Peters 1997; Pinto 2016; Sairanen 2005; Sairanen
2009; Sant 2003; Souza 2012; van Ophoven 2004; Wang 2017a;
Warren 2000; Yang 2011); and 65 years or older in four studies
(Matsumoto 2013; Nomiya 2017; Oliver 2013; van Ophoven 2006).
Mean or median age of participants was not reported in the
remaining 20 studies.
Study funding sources
Twenty-four included studies (30%) were sponsored by
pharmaceutical companies that manufactured the products being
studied (Bosch 2014; Cervigni 2014; Chuang 2017; Davis 2008;
De Ridder 2013; Evans 2011; Leadership 201 Trial 2016; Mirkin
2012; Moldwin 2015; Mulholland 1990; Nickel 2009; Nickel 2010;
Nickel 2012a; Nickel 2012b; Nickel 2015; Nickel 2016; Parsons 2012;
Payne 2005; Payne 2014; Peeker 2000; Peters 1997; Pinto 2016;
van Ophoven 2004; Wang 2017a), and 19 included studies (23%)
were independent or were publicly funded (e.g. from research
councils, government, individual hospitals) (Carrico 2008; Chen
2014; Dimitrakov 2001; Geirsson 1993; Herati 2011; Kanter 2016;
Kim 2012; Kuo 2016; Lee 2014; Matsumoto 2013; Mayer 2005; Nguan
2005; Nomiya 2017; Sairanen 2005; Sant 2003; Taha 2007; van
Ophoven 2006; Warren 2000; Yang 2011). Four studies (5%) stated
that no research funding was received (Kasyan 2012; Lee 2016;
Oliver 2013; Yassin 2011). The other 34 studies (42%) did not specify
the source of funding (Ahmadnia 2011; Bade 1997; Barbalias 2000;
Cartledge 2000; Carty 2017; Chen 2005; El-Hefnawy 2015; FitzGerald
2009; FitzGerald 2012; Foster 2010; Gottsch 2011; Gulpinar 2013;
Gulpinar 2015; Ham 2012; Hanno 2015; Hsieh 2012; Irani 2004;
Ismail 2016; Kim 2015; Korting 1999; Kuo 2009; Lazzeri 1996; Lazzeri
2000; Lu 2015; Manning 2014; Mirkin 2015; O'Reilly 2004; Perez-
Marrero 1988; Sairanen 2009; Shirvan 2015; Singh 2003; Souza 2012;
Thilagarajah 2001; Zakaria 2016).
Interventions
The included studies assessed 65 diFerent active treatments,
given alone or in combination. We grouped these treatments
into treatment categories by mode of action, based on treatment
descriptions for BPS from the 6th ICI wherever possible (Hanno
2017). The analysis included 31 active treatment categories, which
are shown in Table 2. No studies were identified using our search
strategies for the interventions listed in Table 3. A majority of
the treatment categories in the analysis were pharmacological
therapies, and a relatively small number of treatment categories
were related to conservative therapies and surgical interventions.
For trials that compared two or more varieties of the same
treatment against control, trial arms comparing the same
treatment were combined. For example, Chen 2005 comparing
resiniferatoxin (RTX) 0.05 microMol/L, RTX 0.1 microMol/L and
placebo, and Payne 2005 comparing RTX 0.01 microMol/L, RTX 0.05
microMol/L, RTX 0.10 microMol/L and control, were both analysed
as ‘RTX (calcium channel agonist) versus control’; and Chuang 2017
comparing liposomal-formulated onabotulinumtoxinA (lipotoxin),
onabotulinumtoxinA in normal saline and normal saline was
analysed as ‘onabotulinumtoxinA (neuromuscular blockade)
versus control’. One trial comprising four intervention groups using
a factorial design (antihistamines, PPS, PPS + antihistamines and
control) was analysed as a four-intervention arm trial (Sant 2003).
Outcomes
No common single outcome was assessed by all included trials.
Outcomes that were conceptually similar such as pain were
measured by diFerent scales or tools, and a clear definition
oLen was not provided. Continuous outcomes (e.g. pain, daytime
frequency, nocturia) were reported as mean scores at last follow-up
or as mean changes from baseline. Considerable eForts were made
to standardise the reported outcomes to incorporate them into the
analysis. A sizeable number of studies provided no usable outcome
data.
Length of follow-up
A majority of studies provided short follow-up. Only six studies (7%)
had follow-up of 12 months or longer (Irani 2004; Kuo 2009; Lu 2015;
Mayer 2005; Peters 1997; Taha 2007). Follow-up time ranged from 0
months in Mirkin 2012, Nickel 2009 and Souza 2012 to 27 months in
Peters 1997, with a median of three months.
Excluded studies
Sixteen reports of 14 studies were excluded aLer full-text screening.
For example, we excluded studies that enrolled participants with
urethral syndrome (Choa 1983; Costantini 2003), as well as studies
that compared diFerent regimens of the same treatment (Lai 2013;
Lubeck 2001; Nickel 2005; Peters 2007). Further details are provided
in the Characteristics of excluded studies table.
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Risk of bias in included studies
Summaries of 'Risk of bias' judgements for the included studies are
presented in Figure 3 and Figure 4.
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Ahmadnia 2011 ? ? ? ? ? +
Bade 1997 + ? ? ? ? + + + +
Barbalias 2000 + ? ? ? ? ? ?
Bosch 2014 ? ? + + ? ? ? ? + +
Carrico 2008 + + - - - - - - + +
Cartledge 2000 ? ? + + +
Carty 2017 ? ? - - - + +
Cervigni 2014 + + - - + - - + + + + + + +
Chen 2005 + + + + + + + + + + + +
Chen 2014 + ? ? ? + + + + + + + + +
Chuang 2017 + ? + + + + + + + + + + + + +
Davis 2008 ? ? + + + + + +
De Ridder 2013 ? ? - ? - ? - +
Dimitrakov 2001 ? ? ? ? ? +
El-Hefnawy 2015 ? ? - - - - - - - - + +
Evans 2011 + + ? ? - + ? + + +
FitzGerald 2009 ? ? - - + + +
FitzGerald 2012 ? ? - - + + + + + + + +
Foster 2010 ? ? + + + ? + + ? ? + + +
Geirsson 1993 + ? - - ? + +
Gottsch 2011 ? ? ? ? + + + +
Gulpinar 2013 ? ? ? ? ? ? ? ? ? + +
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Figure 3.   (Continued)
Gottsch 2011 ? ? ? ? + + + +
Gulpinar 2013 ? ? ? ? ? ? ? ? ? + +
Gulpinar 2015 ? ? ? ? + + + + +
Ham 2012 ? ? ? ? + ? + + + + + +
Hanno 2015 ? ? ? ? ? ? ? +
Herati 2011 + ? ? ? - +
Hsieh 2012 ? ? - - - - + +
Irani 2004 ? + + + + + + + + + + +
Ismail 2016 ? ? ? ? ? + +
Kanter 2016 + + - - - - - - + +
Kasyan 2012 ? ? ? ? ? ? ? ? + +
Kim 2012 ? ? ? ? + +
Kim 2015 ? ? - - ? + +
Korting 1999 + + + + - + + - + +
Kuo 2009 ? ? - - + + + + + + + + + + +
Kuo 2016 + + + + + + + + + + + + + + +
Lazzeri 1996 ? ? + + + + + + +
Lazzeri 2000 ? ? - - ? ? ? ? + +
Leadership 201 Trial 2016 ? + + + + + + + + + +
Lee 2014 ? ? - - + + + + +
Lee 2016 ? ? ? ? ? ? ? + +
Lu 2015 ? ? ? ? + + + + ? +
Manning 2014 + + + + + + + + + + + + + +
Matsumoto 2013 + + ? ? ? ? ? ? + +
Mayer 2005 ? ? ? ? + + + + + + + + + +
Mirkin 2012 ? ? ? ? ? ? ? + +
Mirkin 2015 ? ? ? ? ? ? + +
Moldwin 2015 ? ? ? ? ? ? +
Mulholland 1990 + + + + + ? ? + +
Nguan 2005 + ? ? ? + + +
Nickel 2009 ? ? ? ? + + + + + + + +
Nickel 2010 + ? + + + + + + + + + +
Nickel 2012a + + + + + + + + + + + +
Nickel 2012b + ? ? ? - - - - + + +
Nickel 2015 + ? + + + + + + + +
Nickel 2016 ? ? ? ? + + + +
Nomiya 2017 ? ? ? ? + - - - - - + + +
O'Reilly 2004 ? ? + + + + + + + +
Oliver 2013 ? ? - ? + +
Parsons 2012 ? + + + + +
Payne 2005 + + + + + + + + +
Payne 2014 + ? ? ? + + - +
Peeker 2000 ? + - - - -
Perez-Marrero 1988 ? ? - - + + +
Peters 1997 ? ? + + ? ? ? + +
Pinto 2016 ? ? ? ? + + + + +
Sairanen 2005 ? + - - + + + + + + + + +
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Figure 3.   (Continued)
Pinto 2016 ? ? ? ? + + + + +
Sairanen 2005 ? + - - + + + + + + + + +
Sairanen 2009 ? ? ? ? ? ? +
Sant 2003 + ? ? ? - ? ? ? + + +
Shirvan 2015 ? ? ? ? + +
Singh 2003 ? ? ? ? +
Souza 2012 + ? + + + + + + + + +
Taha 2007 - - - - + ? +
Thilagarajah 2001 ? ? + + + +
van Ophoven 2004 + ? + + + + + + + + + +
van Ophoven 2006 + ? + + + - + + + ? + +
Wang 2017a + ? + + + + + + + + + +
Warren 2000 ? ? ? ? + + + +
Yang 2011 ? ? + + + + + + + + +
Yassin 2011 ? ? ? ? ? ? + +
Zakaria 2016 ? ? + + + + +
 
 
Figure 4.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Allocation
Twelve studies (15%) were considered to have adequate random
sequence generation and appropriate allocation concealment,
indicating an overall low risk of selection bias (Carrico 2008;
Cervigni 2014; Chen 2005; Evans 2011; Kanter 2016; Korting 1999;
Kuo 2016; Manning 2014; Matsumoto 2013; Mulholland 1990;
Nickel 2012a; Payne 2005). Seventeen studies (21%) had adequate
random sequence generation but it was unclear whether they
assured allocation concealment (Bade 1997; Barbalias 2000; Chen
2014; Chuang 2017; Davis 2008; Geirsson 1993; Herati 2011; Nguan
2005; Nickel 2010; Nickel 2012b; Nickel 2015; Payne 2014; Sant
2003; Souza 2012; van Ophoven 2004; van Ophoven 2006; Wang
2017a), and five studies (6%) had adequate allocation concealment
but it was unclear how the random sequence was generated
(Irani 2004; Leadership 201 Trial 2016; Parsons 2012; Peeker 2000;
Sairanen 2005). In one study that used alternate allocation, both
random sequence generation and allocation concealment were
considered inadequate, indicating an overall high risk of selection
bias (Taha 2007). The other 46 studies (57%) did not provide
suFicient information on which to assess the risk of selection bias.
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Blinding
Performance bias
Twenty-seven studies (33%), most of which were placebo- or
sham-controlled trials, reported adequate methods for blinding
participants and personnel to treatment allocation and were
considered to have low risk of performance bias (Bosch 2014;
Cartledge 2000; Chen 2005; Chuang 2017; Davis 2008; Foster 2010;
Irani 2004; Korting 1999; Kuo 2016; Lazzeri 1996; Leadership 201
Trial 2016; Manning 2014; Mulholland 1990; Nickel 2010; Nickel
2012a; Nickel 2015; O'Reilly 2004; Parsons 2012; Payne 2005; Peters
1997; Souza 2012; Thilagarajah 2001; van Ophoven 2004; van
Ophoven 2006; Wang 2017a; Yang 2011; Zakaria 2016).
In 19 studies (23%), it was assumed that blinding of both patients
and personnel was not done and the risk of performance bias was
considered to be high. These included 13 studies using behavioural,
physical or surgical interventions when blinding was not feasible
due to the nature of the interventions (Carrico 2008; Carty 2017;
El-Hefnawy 2015; FitzGerald 2009; FitzGerald 2012; Geirsson 1993;
Hsieh 2012; Kanter 2016; Kim 2015; Kuo 2009; Lee 2014; Oliver
2013; Taha 2007). The other six studies reported some noticeable
diFerence between the intervention and the comparator, such
as the garlic-like taste or an odour of dimethyl sulfoxide (DMSO)
on the participant's breath (Cervigni 2014; Peeker 2000; Perez-
Marrero 1988); a light warm or burning sensation aLer instillation
of resiniferatoxin solution (Lazzeri 2000); the use of vials of diFerent
sizes (De Ridder 2013); or the use of an ‘open-label’ study design
(Lazzeri 2000).
In the remaining 35 studies (43%), blinding was not mentioned, or
the term 'blinding' was mentioned (e.g. ‘double-blind study’) but
the method used for blinding was not described (e.g. placebo was
unspecified). We judged these studies to be at unclear risk of bias.
Detection bias
For blinding subjective outcome assessment, 26 studies (32%)
reported adequate methods for blinding assessors of subjective
outcomes and were judged to be at low risk of bias (Bosch 2014;
Chen 2005; Chuang 2017; Davis 2008; Foster 2010; Irani 2004;
Korting 1999; Kuo 2016; Lazzeri 1996; Leadership 201 Trial 2016;
Manning 2014; Mulholland 1990; Nickel 2010; Nickel 2012a; Nickel
2015; O'Reilly 2004; Parsons 2012; Payne 2005; Peters 1997; Souza
2012; Thilagarajah 2001; van Ophoven 2004; van Ophoven 2006;
Wang 2017a; Yang 2011; Zakaria 2016). Seventeen studies were
judged to be at high risk because the participants either were not
or could not be blinded to the intervention (Carrico 2008; Carty
2017; Cervigni 2014; El-Hefnawy 2015; FitzGerald 2009; FitzGerald
2012; Geirsson 1993; Hsieh 2012; Kanter 2016; Kim 2015; Kuo 2009;
Lazzeri 2000; Lee 2014; Peeker 2000; Perez-Marrero 1988; Sairanen
2005; Taha 2007). The risk of detection bias was unclear in the
remaining 36 studies (44%) as the blinding of study participants was
not explicitly stated. Risk of bias was not applicable in two studies
that did not report any usable subjective outcome data (Cartledge
2000; Singh 2003).
For blinding objective outcome assessment, we assessed 11 studies
(14%) that reported functional bladder capacity as being at low risk
of bias, as bladder capacity was measured in terms of urine volume
(mL) and therefore was unlikely to be aFected by lack of blinding
(Cervigni 2014; Chuang 2017; Ham 2012; Irani 2004; Kuo 2009; Kuo
2016; Manning 2014; Mayer 2005; Souza 2012; van Ophoven 2004;
van Ophoven 2006). Risk of bias was not applicable in the remaining
70 studies (86%), which did not report this outcome.
Incomplete outcome data
We assessed the risk of attrition bias based on diFerential dropout
rates. We judged that there was high risk of attrition bias when
the number of participants lost at follow-up diFered between
treatment groups by 10% or more.
For the outcome of cure or improvement, as reported in 43
studies (53%), risk of attrition bias was considered to be low in
29 studies (36%) (Chen 2014; Chuang 2017; Davis 2008; FitzGerald
2009; FitzGerald 2012; Foster 2010; Gulpinar 2015; Irani 2004; Kuo
2009; Kuo 2016; Lazzeri 1996; Lu 2015; Manning 2014; Mayer 2005;
Mulholland 1990; Nickel 2009; Nickel 2010; Nickel 2012a; Nickel
2015; Nomiya 2017; Payne 2005; Payne 2014; Perez-Marrero 1988;
Sairanen 2005; Taha 2007; van Ophoven 2004; Wang 2017a; Warren
2000; Yang 2011); high in nine studies (%) (Carrico 2008; Cervigni
2014; De Ridder 2013; Evans 2011; Kanter 2016; Korting 1999; Nickel
2012b; Sant 2003; van Ophoven 2006); and unclear in five studies
(6%) (Bade 1997; Bosch 2014; Peters 1997; Sairanen 2009; Yassin
2011).
For the outcome of pain, as reported in 51 studies (63%), risk
of attrition bias was considered to be low in 30 studies (11%)
(Chen 2005; Chen 2014; Chuang 2017; Evans 2011; FitzGerald 2012;
Gottsch 2011; Ham 2012; Irani 2004; Kuo 2009; Kuo 2016; Lazzeri
1996; Leadership 201 Trial 2016; Lee 2014; Lu 2015; Mayer 2005;
Nguan 2005; Nickel 2009; Nickel 2010; Nickel 2012a; Nickel 2015;
Nickel 2016; O'Reilly 2004; Payne 2005; Pinto 2016; Sairanen 2005;
Souza 2012; van Ophoven 2004; van Ophoven 2006; Wang 2017a;
Yang 2011); high in seven studies (9%) (Carrico 2008; Carty 2017;
Cervigni 2014; El-Hefnawy 2015; Kanter 2016; Nickel 2012b; Nomiya
2017); and unclear in 14 studies (17%) (De Ridder 2013; Foster 2010;
Gulpinar 2013; Hanno 2015; Kasyan 2012; Kim 2015; Lazzeri 2000;
Lee 2016; Matsumoto 2013; Mirkin 2012; Mirkin 2015; Mulholland
1990; Peters 1997; Sant 2003).
For the outcome of daytime frequency, as reported in 40 studies
(49%), risk of attrition bias was considered to be low in 29 studies
(36%) (Bade 1997; Cervigni 2014; Chen 2005; Chen 2014; Chuang
2017; Evans 2011; FitzGerald 2012; Foster 2010; Gulpinar 2015; Ham
2012; Irani 2004; Korting 1999; Kuo 2009; Kuo 2016; Leadership
201 Trial 2016; Lu 2015; Manning 2014; Mayer 2005; Nickel 2009;
Nickel 2010; Nickel 2012a; Nickel 2015; O'Reilly 2004; Pinto 2016;
Sairanen 2005; Souza 2012; van Ophoven 2004; van Ophoven 2006;
Wang 2017a); high in four studies (5%) (El-Hefnawy 2015; Hsieh
2012; Nickel 2012b; Nomiya 2017); and unclear in seven studies
(9%) (Barbalias 2000; Gulpinar 2013; Lazzeri 2000; Matsumoto 2013;
Mirkin 2012; Mirkin 2015; Sant 2003).
For the outcome of nocturia, as reported in 18 studies (22%), risk
of attrition bias was considered to be low in 13 studies (16%)
(Bade 1997; Chen 2005; Chen 2014; Chuang 2017; Foster 2010; Ham
2012; Korting 1999; Kuo 2009; Kuo 2016; Lu 2015; Manning 2014;
Sairanen 2005; Wang 2017a); high in three studies (4%) (El-Hefnawy
2015; Hsieh 2012; Nomiya 2017); and unclear in two studies (2%)
(Gulpinar 2013; Lazzeri 2000).
For the outcome of ICSI, as reported in 31 studies (38%), risk of
attrition bias was considered to be low in 18 studies (22%) (Cervigni
2014; Chen 2005; Chen 2014; Chuang 2017; FitzGerald 2012; Kuo
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2009; Kuo 2016; Leadership 201 Trial 2016; Lee 2014; Manning
2014; Mayer 2005; Nickel 2009; Nickel 2010; Nickel 2012a; O'Reilly
2004; Sairanen 2005; Wang 2017a; Yang 2011); high in five studies
(6%) (Carrico 2008; El-Hefnawy 2015; Kanter 2016; Nickel 2012b;
Nomiya 2017); and unclear in eight studies (10%) (Bosch 2014; De
Ridder 2013; Foster 2010; Gulpinar 2013; Kasyan 2012; Lee 2016;
Matsumoto 2013; Sant 2003).
For the outcome of ICPI, as reported in 28 studies (35%), risk of
attrition bias was considered to be low in 17 studies (21%) (Cervigni
2014; Chen 2005; Chen 2014; Chuang 2017; FitzGerald 2012; Kuo
2009; Kuo 2016; Leadership 201 Trial 2016; Lee 2014; Manning 2014;
Mayer 2005; Nickel 2009; Nickel 2010; Nickel 2012a; O'Reilly 2004;
Sairanen 2005; Yang 2011); high in four studies (5%) (Carrico 2008;
El-Hefnawy 2015; Kanter 2016; Nomiya 2017); and unclear in seven
studies (9%) (Bosch 2014; Foster 2010; Gulpinar 2013; Kasyan 2012;
Lee 2016; Matsumoto 2013; Sant 2003).
For the outcome of functional bladder capacity, as reported in 11
studies (14%), risk of attrition bias was considered to be low in
all 11 studies (Cervigni 2014; Chuang 2017; Ham 2012; Irani 2004;
Kuo 2009; Kuo 2016; Manning 2014; Mayer 2005; Souza 2012; van
Ophoven 2004; van Ophoven 2006).
For the outcome of adverse events, as reported in 52 studies
(64%), risk of attrition bias was considered to be low in 35 studies
(43%) (Cervigni 2014; Chen 2005; Chen 2014; Chuang 2017; Davis
2008; Evans 2011; FitzGerald 2012; Foster 2010; Gottsch 2011;
Gulpinar 2015; Ham 2012; Irani 2004; Kuo 2009; Kuo 2016; Lazzeri
1996; Leadership 201 Trial 2016; Lu 2015; Manning 2014; Mayer
2005; Nickel 2009; Nickel 2010; Nickel 2012a; Nickel 2012b; Nickel
2015; Nickel 2016; Nomiya 2017; Payne 2014; Pinto 2016; Sairanen
2005; Sant 2003; Souza 2012; van Ophoven 2004; Wang 2017a;
Warren 2000; Yang 2011); high in two studies (2%) (El-Hefnawy
2015; Korting 1999); and unclear in 15 studies (19%) (Bosch 2014;
Dimitrakov 2001; Geirsson 1993; Gulpinar 2013; Hanno 2015; Ismail
2016; Kasyan 2012; Lazzeri 2000; Matsumoto 2013; Mirkin 2012;
Moldwin 2015; Mulholland 1990; Peters 1997; van Ophoven 2006;
Yassin 2011).
Selective reporting
We considered that there was low risk of reporting bias when the
results of all outcomes specified in the methods were reported.
Studies were considered at high risk of bias when outcomes
specified in the methods were missing or were partially reported in
the results, or when outcomes not specified in the methods were
reported in the results. Risk of reporting bias was considered to
be high in five studies (6%) (due to limited information available)
(Barbalias 2000; De Ridder 2013; Herati 2011; Payne 2014; Peeker
2000); unclear in eight studies (10%) (Ahmadnia 2011; Dimitrakov
2001; Hanno 2015; Lu 2015; Moldwin 2015; Sairanen 2009; Singh
2003; Taha 2007); and low in the remaining 68 studies (84%).
Other potential sources of bias
In one cross-over study (Peeker 2000), participants were randomly
allocated to a treatment, and if they did not improve, they were
crossed over to the other treatment. The analysis was conducted
at the end of the study period; therefore, treatment eFects in
this study could have been estimated aLer most (if not all) of the
participants had received both treatments. As such, we judged this
study to be at high risk of other bias. No other potential sources of
bias were identified in the other studies.
E:ects of interventions
See: Summary of findings 1 Interventions for treating people with
symptoms of bladder pain syndrome
We included 81 randomised controlled trials (RCTs) with a total
of 4674 participants and a median of 38 participants (range 10
to 369). Most trials compared treatment against control; few
trials compared two active treatments. There were 65 diFerent
active treatments, and some comparisons were informed by direct
evidence from only one trial.
Data from one study could not be included in the statistical
analyses as participants with interstitial cystitis (IC)/painful bladder
syndrome (PBS) were a subgroup of the study population
(including chronic prostatitis (CP)/chronic pelvic pain syndrome
(CPPS)), but randomisation was not stratified according to clinical
diagnosis (FitzGerald 2009).
For some outcomes, certain treatments were not part of a
connected network and therefore could not be evaluated against
control within the network meta-analysis (NMA). This occurred, for
example, when a pair of active treatments were included only in
a particular head-to-head trial but not in any other trials in the
review.
As reported in the Methods, we present one 'Summary of
findings' table with three interventions: antidepressants (including
amitriptyline), pentosan polysulfate and neuromuscular blockade
(injection of botulinum toxin type A). GRADE ratings for the other
interventions can be found in Table 4, Table 5, Table 6 and Table 7.
Primary outcomes
Proportion of participants whose symptoms were cured or
improved
Figure 5 shows the network diagram with the number of trials
assessing each pair of treatments in the network for the proportion
of participants cured or improved. A majority of trials compared an
active treatment versus control. All trials were contained within a
connected network; therefore an NMA was conducted.
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Figure 5.   Network diagram for the proportion of participants whose symptoms were cured or improved. The
thickness of each line is proportionate to the number of included studies.
 
Forty-three trials with usable data for the cure outcome were
identified, forming a network of 20 treatment categories: control,
two types of conservative therapy, 13 types of pharmacological
treatments, one surgical intervention and three combination
therapies of two diFerent pharmacological interventions. Most
trials had two treatment arms, but one trial included four treatment
arms (Sant 2003). Trials were generally small; only five trials
provided data for over 100 participants.
ALer the initial NMA models were run in WinBUGS, the diagnostic
plots suggested that results for hyperbaric oxygen (HBO) were
unstable and the model failed to converge. This treatment was
assessed in only one trial in which three participants in the HBO
group were cured or improved compared with none in the control
group (van Ophoven 2006). As such, the lack of convergence is
likely to be related to the zero cell count. For this trial, we followed
the advice of the National Institute for Health and Care Excellence
Decision Support Unit Technical Support Documents 2 (NICE DSU
TSD 2) and added 1 to the denominator and 0.5 to the numerator in
each group (Dias 2016). No adjustment was necessary for the other
trial that had a zero cell count, as this was one of several studies
that compared neuromuscular blockade with control (Payne 2014).
The results for all other treatments showed good convergence.
Figure 6 and Table 4 show results of the final NMA for each of the
19 active treatment categories versus control. Median odds ratios
(ORs) from the NMA were above 1 for 18 treatment categories,
indicating favourable cure rates versus control, but the 95%
credible intervals (CrIs) were wide, reflecting the small number and
size of available trials. Very low-certainty evidence suggests that
the following treatment categories were eFective versus control:
behavioural therapy (OR 9.42, 95% CrI 1.01 to 110.83), physical
therapy (OR 6.78, 95% CrI 1.08 to 46.85), antidepressants (OR 5.91,
95% CrI 1.12 to 37.56), immune modulators (OR 2.74, 95% CrI 1.16
to 6.57), phosphodiesterase-5 (PDE5) inhibitors (OR 24.53, 95% CrI
1.21 to 1255.14) and neuromuscular blockade (OR 5.80, 95% CrI 2.08
to 18.30).
 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Figure 6.   Meta-analysis results for proportion of participants whose symptoms were cured or improved. For each
treatment category, the unbroken horizontal line represents the odds ratio (95% CrI) versus control from the
network meta-analysis, and the dotted line represents the odds ratio (95% CI) versus control from the pairwise
meta-analysis (if applicable). The number of studies included in each analysis is also shown. Intervals less than 0.3
and greater than 40 have been truncated.
 
A comparison of results of the network and pairwise meta-analyses
is provided in Figure 6 and Table 4. The results were generally
consistent, although in both sets of analyses, there was a wide
range of uncertainty about the true eFects of treatment. The
pairwise results suggested benefits for two additional treatments:
antibiotics and pentosan polysulfate (PPS) plus antihistamines
(Table 6; Figure 4).
We assessed the heterogeneity and consistency assumptions of
the NMA. Three of the nine pairwise comparisons containing more
than one study were associated with an I2 statistic greater than
50%, suggesting important heterogeneity. There were relatively few
closed loops within the network by which to assess the consistency
assumption, but a global test based on a random-eFects design-
by-treatment interaction model in CINeMA suggested evidence of
inconsistency (P = 0.02) that was primarily associated with the
results for chondroitin sulfate versus control. Overall, however,
results of the NMA and the pairwise meta-analysis seemed to be
consistent, considering the wide CrIs and confidence intervals (CIs).
Pain score
We were able to include a variety of continuous pain scales in the
analyses. Scores were re-scaled so that 0 represented no pain and
10 the worst possible pain. No categorical measures of pain were
included in the analyses.
Figure 7 shows the network diagram for the pain outcome.
Most comparisons in the network were against control. One
trial comparing hyaluronic acid with anticoagulants plus local
anaesthetics was disconnected from the rest of the network and
therefore could not be included in the NMA (Lu 2015). Of the 51
studies comprising 25 active treatment categories that could be
included, 28 had final score data for pain. For the remaining 23
studies, change score data had to be used.
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Figure 7.   Network diagram for pain score. The thickness of each line is proportionate to the number of included
studies.
 
Results for the NMA are shown in Figure 8 and Table 5. Moderate-
certainty evidence shows that physical therapy reduced pain
compared with control by around 4 points on a 0 to 10 scale
(mean diFerence (MD) -3.92, 95% CI -5.80 to -1.94). However,
this comparison contained two studies with very heterogeneous
results. One study showed an extreme eFect, with mean (standard
deviation (SD)) pain scores of 2.6 (0.13) and 9.4 (0.21) in the
treatment and control groups, respectively, at four months' follow-
up (Zakaria 2016). The other study showed a more modest
eFect (mean pain scores of 3.8 and 4.3, respectively) (FitzGerald
2012). Due to this heterogeneity, caution should be applied when
interpreting these results. There is no clear evidence that any other
treatment categories were eFective.
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Figure 8.   Meta-analysis results for pain score. For each treatment category, the unbroken horizontal line represents
the mean di:erence (95% CrI) in VAS (0-10) versus control from the network meta-analysis, and the dotted line
represents the mean di:erence (95% CI) versus control from the pairwise meta-analysis (if applicable). The number
of studies included in each analysis is also shown.
 
The pairwise meta-analyses generally provided similar eFect sizes
to the NMA, but CIs tended to be narrower (Figure 8; Table 5). There
was important heterogeneity (I2 > 50%) for four of nine pairwise
comparisons with at least two studies. There were no concerns
about the consistency of the NMA itself (P value for interaction =
0.18), but it was diFicult to assess this assumption as there was only
a small number of closed loops within the network, which meant
that few comparisons between direct and indirect eFect estimates
could be made (the primary way that consistency in an NMA can be
addressed).
Daytime frequency (number of voids)
The network diagram for the frequency outcome is shown in Figure
9. Fourteen treatment categories are included in this network,
but 23 of the 27 trials compared a single treatment against
control, resulting in a network that was nearly completely "star-
shaped", which meant that there were few closed loops within
the network, which makes it diFicult to assess consistency in
results of the NMA. Six treatments could not be included as they
are not connected to the rest of the network. These include
denervation and hydrodistension (compared only in El-Hefnawy
2015); dimethyl sulfoxide (DMSO) and chondroitin sulfate plus
hyaluronic acid (compared only in Cervigni 2014); and hyaluronic
acid and anticoagulants plus local anaesthetics (compared only in
Lu 2015). Eighteen studies in the network contributed final score
data, and six studies contributed change score data.
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Figure 9.   Network diagram for daytime frequency (number of daytime voids). The thickness of each line is
proportionate to the number of included studies.
 
The NMA results are presented in Figure 10 and Table 6.
These yielded moderate-certainty evidence that the combination
of neuromuscular blockade plus DMSO was associated with a
reduction of around nine voids per day compared with control (MD
-8.97, 95% CrI -15.23 to -2.81).
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Figure 10.   Meta-analysis results for daytime frequency (number of daytime voids). For each treatment category,
the unbroken horizontal line represents the mean di:erence (95% CrI) in number of daytime voids versus control
from the network meta-analysis, and the dotted line represents the mean di:erence (95% CI) versus control from
the pairwise meta-analysis (if applicable). The number of studies included in each analysis is also shown.
 
The pairwise meta-analyses generally yielded similar results but
also suggested benefits for four additional treatment categories
(behavioural therapy, anticytokines, PPS and antidepressants)
(Figure 10; Table 6). There was evidence of heterogeneity (I2 >
50%) for one of the four pairwise comparisons with at least two
studies. There were some concerns about consistency within the
only closed loop within the network involving immune modulators,
PPS and control (P value for interaction = 0.007).
Nocturia (number of nighttime voids)
Figure 11 shows the network diagram for nocturia. Again, there
were relatively few closed loops, resulting in a network that
was almost star-shaped, with all treatments compared only
with control, except for one comparison of PPS and immune
modulators. Once again, the denervation and hydrodistension
treatment categories could not be included, as they were not
connected to the rest of the network (El-Hefnawy 2015). Thirteen
studies in the network contributed final score data, and three
studies contributed change score data.
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Figure 11.   Network diagram for nocturia (number of nighttime voids). The thickness of each line is proportionate to
the number of included studies.
 
The NMA results did not yield any treatment categories with a
95% CrI excluding zero, so there was no clear evidence that
any treatments were beneficial in reducing nocturia (Figure 12;
Table 7). The advantage of an NMA in this situation may not
be particularly large due to the star-shaped network. However,
the corresponding pairwise meta-analyses suggested favourable
results for behavioural therapy, PDE5 inhibitors and PPS (Figure
12; Table 7). One of the two comparisons with at least two studies
was associated with important heterogeneity (I2 > 50%). There was
again only a single closed loop within the network, but there were
no concerns about inconsistency (P value for interaction = 0.10).
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Figure 12.   Meta-analysis results for nocturia (number of nighttime voids). For each treatment category, the
unbroken horizontal line represents the mean di:erence (95% CrI) in number of nighttime voids versus control from
the network meta-analysis, and the dotted line represents the mean di:erence (95% CI) versus control from the
pairwise meta-analysis (if applicable). The number of studies included in each analysis is also shown.
 
Secondary outcomes
Subjective symptom measures (combining frequency, nocturia
and pain)
Although studies reported symptoms in a variety of ways, we
included only data for the Interstitial Cystitis Symptom Index (ICSI)
subscale because this was the most commonly reported subjective
measure across trials. On the ICSI subscale, 0 represented the
lowest possible and 20 the highest possible severity of symptoms.
We did not include studies that reported the ICSI and Interstitial
Cystitis Problem Index (ICPI) Scales combined.
The network diagram for the ICSI outcome is shown in Figure
13. Compared with other outcomes, the number of connections
between treatments was relatively high, although most treatments
were compared to control. Eighteen studies contributed final
score data, and 12 studies (including Sant 2003, a four-arm trial)
contributed change score data. Evidence from the NMA suggests
that PDE5 inhibitors reduced symptoms by around 6 points on a 0
to 20 scale (MD -6.02, 95% CrI -9.05 to -2.93) (Table 8).
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Figure 13.   Network diagram for subjective symptom measures (combining frequency, nocturia and pain) - ICSI. The
thickness of each line is proportionate to the number of included studies.
 
The pairwise meta-analyses also suggested benefits for
antidepressants and for AQX-1125 (Table 8).
Quality of life (including symptom bother)
We included only studies that had reported the ICPI subscale
because it was the most commonly reported quality of life measure
across trials. In ICPI, scores of 0 represented the highest possible
quality of life and scores of 16 the lowest possible quality of life.
The network diagram for the ICPI diagram was the same as that for
ICSI but with a slightly reduced number of trials involved (Figure
14). Eighteen studies contributed final score data, and 10 studies
contributed change score data.
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Figure 14.   Network diagram for quality of life - ICSI. The thickness of each line is proportionate to the number of
included studies.
 
There was no clear evidence from the NMA suggesting that any
treatment category was eFective in reducing quality of life as
measured by this scale (Table 9). The corresponding pairwise meta-
analyses suggested benefits for four additional treatments: local
anaesthetics; PDE5 inhibitors; antidepressants; and AQX-1125.
Functional bladder capacity (descriptive statistics)
Limited data were available for the outcome of functional bladder
capacity, and no meta-analyses were performed because of
variation in the way this outcome was reported across studies
(Table 10). In general, diFerences in mean between groups, or
changes in mean from baseline in each group, appear small and
were in the range of 30 mL or less. Although not empirically tested,
it has been suggested that an increase in bladder capacity of 30
mL may not be clinically relevant (Hanno 2017). A slightly larger
diFerence between groups (from about 40 to 60 mL in terms of MD)
was observed in one trial comparing immune modulator (bacillus
Calmette-Guérin (BCG)) and control (Irani 2004), as well as in two
further trials comparing neuromuscular blockade versus control
(Kuo 2009; Manning 2014), but reported P values (0.165, 0.05 and
0.27, respectively) indicate that there is no evidence of a diFerence
between treatment groups.
Adverse events
Table 11 shows the number of participants experiencing at least
one adverse event. Classifications and definitions of adverse events
were described as reported by trial investigators and were not
directly comparable across studies. In many cases, trial authors
grouped adverse events under the broad categories of ‘adverse
events’ or ‘serious adverse events’ without specifying the types of
events. Due to variation in the way in which adverse events were
reported, we were unable to conduct meta-analyses.
Although a large number of participants experienced one or
more adverse event in most trials, these events were reported
to be primarily mild to moderate in severity, and the treatments
under study were reported to be reasonably well tolerated, with
similar percentages of participants between groups experiencing
undesirable eFects.
Some trials reported relatively more adverse events with
intervention than with control. Warren 2000 reported that adverse
events occurred in 80% (20 out of 25) of participants taking
antibiotics compared with 40% (10 of 25) taking placebo, with
nausea and/or vomiting the most common event category. This
led to discontinuation of 10 courses of antibiotics due to perceived
adverse events, compared with two in the placebo group (reported
P value of 0.018). van Ophoven 2004 reported a higher incidence
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of anticholinergic side eFects, particularly mouth dryness, in the
group taking an antidepressant (amitriptyline) compared with the
placebo group (92% (22 of 24) versus 21% (5 of 24)), although
the reported events were not considered by trialists to be severe
(grade 3 or higher). Kuo 2016 reported significantly more adverse
events in the group that received botulinum toxin A compared with
the control group (dysuria was the most common adverse event),
although these adverse events were judged to be manageable
and acceptable. In Sairanen 2005, there were more adverse events
in the immune modulator (cyclosporin A) group than in the PPS
group (94% (30 of 32) versus 56% (18 of 32)), but withdrawals were
reported to be similar in both study arms. In five trials comparing
calcium channel agonists (e.g. capsaicin, resiniferatoxin) versus
control, pain during instillation was commonly reported among
participants in the intervention group (Chen 2005; Ham 2012;
Lazzeri 1996; Lazzeri 2000; Payne 2005).
The number of participants experiencing serious adverse events is
shown in Table 12. Definitions of serious adverse events were those
reported by trial investigators. Overall, serious adverse events
appear uncommon (≤ 3% within the study group). In trials where a
greater number of serious adverse events were reported (possibly
due to diFerent definitions used), overall event rates appear similar
between study arms.
For example, in one trial comparing immune modulators (BCG) and
placebo (Mayer 2005), rates of ‘severe’ events (defined as grade 3 on
the Common Toxicity Criteria) were 50% (64 of 129) in the treatment
group and 48% (63 of 132) in the placebo group. This study also
reported a total of 32 ‘serious’ adverse events in 21 participants,
although the number in each group was not reported. Two of these
were associated with the study drug (BCG hypersensitivity reaction
in one patient in the BCG group, and prostatitis and urinary tract
infection (UTI) in one patient in the placebo group).
Nickel 2009 reported that ‘severe’ adverse events were experienced
by 8% (4 of 50) and 10% (5 of 52) of participants receiving local
anaesthetic (PSD597, intravesical alkalised lidocaine) and placebo,
respectively. The most common event was bladder pain, which
usually resolved within a day of instillation.
Evans 2011 reported ‘serious’ adverse events in 7% (2 of 29) of
participants treated with immune modulator and in 20% (4 of 20)
of those who received placebo. Events associated with immune
modulator treatment included ‘vertigo’ and ‘drug exposure during
pregnancy’, and ‘cholelithiasis’, ‘ovarian mass’, ‘urosepsis/urinary
tract infection’ and ‘transient ischaemic attack’ were associated
with placebo.
D I S C U S S I O N
Summary of main results
Results of the network meta-analysis (NMA) suggest that the
following treatment categories appear eFective versus control for
treatment of bladder pain syndrome (BPS), although a degree of
caution is required in interpreting these results because of the small
number of studies and the wide credible intervals.
Primary outcomes (level of certainty)
• Proportion cured or improved: behavioural therapy (very low),
physical therapy (very low), antidepressants (very low), immune
modulators (very low), phosphodiesterase-5 (PDE5) inhibitors
(very low) and neuromuscular blockade (very low)
• Pain: physical therapy (moderate)
• Frequency: neuromuscular blockade plus dimethyl sulfoxide
(DMSO) (moderate)
• Nocturia: no evidence from the NMA that any treatment category
was eFective
Secondary outcomes
• Interstitial Cystitis Symptom Index (ICSI): PDE5 inhibitors
• Interstitial Cystitis Problem Index (ICPI): no evidence from the
NMA that any treatment category was eFective
Because relatively few trials compared two non-control treatments,
the benefit of using an NMA approach for some outcomes may
have been relatively small, and this method may have produced
results that were more conservative than the corresponding
pairwise meta-analysis results. The results of these were generally
consistent with the NMA, but as confidence intervals (CIs) tended
to be slightly narrower, a wider range of treatments had CIs that
excluded the null eFect.
For the proportion of participants who were cured or improved,
the point estimate for the odds ratios (ORs) for treatment versus
control was generally above two, suggesting large eFects that could
perhaps be considered clinically important. However, credible
intervals (CrIs) were very wide, reflecting that only a small
number of studies were available for each comparison, and that
sample sizes for included studies were generally small. For most
treatments, the CrI also included values that were within the range
specified as unlikely to be clinically important for our review (0.8 to
1.25). Similar findings were observed for continuous outcomes.
A descriptive analysis based on limited available data for
assessment of functional bladder capacity suggests a relatively
small diFerence between study arms. This diFerence is unlikely to
be clinically relevant.
In general, treatments under investigation were reported to
be reasonably well tolerated, and adverse events were usually
reported to be mild or moderate in severity. Serious adverse
events appear relatively uncommon for all interventions under
investigation. As information on adverse events is limited, and
given that adverse events were reported in various ways, we could
not meta-analyse results or assess certainty of the evidence.
Overall completeness and applicability of evidence
This review included 81 randomised controlled trials (RCTs)
involving a total of 4674 participants. A majority of studies were
parallel-arm trials with a small sample size (median 38) and
short follow-up (median three months). Six studies were cross-
over RCTs. The included studies evaluated 31 active treatment
categories (grouped by mode of action). The most commonly
evaluated treatment categories were immune modulators (e.g.
bacille Calmette-Guérin (BCG), tanezumab) in 15 studies (Bosch
2014; Dimitrakov 2001; Evans 2011; Irani 2004; Mayer 2005; Nickel
2016; Oliver 2013; Peeker 2000; Peters 1997; Sairanen 2005;
Sairanen 2009; Shirvan 2015; Taha 2007; Wang 2017a; Yang 2011);
neuromuscular blockade in 13 studies (e.g. onabotulinumtoxinA)
(Ahmadnia 2011; Chuang 2017; Gottsch 2011; Ismail 2016; Kasyan
2012; Kuo 2009; Kuo 2016; Manning 2014; Mirkin 2012; Payne 2014;
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Pinto 2016; Taha 2007; Yassin 2011); calcium channel agonists in
seven studies (e.g. capsaicin, resiniferatoxin (RTX)) (Chen 2005;
Ham 2012; Kim 2012; Lazzeri 1996; Lazzeri 2000; Nickel 2012b;
Payne 2005); DMSO in six studies (Cervigni 2014; De Ridder 2013;
Peeker 2000; Perez-Marrero 1988; Sairanen 2009; Singh 2003); and
pentosan polysulfate (PPS) in six studies (Bade 1997; Davis 2008;
Mulholland 1990; Nickel 2015; Sairanen 2005; Sant 2003). However,
most treatment categories were assessed only in single trials. Study
participants had various diagnoses including interstitial cystitis
(IC), bladder pain syndrome (BPS), painful bladder syndrome
(PBS) and painful bladder disease (PBD). It is worth noting that
although there is significant overlap, these clinical diagnoses are
not identical. This reflects the fact that the aetiology of BPS and
validated diagnostic criteria have yet to be established.
We did not impose any language or other limitations on the
literature search, which should help ensure overall completeness
of the evidence. A further updated search of the Cochrane
Incontinence Specialised Register was undertaken on 5 June 2019.
Of the 45 records retrieved by the search, 15 reports of 14 studies
appeared to meet the inclusion criteria for this evidence synthesis:
five reports of four new studies; three additional reports of three
already included studies; and seven trial registrations of seven
ongoing studies. The four new studies were all small (ranging
from 15 to 42 participants) (Aboyan 2018; Bosch 2018; Cervigni
2018; Oh-Oka 2017). Only one of these studies covered one of the
comparisons included in our NMA (hyaluronic acid alone compared
with hyaluronic acid in combination with chondroitin sulphate)
(Aboyan 2018). Further details are given in the Characteristics of
studies awaiting classification table. None of these study reports
have been incorporated into the current evidence synthesis.
A strength of this work is that we have been able to assess
all treatments for BPS, including many diFerent conservative,
pharmacological and surgical interventions, within a single
analysis. NMA is a relatively new method that is well suited to
this type of evidence synthesis, wherein a large number of trials
evaluate a large number of treatments. Its key advantage is that
it can incorporate both direct and indirect evidence between each
pair of treatments.
Nevertheless, the limited number of small trials available for
each treatment category hindered our ability to fully exploit the
advantages of NMA. This was compounded by the fact that most
treatments were compared with placebo or control, sometimes
resulting in a so-called ‘star-shaped’ network. Consequently, Crls
tended to be wide, indicating great uncertainty in eFect estimates.
There were also some diFerences in results of the pairwise meta-
analyses. These more conservative results from NMA are not
unexpected when the network is mainly star-shaped and there are
few connections between pairs of non-control treatments (Filippini
2013).
We did not compare pairs of active treatments directly because
there were too many combinations of treatments and the degree
of uncertainty was considerable. A small number of treatments
could not be assessed because they were disconnected from the
rest of the network. We also decided not to use the NMA to rank
treatments. It was diFicult to assess the consistency assumption
of the NMA due to the small number of closed loops within most
networks, which meant that we were generally unable to compare
the evidence from direct and indirect estimates of eFect to check
that these were consistent.
A further methodological challenge was that definitions of
treatments and reported outcomes were heterogeneous across
trials. We grouped treatments into broad categories, and within
these there was oLen variation in types of treatments and
how these were delivered. Some trials evaluated two treatments
delivered in combination, and incorporating these into the
analyses was sometimes challenging. Finally, we included a range
of therapies that may be considered either first- or second-
line treatments but did not consider this in our analyses. The
populations of included participants in each trial may have diFered
in terms of symptom severity. An assumption of the NMA is that
included patients could be randomised to any of the treatments,
but in practice this may not have been the case.
No common single outcome was assessed by all included trials.
Outcomes that were conceptually similar were measured in
diFerent ways. For example, pain was reported as measured
by diFerent scales or assessment tools. Continuous outcomes
were reported as mean scores at last follow-up or as mean
changes from baseline, and very few studies reported data in both
formats. Outcome definitions were oLen unclear or ambiguous,
and standard deviations (SDs) and denominators were not always
provided. Considerable additional work was required to make
extracted data suitable for the statistical analyses. Despite this
additional eFort, a sizeable number of studies oLen provided no
usable data.
For the small number of cross-over trials that provided usable
data, we used data from the first period only, as none provided
information to approximate a paired analysis. This may have
introduced bias and loss of precision, but the impact is likely to be
small.
Although Cochrane recommends using final scores rather than
change scores for continuous outcomes, roughly half of the
included studies reported only change scores. We were successful
in incorporating both types in the meta-analyses, but this
complicated the analysis. We were able to utilise National Institute
for Health and Care Excellence Decision Support Unit (NICE DSU)
programmes that allowed data as both change and final scores, as
well as multi-arm trials, to be used.
Another limitation of this work is that no subgroup analyses nor
sensitivity analyses were carried out. Due to the multi-factorial
aetiology of BPS, which is yet to be established, heterogeneity of the
trial populations was anticipated, but we were not able to identify
specific sources of heterogeneity worthy of further exploration.
Future updates of this review could consider subgroup analyses
or network meta-regression, if possible, and could consider a
sensitivity analysis to explore the eFect of including studies with
high risk of bias.
Clinical characteristics of study participants included BPS with
Hunner's lesions (classic diagnosis of IC). However, in most of
the included studies, results were not reported separately for this
subgroup. Therefore, we are not in a position to comment on
the applicability of findings to patients with or without Hunner's
lesions, who may show diFerent responses to treatment.
Quality of the evidence
We assessed the overall certainty (quality) of evidence for the
primary outcomes using the GRADE approach as modified for
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network meta-analysis (Salanti 2014), via the CINeMA 2017 web
application. The overall certainty of evidence was moderate at best,
and was low or very low for most outcomes. Evidence level was
most oLen downgraded for within-study risk of bias, imprecision
and heterogeneity. The quality of reporting was insuFicient in
most trial reports included in the review, and this may have
contributed to downgrading of the certainty of evidence. However,
these assessments may be conservative, as they were dependent
on the choice of minimal clinically important diFerence (MCID) and
subjective judgements in interpreting CINeMA guidance to enable
GRADE assessment.
Potential biases in the review process
Although two review authors independently assessed the eligibility
of published trial reports for inclusion in this review, data extraction
and risk of bias assessment were carried out by one review
author and were checked by another review author. The GRADE
assessment of the certainty of evidence was conducted by two
review authors working together, not independently, reaching
consensus in discussion. This was a pragmatic decision due to
resource constraints and may carry some risk of bias.
Agreements and disagreements with other studies or
reviews
To the best of our knowledge, this review represents the
first comprehensive assessment of published evidence for all
interventions for BPS evaluated in RCTs. A narrative systematic
review on interventions for BPS and IC published in 2016 identified
the lack of high-level evidence in this area, as well as clinical and
methodological heterogeneity in published studies (Pazin 2016),
which is in line with the findings of the current review.
Recent systematic reviews of RCT evidence focused on individual
interventions including PPS and onabotulinumtoxinA (Lee 2019;
van Ophoven 2019). Other recent systematic reviews incorporating
non-randomised evidence also focused on specific interventions
such as cyclosporin A (Wang 2016); intravesical therapy (Barua
2016); intravesical hyaluronic acid with chondroitin sulfate (Pyo
2016); hydrodistension (Olson 2018); sacral modulation (El-Azab
2019; Wang 2017b); and complementary therapy (Verghese 2016).
These reviews found only limited eFicacy and pointed to a small
evidence base and diversity in study populations, interventions
and outcome measures, as well as insuFicient descriptions of
study methods used, which hindered further assessment to identify
eFective treatment options for BPS.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review includes evidence from direct and indirect
comparisons of existing treatments for BPS. These range from
conservative treatments to surgical interventions. Very low-
certainty evidence suggests that behavioural therapy, physical
therapy, antidepressants, immune modulators, PDE5 inhibitors
and neuromuscular blockade may be eFective in treating some, if
not all, of the symptoms of BPS. However, due to limitations of the
current evidence base, it is diFicult to identify treatments that are
superior to others.
Until further evidence for therapies for managing and treating
pelvic floor dysfunction becomes available, developing a multi-
disciplinary model of care, which involves not only the
clinicians who traditionally treat BPS but also other professionals
(including physical therapists, psychotherapists, pain management
specialists and clinicians from other specialties) when non-bladder
symptoms or disorders, as well as patient support groups, are part
of the clinical picture, seems to be the best way forward.
Implications for research
An attempt to harmonise definitions and measurement tools across
research groups would be useful, as would the use of tools that
capture patient-reported outcomes. In particular, a definition of
pain and the way to measure it should be clearly reported in future
studies.
It is worth noting that BPS remains an unclear and controversial
condition with unknown aetiology and no accepted diagnostic
markers. Future research designed to better understand this
clinical condition and consequently manage patients more
eFectively is clearly needed. In particular, there is a need to
understand the pathophysiological processes involved in BPS and
how these interrelate with chronic pelvic pain syndromes, and to
identify both systemic and bladder-specific biomarkers (e.g. nerve
growth factors, angiogenic growth factors, cytokines chemokine
profiles). Better clinical phenotyping of BPS patients would allow
health professionals to tailor specific treatments to individual
patients. For trials that focus on BPS patients, it would be helpful
to analyse data from patients with Hunner’s lesion and from those
with non-lesion disease separately, as these two groups of patients
may respond diFerently to treatment.
According to the 6th International Consultation on Incontinence
(Hanno 2017), as well as the US Food and Drug Administration
(FDA) Bone, Reproductive and Urologic Drugs Advisory Committee
(BRUDAC) 2018 criteria for IC/BPS (Nickel 2018), future research
should cover the following clinical areas.
• Pathology of BPS.
• Biomarker development.
• Immunology of BPS.
• Neurological aspects, with particular attention to the
relationship of BPS and overactive bladder.
• The relationship of bladder pain syndrome to chronic pelvic pain
syndrome (non-bacterial prostatitis).
• Expanded definitions of bladder pain developed with the
patient.
• Input, to include burning, pressure and discomfort.
• Validated patient-reported outcome instruments as
recommended when the eFicacy of drugs for treatment of
patients with symptoms of BPS is assessed.
• Development of a simple, non-invasive diagnostic test for BPS.
• Development of a multi-disciplinary care model.
In addition, patient-relevant outcomes should be used in future
trials for assessing interventions for BPS. Large, high-quality trials
assessing specific interventions or comparisons of interventions
with longer follow-up are needed. Current small trials testing
numerous diFerent interventions may be considered as research
waste if they do not yield clinically useful knowledge. It is clear
that researchers need to perform sample size calculations to ensure
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that studies have appropriate statistical power to answer research
questions.
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Study characteristics
Methods Study design: RCT
Study duration (months): 1
Ahmadnia 2011 
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Age, years: not reported
Diagnosis: PBS
Inclusion criteria: patients (female) with painful bladder syndrome refractory to conventional oral
therapies
Exclusion criteria: not reported
Interventions Group A (n = 12): 200 IU botulinum toxin A into trigone and lateral walls
Group B (n = 12): NaCl
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis (no usable data)
Funding Not reported.
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly divided"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. "Under short general anesthesia in the study group
botulinum toxin A … was used, and in the control group, normal saline was in-
jected through cystoscopic needle submucosally into trigone and lateral walls
of the bladder"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Blinding not mentioned. "Under short general anesthesia in the study group
botulinum toxin A … was used, and in the control group, normal saline was in-




Unclear risk Outcomes not specified in Methods (abstract only)





Methods Study design: RCT
Bade 1997 
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Study duration (months): 3




Age, years: mean 52.8, range 24 to 79
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients with IC
Exclusion criteria: not reported
Interventions Group A (n = 10): pentosan polysulfate (PPS)
Group B (n = 10): unspecified placebo
Three months of twice-weekly instillations; each instillation for as long as tolerable
Treatment category in NMA: PPS vs control
Outcomes Outcome data in analysis
Cure or improvement: improved subjective symptoms using visual analogue scale (1 point or greater
reduction on the severity scale scoring 0 to 5 points): at 3 months
Frequency: at 3 months
Nocturia: at 3 months
Funding Not reported
Notes Publication status: full text
[Notes from previous versions of the review] Attempted study author contact regarding SD for data,
pain as outcome and who had UTI; received no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "assigned randomly using a code... After receiving treatment for 3
months, the code was broken..."
Allocation concealment
(selection bias)
Unclear risk Quote: "assigned randomly using a code... After receiving treatment for 3
months, the code was broken..."





Unclear risk "double-blind, placebo-controlled study". Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk "double-blind, placebo-controlled study". Placebo not described
Bade 1997  (Continued)
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Low risk 9/10 (90%) included in intervention group (1 dropped out due to persisting




Low risk 9/10 (90%) included in intervention group (1 dropped out due to persisting
symptoms); 10/10 included in control group
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6




Age, years: mean 45, range 26 to 69
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: women with diagnosis of IC
Exclusion criteria: not reported
Interventions Group A (n = 24): oxybutinin (10 mg tablets dissolved in 500 mL saline)
Group B (n = 12): saline alone
Filling to point of first desire to void. Catheter then clamped and released when at functional capacity.
Further single days of treatment, weekly for 6 weeks, then monthly for 3 months. One week of inpatient
treatment involving repeated cycles of bladder filling
Treatment category in NMA: anticholinergics vs control
Outcomes Outcome data in analysis
Frequency: at 6 months
Funding Not reported
Notes Publication status: full text
[Notes from previous versions of the review] Attempted study author contact re SD for data, pain as
outcome, details of dropouts; received no response
Barbalias 2000 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "in a randomized fashion by computer assigned numbers"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. "In the control group the bladder was filled only with
normal saline and the same protocol guidelines were maintained as in the oxy-
butynin group". Intravesical instillation
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Blinding not mentioned. "In the control group the bladder was filled only with
normal saline and the same protocol guidelines were maintained as in the oxy-




Unclear risk Number analysed unclear. 1/24 dropped out from intervention group; 4/12
dropped out from control group; it is not clear how missing data were handled
Selective reporting (re-
porting bias)
Unclear risk "Clinical amelioration" (cure) was defined but not fully reported in results





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 43
Setting: single centre
Country: USA
Sex: 34 females and 9 males
Age, years: mean 45.2 (SD 14.0) for Group A, mean 46.5 (SD 13.4) for Group B
Diagnosis: IC/BPS, moderate to severe
Inclusion criteria: men and women 18 to 65 years old, previously diagnosed with moderate or severe
IC/BPS. Fulfilment of certain criteria including symptoms of urinary urgency, frequency or pain longer
than 6 months, urinating at least 7 times a day, total score of 18 or greater on the OSPI and score of 15
or greater on the PUF
Exclusion criteria: microbiologically proven urinary tract infection within 6 weeks at screening or ran-
domisation; gross haematuria; intravesical therapy a month before or during the study; and/or histo-
ry of malignancy, diabetes, central nervous system demyelinating disease, tuberculosis, hepatitis B,
hepatitis C or human immunodeficiency disease. Female patients must not have been pregnant or lac-
tating and must have used adequate birth control during the study. History and physical examination,
comprehensive metabolic chemistry panel, complete blood count, urinalysis and culture, hepatitis B
virus serology and a purified protein derivative skin test were also required
Bosch 2014 
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Interventions Group A (n = 21): subcutaneous adalimumab. 80 mg loading dose, followed by 40 mg every 2 weeks
Group B (n = 22): subcutaneous placebo
Participants were allowed to continue on current medications except medications listed in the exclu-
sion criteria
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Cure or improvement: 'moderately' or 'markedly' improved on GRA: at 12 weeks
ICSI: at 12 weeks
ICPI: at 12 weeks
Adverse events: at 12 weeks (assumed from paper)
Funding AbbVie (pharma business)
Notes Publication status: full text
The study was terminated early 'after half of the 43 patients demonstrated a dramatic and statistically
significant clinical improvement'
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomised"
Allocation concealment
(selection bias)
Unclear risk Quote: "randomised in blinded fashion"





Low risk Quote: "'double blind"; "the study drug and placebo were provided in ready to
use unit dose syringes that were identical"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Unclear risk Number analysed unclear. 2/21 dropped out from intervention group (due to
"lack of efficacy"); 2/22 dropped out from placebo group (medical reasons un-










Unclear risk Number analysed not stated
Bosch 2014  (Continued)
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Unclear risk Number analysed not stated
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 2




Age, years: average 44
Diagnosis: IC
Inclusion criteria: women with IC
Exclusion criteria: not reported
Interventions Group A (n = 15): guided imagery. Listen to a 25-minute CD twice a day for 8 weeks
Group B (n = 15): rest for 25 minutes twice daily for 8 weeks
Treatment category in NMA: behavioural therapy vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 8 weeks
Pain: VAS (assumed range 0 to 10): at 8 weeks
ICSI: at 8 weeks
ICPI: at 8 weeks
Funding Ministrelli Program for Urology Research and Education (MPURE)
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized … by drawing from a shuffled set of folders that included
hidden notations of "Treatment group" or "Control group""
Carrico 2008 
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Allocation concealment
(selection bias)
Low risk Quote: "randomized by a blinded research staF member not involved in the
study by drawing from a shuffled set of folders that included hidden notations





High risk Probably not done. 25-minute guided imagery compact disc vs sitting or lying
down for 25 minutes
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Probably not done. 25-minute guided imagery compact disc vs sitting or lying




High risk 11/15 (73%) included in intervention group; 14/15 (93%) included in control





High risk 11/15 (73%) included in intervention group; 14/15 (93%) included in control






High risk 11/15 (73%) included in intervention group; 14/15 (93%) included in control






High risk 11/15 (73%) included in intervention group; 14/15 (93%) included in control




Low risk Results included all outcomes specified in the methods section





Methods Study design: cross-over randomised trial
Study duration (months): 1
Participants Number randomised: 16
Setting: not reported
Country: UK
Sex: 12 females and 4 males
Age, years: mean 51, range 26 to 76
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: male or female with IC by NIDDK criteria
Exclusion criteria: history of diabetes or liver disease
Cartledge 2000 
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Interventions Group A: L-arginine, given as capsules containing 400 mg of active compound, at a total dose of 2.4
grams/d
Group B: an inert placebo, in identical capsules
Number in each group not reported
Treatment category in NMA: amino acid vs control
Outcomes Outcome data in analysis (no usable data)
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomised"
Allocation concealment
(selection bias)









Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 1.5




Age, years: mean 46.03 (SD 15.10) for whole group, mean 44.89 (SD 15.34) for Group A, mean 47.72 (SD
14.88) for Group B
Diagnosis: "chronic urogenital pain"
Inclusion criteria: women with chronic urogenital pain conditions; 18 to 80 years old
Exclusion criteria: patients who (a) had a current psychotic disorder; (b) were unable to communicate
in English; (c) were unable to read; (d) were cognitively impaired or had dementia; or (e) were deemed
too psychiatrically unstable by their clinician at the Women’s Urology Center to meaningfully complete
Carty 2017 
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this study. Participants were allowed to engage in the study regardless of current medication use and
engagement in other treatment
Interventions Group A (n = 45): 90-minute life stress interview (stress and emotion interview)
Group B (n = 20): wait-list control (no interview)
Treatment category in NMA: behavioural therapy vs control
Outcomes Outcome data in analysis
Pain: Brief Pain Inventory pain severity subscale; average of 4 items ranking pain on a scale ranging
from 0 to 10: at 6 weeks
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





High risk Probably not done. Interview vs wait-list
Quote: "both the interviewer and participant were blinded to condition until
baseline measures were completed"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Probably not done. Interview vs wait-list
Quote: "both the interviewer and participant were blinded to condition until




High risk 37/45 (82%) included in intervention group (8 did not receive intervention) and
25/25 included in control group. 4/25 (16%) in control group did not "complete
their follow-up evaluation", but it is unclear how missing data were handled
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 110
Setting: 6 centres
Cervigni 2014 
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Country: Italy
Sex: female
Age, years: mean 50.2, range 18 to 88
Diagnosis: BPS/IC. Diagnosis according to European Society for the Study of IC/PBS (ESSIC) criteria
Inclusion criteria: patients aged 18 years or older with a diagnosis of BPS/IC, unresponsive to first-line
non-invasive treatment (e.g. oral drugs considered to be a standard treatment for BPS/IC, such as an-
tidepressants, antiepileptics, antihistaminics, cyclosporin A, pentosan polysulfate) or at first observa-
tion. Relevant inclusion criteria included the presence of pain (pelvic, pressure or discomfort) with at
least 1 other urinary symptom such as urgency, increased urination frequency for at least 6 months,
discomfort or pain during sexual intercourse
Exclusion criteria: pregnant or breastfeeding women, presence of other confusable disease as the
main cause of urinary symptoms, those who had undergone previous intravesical treatments. A mini-
mum time of 3 months from last treatment to start of therapy was required for all patients
Interventions Group A (n = 74): iAluRil®
Group B (n = 36): DMSO (dimethyl sulfoxide)
Treatment category in NMA: chondroitin sulfate + hyaluronic acid vs DMSO
Outcomes Outcome data in analysis
Cure or improvement: at least 50% VAS reduction in pain from baseline: at 6 months
Pain: VAS (range 0 to 100): at 3 months
Frequency: at 3 months
ICSI: at 6 months
ICPI: at 6 months
Functional bladder capacity: at 3 months
Adverse events: at 6 months
Funding Sponsored by IBSA Farmaceutici Italia. This assistance was funded by IBSA Institut Biochimique SA
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk "An open-label design"; "due to the garlic-like taste of DMSO after intravesical
administration, which would have been impossible to mask"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk "An open-label design"; "due to the garlic-like taste of DMSO after intravesical
administration, which would have been impossible to mask"
Cervigni 2014  (Continued)
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Blinding of outcome as-
sessment (detection bias)
Objective outcome




High risk Review authors chose to use per-protocol analysis. 66/74 (89%) included in





High risk Review authors chose to use per-protocol analysis. 66/74 (89%) included in























Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 22
Setting: multi-centre
Country: Canada
Sex: 17 females and 5 males
Age, years: mean 43.7 for Group A, mean 56.6 for Group B; range 18 to 85 for whole group
Diagnosis: IC (NIDDK criteria)
Chen 2005 
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Inclusion criteria: patients on medication to control irritative symptoms, provided dosage had not
changed within the 30 days leading to the study. No dosage change was permitted during the protocol
Exclusion criteria: pregnant or nursing, or other pathologies of the lower urinary tract (infection, de-
trusor overactivity and urologic manifestation of neurological disease), ulcerative IC, intravesical thera-
py or bladder hydrodistension 6 weeks before, current or previous malignancy, known chemical addic-
tion, seizure or major psychiatric disorder, pertinent allergy, significant medical condition
Interventions Group A (n = 18): 2 arms combined for this review. Arm 1: resiniferatoxin (RTX) 0.05 microMol/L solu-
tion in 10% ethanol in saline. Arm 2: RTX 0.1 microMol/L in 10% ethanol in saline
Group B (n = 4): 10% ethanol in saline (placebo)
All 3 trial arms had the option of 10 minute pre-treatment instillation of 2% lidocaine. Single-instillation
treatment of 50 mL of solution retained for 30 minutes. Bladder then rinsed with saline
Treatment category in NMA: calcium channel agonists vs control
Outcomes Outcome data in analysis
Pain: VAS (assumed range 0 to 10): at 12 weeks
Frequency: at 12 weeks
Nocturia: at 12 weeks
ICSI: at 12 weeks
ICPI: at 12 weeks
Adverse events: at 12 weeks
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized via a computer generated randomization schedule"
Allocation concealment
(selection bias)
Low risk Quote: "the size of the randomization block was not disclosed. Bliniding infor-
mation was contained in sealed envelopes …. Breaking the blind was permit-





Low risk "double-blind, placebo-controlled study". Solutions used for intervention and
placebo groups "were identical in appearance"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind, placebo-controlled study". Solutions used for intervention and




Low risk All randomised participants were included in analysis
Chen 2005  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 48
Setting: 3 departments of urology
Country: China
Sex: female
Age, years: mean 38.3 (SD 5.4) for Group A, mean 37.8 (SD 4.4) for Group B, range 28 to 55 for whole
group
Diagnosis: IC/PBS (NIDDK criteria)
Inclusion criteria: women with IC/PBS
Exclusion criteria: patients with diabetes mellitus, mental disorder, hypertension, hypohepatia or re-
nal insufficiency; receiving any treatment for IC/PBS within 3 months
Interventions Group A (n = 24): sildenafil 25 mg (sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor)
Group B (n = 24): placebo regimen: daily low-dose sildenafil 25 mg or placebo for 12 weeks
Treatment category in NMA: PDE5 inhibitor vs control
Outcomes Outcome data in analysis
Chen 2014 
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Cure or improvement: PORIS (Patient Overall Rating of Improvement in Symptoms) assessed and divid-
ed into worse, 0%, 25%, 50%, 75% and 100% improvement. The value of PORIS surpassing 50% was re-
garded as effective remedy: at 24 weeks
Pain: VAS score (range 0 to 5): at 24 weeks
Frequency per day: at 24 weeks
Nocturia: at 24 weeks
ICSI: at 24 weeks
ICPI: at 24 weeks
Adverse events: at 24 weeks
Funding Zhejiang Provincial Top Key Discipline and Technology Foundation of Zhejiang Province
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a computer-generated block scheme for randomization"
Allocation concealment
(selection bias)





Unclear risk "double blind, placebo-controlled trial", using oral tablet. Placebo not de-
scribed
Blinding of outcome as-
sessment (detection bias)
Subjective outcome






















Low risk All randomised participants were included in analysis
Chen 2014  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 1
Participants Number randomised: 90
Setting: 2 centres
Country: Taiwan
Sex: 80 females and 10 males
Age, years: mean 53.9 (SD 12.9) for lipotoxin group (Group A), mean 47.8 (SD 9.9) for 'onabotulinumtox-
inA in normal saline' group (Group A), mean 55.9 (SD 8.6) for Group B
Diagnosis: IC/BPS (NIDDK criteria); Hunner's lesion not included
Inclusion criteria: patients 20 years of age or older with IC/BPS in whom at least 6 months of conven-
tional treatments had failed
Exclusion criteria: not reported
Interventions Group A (n = 59): 2 arms combined for this review. Arm 1: lipotoxin (a liposomal formulated botulinum
toxin A), containing onabotulinumtoxinA 200 U with 80 mg sphingomyelin. Arm 2: 200 U g onabotu-
linumtoxinA in normal saline
Group B (n = 31): normal saline
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 4 weeks
Pain: 10-point VAS: at 4 weeks
Frequency: at 4 weeks
Nocturia: at 4 weeks
ICSI: at 4 weeks
ICPI: at 4 weeks
Chuang 2017 
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Functional bladder capacity: at 4 weeks
Adverse events: at 4 weeks
Funding Chang Gang Medical Foundation-Kaohsiung Branch (CMRPG8D004), Buddhist Tzu Chi General Hospital
(TCRD-I-104-02) and Lipella Pharmaceuticals
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk "double-blind", "placebo-controlled" study. Study drugs and saline (placebo)
for bladder instillation "were obtained in blinded fashion without recognizable
labels from the hospital pharmacy"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind", "placebo-controlled" study. Study drugs and saline (placebo)
for bladder instillation "were obtained in blinded fashion without recognizable
labels from the hospital pharmacy"
Blinding of outcome as-
sessment (detection bias)
Objective outcome




Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-




Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-




Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-




Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-





Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-





Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-
cacy); 31/31 included in control group
Chuang 2017  (Continued)
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Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-




Low risk 59/61 (97%) included in intervention group (2 discontinued due to lack of effi-
cacy); 31/31 included in control group
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 4.5




Age, years: median 36.9 (IQR 31.9 to 45.1) for Group A, median 38.7 (IQR 26 to 42.7) for Group B
Diagnosis: IC
Inclusion criteria: females who were older than 18 years, diagnosed with IC within 1 year of the begin-
ning of the study and previously untreated with either intravesical or oral PPS. To be included in the
study, all subjects had to have the following examination requirements: cystoscopic examination un-
der anaesthesia with hydrodistension and photo documentation showing petechial haemorrhage or ul-
cers; negative urine culture; score of at least 4 on a 9-point pain scale; 5 on the O’Leary-Sant IC Symp-
tom Index; and 4 on IC Problem Index
Exclusion criteria: bladder capacity greater than 350 mL on an awake cystometrogram; absence of in-
tense urge with bladder filled to 150 mL water on cystometrogram; biphasic involuntary bladder con-
tractions; absence of nocturia; voiding frequency less than 8 times per day (voiding diaries); remission
of symptoms by antimicrobials, urinary antiseptics, anticholinergics or antispasmodics; bacterial cys-
titis within 3 months; recurrent bladder; genital herpes within 3 months; cervical, vaginal or urethral
cancer; chemical, tubercular or radiation cystitis; benign or malignant bladder tumour; vaginitis; vesi-
cle ureteral reflux or urethral diverticula; neurogenic bladder dysfunction; prior urinary diversion; re-
ceiving any intravesical treatment at time of enrolment; pregnant or lactating mother. A total of 33 sub-
jects had a cystometrogram (median bladder capacity 131 mL). Subjects lacking this criterion (because
it was painful) were entered into the study but must have met all other standard criteria for IC
Interventions Group A (n = 20): intravesical 200 mg in 30 mL NaCl pentosan polysulfate sodium (PPS) + oral PPS
Group B (n = 20): 30 mL of NaCl + oral PPS twice weekly for 6 weeks
Treatment category in NMA: PPS vs control
Outcomes Outcome data in analysis
Davis 2008 
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Cure or improvement: moderately, greatly or completely improved, on patient global assessment ques-
tionnaire: at 18 weeks
Adverse events: at 18 weeks
Funding Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, New Jersey
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk "double-blind", using intravesical saline solution as placebo. "The blinding
process was monitored... by an independent pharmacist, who was responsible
for preparing the trial intravesical treatment and placebo according to an FDA
approved method"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind", using intravesical saline solution as placebo. "The blinding
process was monitored... by an independent pharmacist, who was responsible









Low risk 21/21 included in intervention group; 20/21 included in control group
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): not reported
Participants Number randomised: 36
Setting: 4 centres
Country: Belgium
Sex: 31 females and 5 males
De Ridder 2013 
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Age, years: not reported
Diagnosis: PBS/IC
Inclusion criteria: men and women aged 18 to 75 years with history of symptoms of bladder pain/dis-
comfort described as suprapubic pain related to bladder filling, accompanied by other symptoms such
as daytime and/or nighttime frequency in the absence of infection or other pathology. All patients un-
derwent urodynamic evaluation and cystoscopy with evidence of early bladder sensation and low max-
imum bladder capacity. We also considered in this study patients with negative macroscopic and biop-
tic findings of interstitial cystitis if significant symptoms were present. Patients should be willing and
able to complete the necessary questionnaires
Exclusion criteria: transitional cell carcinoma of the bladder or other significant malignancy; preg-
nant or lactating; suffering from significant bacteriuria; diagnosis of haematuria; neurogenic bladder;
indwelling catheter; chronic bacterial prostatitis; currently receiving or having received investigation-
al drugs ≤ 30 days before screening; currently receiving or having had prior therapy with intravesical
treatment (e.g. Uracyst, Cystistat®, heparin, bacillus Calmette-Guérin (BCG)); receiving therapy for < 3
months with antidepressants, antihistaminics, hormonal agonists or antagonists; hence patient not
stabilised on therapy (stable therapy defined as continuous treatment for ≥ 3 months); IC symptoms
relieved by antimicrobials, anticholinergics or antispasmodics; functional bladder capacity > 400 mL;
neurological disease affecting bladder function; any previous surgery or procedure having affected
bladder function; current diagnosis of chemical, tuberculous or radiation cystitis; bladder or lower
ureteral calculi; history of cancer within the last 5 years other than adequately treated non-melanoma
skin cancer; active sexually transmitted disease; current vaginitis, endometriosis or any condition/dis-
ease that in the opinion of the investigator could interfere with patient compliance and/or interfere
with interpretation of treatment results
Interventions Group A (n = 22): 1 g/50 mL sodium chondroitin sulfate (2%) (Uracyst™)
Group B (n = 14): DMSO (dimethyl sulfoxide, 5.4%) 27 g in 50 mL (RIMSO-50®)
Weekly for 6 weeks
Treatment categoryin NMA: chondroitin sulfate vs DMSO
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: unclear time of measurement
Pain: O'Leary-Sant Questionniare (Interstitial Cystitis Symptom and Problem Index) pain subscale (as-
sumed 0 to 10 scale): unclear time of measurement
ICSI: unclear time of measurement
Funding EUROCEPT, The Netherlands
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)




High risk Stated as "patients were single-blind randomized", but methods of blinding
were not described. Personnel probably not blinded. Intravesical instillation of
chondroitin sulfate "in 20 ml vials" or DMSO "in 50 ml physiologic serum"
De Ridder 2013  (Continued)
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All outcomes
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Stated as "patients were single-blind randomized", but methods of blinding
were not described. Intravesical instillation of chondroitin sulfate "in 20 ml




High risk 16/22 (73%) included in chondroitin sulfate group (withdrawal mainly due to
lack of efficacy or side effects); 6/14 (43%) included in DMSO group (withdraw-




Unclear risk Number analysed unclear
Selective reporting (re-
porting bias)
High risk Pain VAS (visual analogue scale), frequency and nocturia were specified in the
methods section but were reported only as baseline characteristics in the re-
sults section. Functional bladder capacity was specified in the methods but
was not reported in the results





Methods Study design: RCT
Study duration (months): 3




Age, years: not reported
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients with symptoms and signs of IC
Exclusion criteria: not reported
Interventions Group A (n = not reported): 1 of 2 doses (0.1 and 0.3 mg/kg of body weight) of recombinant human
nerve growth factor
Group B (n = not reported): placebo
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis (no usable data)
Funding Prostatitis Foundation of America and the Bulgarian Ministry of Health
Notes Publication status: abstract
Risk of bias
Dimitrakov 2001 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "… patients … randomly received" either intervention or placebo
Allocation concealment
(selection bias)





Unclear risk No information provided. Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk No information provided. Placebo not described
Selective reporting (re-
porting bias)
Unclear risk Outcomes not specified in the methods section (abstract only)





Methods Study design: RCT
Study duration (months): 1
Participants Number randomised: 26
Setting: single centre (assumed from reports)
Country: Egypt
Sex: female
Age, years: mean 32 (SD 6) for Group A, mean 33 (SD 7) for Group B
Diagnosis: IC/BPS. Diagnosis according to IC Database Study criteria (Hanno 1999)
Inclusion criteria: Patients with complaint suggestive of IC/BPS. Patients who were not improved on
pain killers and analgesics after treatment for at least 3 months and were willing to participate in the
study. At least 4 weeks elapsed before receiving either line of treatment
Exclusion criteria: not reported
Interventions Group A (n = 14): superior hypogastric plexus neurolysis
Group B (n = 12): hydrodistension
Treatment category in NMA: denervation vs hydrodistension
Outcomes Outcome data in analysis
Pain: VAS (assumed range 0 to 10): at 4 weeks
Daytime frequency: at 4 weeks
Nocturia: at 4 weeks
El-Hefnawy 2015 
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ICSI: at 4 weeks
ICPI: at 4 weeks
Adverse events: at 4 weeks
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly allocated to receive either HD or SHN block according to re-
sults of closed envelope"
Comment: unclear how envelopes were used to ensure random allocation
Allocation concealment
(selection bias)
Unclear risk Quote: "randomly allocated to receive either HD or SHN block according to re-
sults of closed envelope"





High risk Superior hypogastric plexus neurolysis (SHN) vs hydrodistension (HD). SHN
performed "In operating room, conscious sedation". Probably not done
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Superior hypogastric plexus neurolysis (SHN) vs hydrodistension (HD). SHN




High risk 12/14 (86%) included in SHN group (2 excluded due to failed initial test); 12/12




High risk 12/14 (86%) included in SHN group (2 excluded due to failed initial test); 12/12




High risk 12/14 (86%) included in SHN group (2 excluded due to failed initial test); 12/12





High risk 12/14 (86%) included in SHN group (2 excluded due to failed initial test); 12/12





High risk 12/14 (86%) included in SHN group (2 excluded due to failed initial test); 12/12




High risk 12/14 (86%) included in SHN group (2 excluded due to failed initial test); 12/12
included in HD group
El-Hefnawy 2015  (Continued)
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Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 4
Participants Number randomised: 64
Setting: 23 centres
Country: USA
Sex: reported as 'mostly female (89%)'. Unclear denominator
Age, years: range 21 to 85
Diagnosis: IC, moderate to severe
Inclusion criteria: moderate to severe IC defined as scores of 13 or greater on the Pelvic Pain and Ur-
gency/Frequency symptom questionnaire, and 7 or more on the O’Leary-Sant ICSI
Exclusion criteria: IC symptoms for less than 6 months, PVR volume greater than 200 mL, history of al-
lergic or anaphylactic reaction to mAbs or IgG fusion proteins
Interventions Group A (n = 34): tanezumab (humanised anti-NGF (nerve growth factor) monoclonal antibody) intra-
venous dose of 200 g/kg
Group B (n = 30): placebo
Patients remained on existing non-prohibited oral medications as background therapy for interstitial
cystitis
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Cure or improvement: 'moderately' or 'markedly improved on GRA: at 16 weeks
Pain: numerical rating scale (range 0 to 10): at 16 weeks
Frequency: at 6 weeks
Adverse events: at 16 weeks
Funding Pfizer
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized using an automated tele-randomization system"
Evans 2011 
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Allocation concealment
(selection bias)





Unclear risk "double-blind, placebo-controlled trial", using intravenous (IV) dose. Placebo
not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
























Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 47
Setting: 6 clinical centres
Country: USA
Sex: 24 females and 23 males
Age, years: mean 43, range 22 to 76
Diagnosis: IC/PBS or CP/CPPS. Clinical diagnosis
Inclusion criteria: patients with symptoms for less than 3 years. Patients must have previously under-
gone at least 1 course of another form of therapy for their symptoms
Exclusion criteria: patients who were intolerant to digital vaginal or rectal examination (i.e. unable to
tolerate myofascial physical therapy treatments); participants who had previously undergone myofas-
cial physical therapy for symptoms
FitzGerald 2009 
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Interventions Group A (n = 23): myofascial physical therapy
Group B (n = 24): global therapeutic massage
Treatment category in NMA: physical therapy vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 12 weeks
Funding The Urological Pelvic Pain Collaborative Research Network is a co-operative network of investigators
from 20 clinical centres and a Data Co-ordinating Center funded by NIDDK, NIH
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned … via a prespecified sequence"
Allocation concealment
(selection bias)
Unclear risk Quote: "a prespecified sequence distributed in a series of sealed envelopes"





High risk Quote: "single-blind". Participants were not informed of treatment assign-
ment but investigators stated that participants could not be blinded: "more
than 90% were aware of their treatment group when queried at the end of the
study". Study co-ordinator was blinded
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Quote: "single-blind". Participants were not informed of treatment assign-
ment but investigators stated that participants could not be blinded: "more









Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 81
Setting: 11 clinical centres
Country: USA
FitzGerald 2012 
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Sex: female
Age, years: median 43, range 18 to 77
Diagnosis: IC/PBS
Inclusion criteria: women with a clinical diagnosis of IC/PBS and recorded ratings for bladder pain,
frequency and urgency, each at a usual level of at least 3 on a 0 to 10 scale, present for at least 3 months
but not for longer than 3 years. An additional eligibility requirement was the finding of pelvic floor ten-
derness during vaginal examination by the study physician and confirmed by the study physical thera-
pist
Exclusion criteria: women were excluded from the study if they had not previously undergone at least
1 course of a standard therapy for IC/PBS, or if they had previously received treatment with pelvic floor
myofascial physical therapy
Interventions Group A (n = 39): pelvic floor myofascial physical therapy
Group B (n = 42): global therapeutic massage
Treatment category in NMA: physical therapy vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 12 weeks
Pain: numerical Likert scale (range 0 to 10): at 12 weeks
ICSI: at 12 weeks
ICPI: at 12 weeks
Adverse events: at 12 weeks
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Comment: method of sequence generation judged to be unclear in FitzGerald
2009, which uses identical methods to this trial
Allocation concealment
(selection bias)
Unclear risk No information. Method of allocation concealment judged to be unclear in





High risk Quote: "single-blind". Participants probably not blinded, as study authors state
"the design and methods of this randomized trial are identical" to FitzGerald
2009, included in this review
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Quote: "single-blind". Participants probably not blinded. "Physician examin-





Low risk All randomised participants were included in analysis
FitzGerald 2012  (Continued)
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Low risk 38/39 (97%) included in intervention group; 40/42 (95%) included in control
group. 3 withdrew from study, 1 due to dissatisfaction with treatment and 2









Low risk 38/39 (97%) included in intervention group; 40/42 (95%) included in control
group. 3 withdrew from study, 1 due to dissatisfaction with treatment and 2





Low risk 38/39 (97%) included in intervention group; 40/42 (95%) included in control
group. 3 withdrew from study, 1 due to dissatisfaction with treatment and 2




Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 271
Setting: multi-centre
Country: USA
Sex: 226 females and 45 males
Age, years: mean 38.0 (SD 13.8) for Group A, mean 39.9 (SD 14.0) for Group B, median 38 for whole
group
Diagnosis: IC/PBS
Inclusion criteria: men and women at least 18 years old who reported bladder pain/discomfort and
urinary frequency of 3 or greater on separate 0 to 10 Likert scales during the previous 4 weeks at each
of 2 baseline screening visits. Current symptoms had to have been present for a minimum of 6 weeks,
and subjects were required to be treatment naïve, defined as having no prior significant treatment for
IC/PBS
Exclusion criteria: not reported
Interventions Group A (n = 135): amitriptyline + educational and behavioural modification programme (EBMP)
Group B (n = 136): placebo + EBMP
Foster 2010 
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Dose regimen: dose of study drug was increased on a weekly basis from 10 to 25 mg, then to 50 mg
after a call from the research co-ordinator confirming tolerability. At the end of 3 weeks, participants
were evaluated and their dose increased to 75 mg daily
Treatment category in NMA: antidepressants vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 12 weeks
Pain: Likert pain scale (range 0 to 10): at 3 months
Frequency: at 3 months
Nocturia: at 3 months
ICSI: at 3 months
ICPI: at 3 months
Adverse events: at 3 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Low risk "double-blind", "placebo-controlled" trial, using oral tablet. Participants were
randomised to study drug or "matching placebo". Probably done
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Low risk Review authors chose to use number who completed the trial. 112/135 (83%)
included in intervention group (7 missing due to AE); 119/136 (88%) included














Low risk 92/135 (68%) included in intervention group; 95/136 (70%) included in control
group
Foster 2010  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: cross-over randomised trial
Study duration (months): 1 (assumed from reports)




Age, years: median 41, range 22 to 80
Diagnosis: IC
Inclusion criteria: female IC patients. No further details, but it is stated that "all patients had been
treated with various conservative measures with lack of response or recurrence of symptoms"
Exclusion criteria: not reported
Interventions Group A (n = not reported): acupuncture 2 to 3 times a week for 4 to 5 weeks
Group B (n = not reported): transcutaneous tibial nerve stimulation (TENS) by patients at home, 30
minutes per day for 4 weeks
Treatment category in NMA: behavioural therapy vs physical therapy
Outcomes Outcome data in analysis
Adverse events: at 1 month (assumed from reports)
Funding Supported by Swedish Medical Research Council and Gothenburg Medical Society
Notes Publication status: full text
Risk of bias
Geirsson 1993 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized … according to a cross-over design"; "allocation to initial




Unclear risk Quote: "allocation to initial treatment was done by the patient selecting an en-
velope containing a mark for either method"






High risk Probably not done. Accupuncture by a Chinese medical doctor vs TENS at
home. TENS is defined as trancutaneous nerve stimulation of the tibial nerve
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Probably not done. Accupuncture by a Chinese medical doctor vs TENS at




Unclear risk Number analysed unclear
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3




Age, years: mean 43.9 (range 27 to 61) for Group A, mean 47.7 (range 22 to 61) for Group B
Diagnosis: IC/PBS
Inclusion criteria: adult women with IC/PBS were identified from the Female Urology Clinic at our hos-
pital, which is a tertiary care referral centre. Women were eligible for enrolment if they had refractory
pelvic pain in the bladder, urethra, vagina or perineum; pain with bladder filling or voiding; and urinary
frequency greater than 12 voids per day
Exclusion criteria: women with isolated overactive bladder symptoms, active urinary tract infection,
pregnancy, genitourinary malignancy, suicidal or overtly psychotic behavior, postsurgical pain, pain
from another source in the genitourinary tract (e.g. renal calculi), history of radiation therapy or history
of genitourinary tuberculosis
Interventions Group A (n = 9): periurethral injection of 50 U botulinum toxin A diluted in 2 cm3 normal saline
Gottsch 2011 
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Group B (n = 11): placebo injection of 2 cm3 normal saline
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Pain: CPSI-F (a female modification of Chronic Prostitis Symptom Index) pain subscale (range 0 to 21):
at 3 months
Adverse events: at 3 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk "double-blind"; blinding methods not described. Periurethral injection botu-
linum toxin A vs saline (placebo). "The placebo injection … delivered in a simi-
lar fashion"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk "double-blind"; blinding methods not described. Periurethral injection botu-









Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 53
Gulpinar 2013 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)













Age, years: mean 48.47
Diagnosis: PBS/IC
Inclusion criteria: patients with history of painful bladder syndrome/interstitial cystitis(PBS/IC) who
had poor response or were refractory to previous treatment(s)
Exclusion criteria: not reported
Interventions Group A (n = 30): 800 mg/50 mL sodium hylauronic acid (1.6%) + 1 g/50 mL sodium chondroitin sulfate
(2%) (iAluRil®)
Group B (n = 23): 50 mL hyaluronic acid (Hyacyst®)
Weekly in first month, once in 15 days in second month and monthly in third and fourth months, as to-
tal of 8 intravesical doses
Treatment category in NMA: chondroitin sulfate vs control
Outcomes Outcome data in analysis
Pain: VAS (assumed 0 to 10): at 6 months
Nocturia: at 6 months
ICSI: at 6 months
ICPI: at 6 months
Adverse events: at 6 months
Funding Not reported
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk No information provided. Intravesical therapy of 50 mL chondroitin sulfate or
hyaluronic acid
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Unclear risk Number analysed not stated
Gulpinar 2013  (Continued)
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Unclear risk Number analysed not stated
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6




Age, years: mean 47.10 (SD 10.70) for Group A, mean 48.90 (SD 17.18) for Group B
Diagnosis: BPS/IC
Inclusion criteria: female patients with BPS/IC were included in the study. Patients with complaints
of chronic pelvic pain related to bladder filling accompanied by voiding frequency ≥ 8 times/24 h; noc-
turia ≥ 2 times per night or persistent urge for at least 24 weeks; an average pain score of ≥ 4 (VAS; 0 no
pain, 10 unbearable pain); a negative pregnancy test; a sterile urine culture; and inadequate clinical re-
sponse after 6 months of conservative and medical treatment were included in the study
Exclusion criteria: patients with positive pregnancy test, current urinary infection or sexually transmit-
ted disease; chemical cystitis; tuberculous or radiation cystitis; urolithiasis; urological malignancy; or
endometriosis or urethral diverticulum; breastfeeding women were excluded from the study
Interventions Group A (n = 21): 800 mg/40 mL sodium chondroitin sulfate (Gepan Instill®)
Group B (n = 21): 50 mL/120 mg hyaluronic acid (Hyacyst®)
Weekly in first month, once in 15 days in second month and monthly in third and fourth months, as to-
tal of 8 intravesical doses
Treatment category in NMA: chondroitin sulfate vs hyaluronic acid
Gulpinar 2015 
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Outcomes Outcome data in analysis
Cure or improvement: treatment response according to VAS pain score changes ('strong benefit' de-
fined as > 50% reduction in VAS score): at 6 months
Adverse events: at 6 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk No information provided. Intravesical therapy of 40 mL chondroitin sulfate vs
50 mL hyaluronic acid
Blinding of outcome as-
sessment (detection bias)
Subjective outcome












Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 18
Ham 2012 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)













Age, years: mean 54.5 (SD 9.1) for Group A, mean 56.9 (SD 7.8) for Group B, median 55.8 for whole
group
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: women with IC refractory to classic medical treatment
Exclusion criteria: not reported
Interventions Group A (n = 8): 50 mL resiniferatoxin (RTX) in 10% ethanol + hydrodistension. (RTX = ultra potent ana-
logue of chili pepper extract capsaicin)
Group B (n = 10): hydrodistension
Treatment category in NMA: calcium channel agonists vs control
Outcomes Outcome data in analysis
Pain: VAS (range 0 to 5): at 3 months
Frequency (mean voids/d): at 3 months
Nocturia: at 3 months
Functional bladder capacity: at 3 months
Adverse events: at 3 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Hydrodistension vs hydrodistension + intravexial RTX
"under general anesthesia"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Blinding not mentioned. Hydrodistension vs hydrodistension + intravexial RTX
"under general anesthesia"
Blinding of outcome as-
sessment (detection bias)
Objective outcome
Low risk Outcome measurement is not likely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias)
Unclear risk All randomised participants were included in analysis
Ham 2012  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 1




Age, years: not reported
Diagnosis: IC/PBS
Inclusion criteria: women 18 to 80 years of age who had clinical evidence of IC/BPS for at least 6
months with moderate to severe pain and urinary frequency
Exclusion criteria: not reported
Interventions Group A (n = 36): AF-219 (P2X3 antagonist)
Group B (n = 38): placebo
Treatment category in NMA: P2X3 antagonist vs control
Outcomes Outcome data in analysis
Pain: numerical pain rating scale (assumed range 0 to 10): at 4 weeks
Adverse events: at 4 weeks
Hanno 2015 
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Funding Not reported
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "'randomized"
Allocation concealment
(selection bias)





Unclear risk Participants randomised to an oral drug or placebo. Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome








Unclear risk Number analysed unclear
Selective reporting (re-
porting bias)
Unclear risk Outcomes not specified in methods (abstract only)





Methods Study design: RCT
Study duration (months): 0.06 (48 hours)




Age, years: not reported
Diagnosis: IC/PBS
Inclusion criteria: consecutive IC/PBS patients
Exclusion criteria: not reported
Herati 2011 
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Number randomised: 30
Interventions Group A (n = 14): caffeine 100 mg
Group B (n = 16): placebo
Treatment category in NMA: caffeine vs control
Outcomes Outcome data in analysis - no usable data
Funding The Fishbein Family IC Research Foundation Grant
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk "placebo-controlled, double-blind study", using a pill or placebo. Placebo not
described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk "double-blind", using a pill or placebo. Placebo not described
Selective reporting (re-
porting bias)
High risk ICPI listed in methods but not reported in results





Methods Study design: RCT
Study duration (months): 6




Age, years: mean 45.9 (SD 7.8) for Group A, mean 46.1 (SD 7.6) for Group B
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients with IC
Hsieh 2012 
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Exclusion criteria: not reported
Interventions Group A (n = 35): hydrodistension plus bladder training (talk with physician, attempt to increase inter-
void interval)
Group B (n = 35): hydrodistension (bladder filled with normal saline to maximal capacity at pressure of
80 cmh2)
Treatment category in NMA: behavioural therapy vs control
Outcomes Outcome data in analysis
Frequency: at 24 weeks
Nocturia: at 24 weeks
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned"
Allocation concealment
(selection bias)





High risk Hydrodistension (HD) + bladder training (BT) vs HD. Probably not done
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




High risk 28/35 (80%) included in HD + BT group; 23/35 (66%) included in HD group.





High risk 28/35 (80%) included in HD + BT group; 23/35 (66%) included in HD group.




Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Irani 2004 
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Study duration (months): 24
Participants Number randomised: 30
Setting: multi-centre (assumed from reports)
Country: Iran
Sex: female
Age, years: mean 40.8 (SD 13.96) for Group A, mean 36 (SD 12.84) for Group B
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: met NIDDK diagnostic criteria, selected from among women with irritative symp-
toms and bladder pain, post cystoscopy under anaesthesia, bladder hydrodistension, other prelimi-
nary evaluations
Exclusion criteria: immunocompromising conditions; steroid, warfarin or immunosuppressant admin-
istration; pregnancy; vesicoureteral reflux; history of intravesical instillation in the last 3 months; posi-
tive HIV serology; positive cutaneous PPD; males (due to risk of catheterisation)
Interventions Group A (n = 15): 120 mg bacillus Calmette-Guérin (BCG)
Group B (n = 15): 50 cc NaCl
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Cure or improvement: 'responded to treatment' defined as over 40% improvement in valid scores of
Wisconsin University for interstitial cystitis at 24 months
Pain: pelvic pain VAS (10 cm rulers) at 24 months
Frequency: at 24 months
Functional bladder capacity: at 24 months
Adverse effects: at 24 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)
Low risk Quote: "... nominating the drugs and listing the patients were done by a third





Low risk "double-blind", "placebo-controlled" study, using "vials of placebo with sim-
ilar appearance", "vials nominated blindly as drugs A and B"; "the staF who
were involved with the therapy were blind to the drug type"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind", "placebo-controlled" study, using "vials of placebo with sim-
ilar appearance", "vials nominated blindly as drugs A and B"; "the staF who
were involved with the therapy were blind to the drug type"
Irani 2004  (Continued)
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Blinding of outcome as-
sessment (detection bias)
Objective outcome





















Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 2
Participants Number randomised: 30
Setting: not reported
Country: not reported
Sex: 26 females and 4 males
Age, years: range 17 to 45
Diagnosis: IC/BPS
Inclusion criteria: patients diagnosed to have IC/BPS
Exclusion criteria: not reported
Interventions Group A (n = 15): intravesical 100 U botulinum toxin A injected into trigone under general anaesthesia
Group B (n = 15): equivalent amount of normal saline
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Ismail 2016 
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Adverse events: at 0.5 months
Funding Not reported
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Quote: "single-blinded". Unclear who is blinded and how. Intravesical instil-
lation of BoNT-A or "the equivalent amount of normal saline" under general
anaesthesia
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Quote: "single-blinded". Unclear who is blinded and how. Intravesical instil-





Unclear risk Number analysed not stated
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 2




Age, years: mean 46.3 (SD 15.2) for Group A, mean 44.4 (SD 13.9) for Group B
Diagnosis: IC/BPS (American Urological Association criteria)
Inclusion criteria: patients with IC/BPS. Negative urinalysis or urine culture within 2 months of enrol-
ment and ability to speak and understand English. We recruited only patients who were currently un-
dergoing first- or second-line treatments, as defined by the AUA (American Urological Association), and
who had not made changes in their IC/BPS treatment regimen within 4 weeks of beginning their as-
signed intervention. First-line treatments include relaxation/stress management, pain management
Kanter 2016 
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and self-care/behavioural modification. Second-line therapy involves physical therapy, in addition to
oral or intravesical medications
Exclusion criteria: patients who were treatment-naïve or undergoing third-line or higher treatments at
the time of enrolment; patients with unevaluated haematuria, urinary retention, history of cystectomy,
augmentation cystoplasty or urinary diversion; history of radiation- or chemotherapy-induced cystitis
or pregnant or lactating
Interventions Group A (n = 9): 8-week group mindfulness-based stress reduction meditation programme (seven 2
hour courses, every week, with all-day retreat in 5th week) plus current care regimen. Also given 4-CD
guide and a book
Group B (n = 11): usual care
Treatment category in NMA: behavioural therapy vs control
Outcomes Outcome data in analysis
Cure or improvement: Global Response Assessment as 'being improved'. Not clear whether this is de-
fined as 'moderate' and 'marked' improvement or 'moderate', 'marked' and 'slight' improvement: at 8
weeks
Pain: VAS (assumed range 0 to 10): at 8 weeks
ICSI: at 8 weeks
ICPI: at 8 weeks
Funding National Center for Research Resources and National Center for Advancing Translational Sciences of
the NIH (grant # ULI TR001449)
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized … by a computer-generated sequence"
Allocation concealment
(selection bias)






High risk Probably not done. Stress reduction class + usual care vs usual care
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




High risk 8/9 (89%) included in intervention group (1 lost to follow-up before interven-




High risk 8/9 (89%) included in intervention group (1 lost to follow-up before interven-
tion); 11/11 in control group
Kanter 2016  (Continued)
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High risk 8/9 (89%) included in intervention group (1 lost to follow-up before interven-





High risk 8/9 (89%) included in intervention group (1 lost to follow-up before interven-
tion); 11/11 in control group
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3




Age, years: not reported
Diagnosis: BPS/IC
Inclusion criteria: female patients with BPS/IC
Exclusion criteria: not reported
Interventions Group A (n = 15): 100 IU of botulinum toxin A in 10 mL of NaCl into the trigone
Group B (n = 17): hydrodistension
Treatment category in NMA: neuromuscular blockade vs hydrodistension
Outcomes Outcome data in analysis
Pain: 10-point VAS (unclear minimum/maximum score): at 3 months
ICSI: at 3 months
ICPI: at 3 months
Adverse events: at 3 months
Funding None
Notes Publication status: abstract
Risk of bias
Kasyan 2012 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Hydrodistension vs injection (under spinal anaesthe-
sia through a cystoscope using a flexible needle in the trigone of the bladder)
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Blinding not mentioned. Hydrodistension vs injection (under spinal anaesthe-


















Unclear risk Number analysed not stated
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3




Age, years: median 55.8 ± 6.9 (unknown whether IQR)
Diagnosis: PBS/IC
Kim 2012 
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Inclusion criteria: consecutive patients with proven PBS/IC refractory to traditional medical treatment
Exclusion criteria: not reported
Interventions Group A (n = not reported): resiniferatoxin (RTX) + hydrodistension (RTX = ultra potent analogue of
chili pepper extract capsaicin)
Group B (n = not reported): hydrodistension
Treatment category in NMA: calcium channel agonists vs control
Outcomes Outcome data in analysis - no usable data
Funding Industrial Source Technology Development Programme of the Ministry of Knowledge Economy (MKE)
of Korea and the National Research Foundation of Korea (NRF) grant funded by the Korean government
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Hydrodistension + intravesical RTX vs hydrodisten-
sion
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 1




Age, years: mean 63.76 (SD 7.70) for Group A, mean 63.62 (SD 9.34) for Group B
Diagnosis: IC/PBS
Kim 2015 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)
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Inclusion criteria: patients who have had symptoms of IC/BPS for at least 6 months and had Hunner's
lesion
Exclusion criteria: not reported
Interventions Group A (n = 21): transurethral fulguration
Group B (n = 17): hydrodistension
Treatment category in NMA: fulguration vs hydrodistension
Outcomes Outcome data in analysis
Pain: VAS (assumed range 0 to 10): at 1 month
Funding Not reported
Notes Publication status: abstract
Trial stopped early: "… the authors felt a clear superiority of one procedure over the other and enroll-
ment after the 38th patient was stopped for ethical reasons"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly divided".
Allocation concealment
(selection bias)





High risk Probably not done. Fulguration vs hydrodistension (HD)
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Unclear risk Number analysed not stated. 7/21 (33%) dropped out from fulguration group;




Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 53
Korting 1999 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)













Age, years: mean 46.6 (SD 14.3) for Group A (n = 21), mean 52.7 (SD 13.6) for Group B (n = 26), mean 56.3
(SD 10.2) for Group A withdrawals (n = 6)
Diagnosis: IC (NIH criteria)
Inclusion criteria: female patients with IC
Exclusion criteria: male sex, pregnancy or unreliable plans for avoiding pregnancy, unstable medical
condition, prior use of L-arginine
Interventions Group A (n = 27): L-arginine 500 mg TDS for 3 months
Group B (n = 26): placebo
Treatment category in NMA: amino acid vs control
Outcomes Outcome data in analysis
Cure or improvement: change for the better in overall symptoms on 2 questionnaires: at 3 months
Frequency per day: at 3 months
Nocturia: at 3 months
Adverse events: at 3 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "'simple block randomization … using a random numbers table"
Allocation concealment
(selection bias)
Low risk Randomisation "was performed by the Investigational Drug Service of the Yale
New Haven Hospital Pharmacy"; "the researchers and patients were blinded






Low risk "double-blind"; participants received study drug or "identical appearing
placebo … capsules"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome





High risk Reviewers extracted per-protocol analysis data. 21/27 (78%) included in inter-
vention group; 26/26 included in control group
Incomplete outcome data
(attrition bias)
Low risk Number analysed not stated, but "an intention to treat analysis … was per-
formed … using the methods suggested by Lewis and Machin"
Korting 1999  (Continued)
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Low risk Number analysed not stated, but "an intention to treat analysis … was per-




High risk 21/27 (78%) included in intervention group (6 withdrew); 25/26 included in
control group (1 withdrew)
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 24
Participants Number randomised: 70
Setting: not reported
Country: Taiwan
Sex: 56 females and 11 males
Age, years: not reported
Diagnosis: IC/PBS
Inclusion criteria: patients with IC/PBS who had failed conventional treatments
Exclusion criteria: not reported
Interventions Group A (n = 46): botulinum toxin A (100 or 200 units) + hydrodistension 2 weeks later. In Group A, 15
patients: 200 IU botox, 29 patients: 100 IU botox
Group B (n = 24): hydrodistension
All patients continued with oral pentosan polysulfate during the trial
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 12 months
Pain: 10-point VAS (unclear minimum/maximum score): at 3 months
Daytime frequency: at 3 months
Nocturia: at 3 months
ICSI: at 3 months
ICPI: at 3 months
Functional bladder capacity: at 3 months
Kuo 2009 
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Adverse events: at > 6 months
Funding Not reported. One of the study authors is a consultant and investigator for Allergan
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned"
Allocation concealment
(selection bias)





High risk Sub-urothelial injection of BoNT-A followed by cystoscopic hydrodistension
(HD) 2 weeks later vs cystoscopic HD using "similar methods as in BoNT-A
groups"
Unclear if HD was repeated 2 weeks later in HD group. Blinding probably not
done
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Sub-urothelial injection of BoNT-A followed by cystoscopic hydrodistension
(HD) 2 weeks later vs cystoscopic HD using "similar methods as in BoNT-A
groups"
Unclear if HD was repeated 2 weeks later in HD group. Blinding probably not
done
Blinding of outcome as-
sessment (detection bias)
Objective outcome




Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on




Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on




Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on




Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on





Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on





Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on
the day it was scheduled)
Kuo 2009  (Continued)
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Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on




Low risk 44/46 (96%) included in intervention group (2 refused treatment on the day it
was scheduled); 23/24 (96%) included in control group (1 refused treatment on
the day it was scheduled)
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 2
Participants Number randomised: 60
Setting: 2 teaching hospitals
Country: Taiwan
Sex: 52 females and 8 males
Age, years: mean 52.9 (SD 14.3, range 20 to 82) for Group A, mean 50.2 (SD 13.2, range 22 to 71) for
Group B
Diagnosis IC/BPS (NIDDK criteria); Hunner's lesion not included
Inclusion criteria: IC/BPS patients who had failed at least 6 months of conventional treatments. Pa-
tients who had been treated with at least 2 types of treatment modalities including non-steroid anti-in-
flammatory drugs, oral pentosan polysulfate sodium, intravesical instillation of heparin, hyaluronic
acid or tricyclic antidepressant for at least 6 months but symptoms remained unchanged or relapsed
Exclusion criteria: (1) exclusion criteria by NIDDK; (2) use of anticholinergic drugs for treatment of
lower urinary tract symptoms that have an effect; (3) severe cardiopulmonary disease such as conges-
tive heart failure, arrhythmia, poorly controlled hypertension; not able to receive regular follow-up;
(4) bladder outlet obstruction on enrolment; (5) urinary retention, PVR (postvoid residual) 150 mL;
(6) uncontrolled, confirmed diagnosis of acute urinary tract infection; (7) laboratory abnormalities at
screening including alanine aminotransferase (ALT) > 3 times upper limit of the normal range, aspar-
tate aminotransferase (AST) > 3 times upper limit of the normal range, abnormal serum creatinine lev-
el > 2 times upper limit of the normal range; (8) use of transurethral catheter; (9) pregnant and lactat-
ing woman or woman who intends to become pregnant during the study or who has myasthenia gravis
or Eaton-Lambert syndrome; (10) any other serious disease or condition considered by the investigator
not suitable for entry into the trial; (11) participation in an investigational drug trial within 1 month be-
fore entering this study; (12) unable or unwilling to provide written informed consent for the study; (13)
incomplete 3-day micturition diary, according to the study protocol; (14) intestinal bladder augmenta-
tion with angioplasty for treatment of overactive bladder
Interventions Group A (n = 40): botulinum toxin A (100 units) + hydrodistension
Group B (n = 20): NaCl injection + hydrodistension
Treatment category in NMA: neuromuscular blockade vs control
Kuo 2016 
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Outcomes Outcome data in analysis
Cure or improvement: patients considered 'successful' when they reported improvement on GRA of 1
or more points): at 3 months
Pain: 10-point VAS (unclear minimum/maximum score): at 8 weeks
Frequency (voids/day): at 8 weeks
Nocturia: at 8 weeks
ICSI: at 8 weeks
ICPI: at 8 weeks
Functional bladder capacity: at 8 weeks
Adverse events: at 2 months.
Funding Buddhist Tzu Chi General Hospital
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "'permuted block randomization code in a 2:1 ratio, which was central-




Low risk Quote: "'permuted block randomization code in a 2:1 ratio, which was central-





Low risk "double-blind, placebo-controlled trial". Sub-urothelial injection of either
BoNT-A or "the equivalent amount of normal saline"; doctors, patients and
nurses "did not know which solution was injected into their bladders"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind, placebo-controlled trial". Sub-urothelial injection of either
BoNT-A or "the equivalent amount of normal saline"; doctors, patients and
nurses "did not know which solution was injected into their bladders"
Blinding of outcome as-
sessment (detection bias)
Objective outcome












Low risk All randomised participants were included in analysis
Kuo 2016  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 36
Setting: not reported
Country: Italy
Sex: 23 females and 13 males
Age, years: mean 50.9 (SD 13.1) for Group A, mean 53.2 (SD 11.4) for Group B
Diagnosis: "severe bladder pain"
Inclusion criteria: women and men with severe bladder pain. Pelvic pain for at least 6 months and no
urinary tract infection (tuberculosis included) within the last 3 months, functional disorders of the low-
er urinary tract such as detrusor instability, calculi or proliferative vesical pathology
Exclusion criteria: patients with urethral syndrome were excluded based on abnormalities noted dur-
ing urodynamic evaluation (dysfunctional external urethral sphincter); patients with Hunner’s ulcer at
cystoscopy were also excluded, but those with moderate pathological abnormality of the bladder mu-
cosa (edema, rare mast cells and plasma cellular inflammation) were included in the study. Before the
study was begun, all patients were assessed for current or previous psychiatric illness, and those with
significant psychiatric disease were excluded. However, psychological or related symptoms were noted
Interventions Group A (n = 18): 10 µm capsaicin 30 cc NaCl
Lazzeri 1996 
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Group B (n = 18): NaCl at 42°C
Twice weekly for 1 month
Treatment category in NMA: calcium channel agonists vs control
Outcomes Outcome data in analysis
Cure or improvement: improvement in pain and symptoms (e.g. frequency), to the point that no med-
ication was required: at 6 months
Pain: numerical rating scale (range 0 to 9) on pain frequency and intensity: at 6 months
Adverse events: at 6 months
Funding Not reported
Notes Publication status: full text
Notes from previous versions of the review: previous review authors excluded this trial from the origi-
nal review because patients with Hunner's lesions were excluded. We have included this trial as inclu-
sion criteria meet the diagnosis of bladder pain syndrome
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Low risk Blinding not mentioned, but in the control group, "the same procedure [as in-
travesical capsaicin intervention] was used but with saline 42°C, which mimics
the burning or warm sensation of capsaicin as described previously [ref pro-
vided]"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk Blinding not mentioned, but in the control group, "the same procedure [as in-
travesical capsaicin intervention] was used but with saline 42°C, which mimics





Low risk 17/18 included in intervention group (1 refused treatment at 4 weeks and with-




Low risk 17/18 included in intervention group (1 refused treatment at 4 weeks and with-




Low risk 17/18 included in intervention group (1 refused treatment at 4 weeks and with-
drew); 18/18 included in control group
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section
Other bias Low risk None detected
Lazzeri 1996  (Continued)
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Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 18
Setting: not reported
Country: Italy
Sex: 15 females and 3 males
Age, years: mean 43.4
Diagnosis: "hypertensive disorder and severe pain"
Inclusion criteria: men and women with hypersensitive disorder and severe bladder pain. Frequen-
cy greater than 8 voids, nocturia greater than 2 voids, daily urgency and bladder pain for at least 6
months. Furthermore, we considered absent urinary tract infection, including tuberculosis, within the
last 3 months; absent functional disorders of the lower urinary tract as detrusor overactivity; and no
calculi or proliferative vesical pathology
Exclusion criteria: patients diagnosed with urethral syndrome were excluded from the study based on
abnormalities identified at urodynamic evaluation such as dysfunctional behaviour of the external ure-
thral sphincter. Those for whom cystoscopy revealed Hunner’s ulcer were also excluded, but we includ-
ed in our analysis patients with moderate pathological abnormalities such as edema, rare mast cells
and plasmacellular inflammation. Before study initiation, all patients were assessed for current or pre-
vious psychiatric illness; those with significant psychiatric disease were also excluded from analysis.
However, psychological or associated symptoms were recorded
Interventions Group A (n = 9): resiniferatoxin (RTX) 10 µm in 0.1% ethanol (RTX = ultra potent analogue of chili pep-
per extract capsaicin)
Group B (n = 9): NaCl
Treatment category in NMA: calcium channel agonists vs control
Outcomes Outcome data in analysis
Pain: numerical rating scale (range 0 to 9) on pain frequency and intensity: at 3 months
Frequency: at 3 months
Nocturia: at 3 months
Adverse events: at 3 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)
Unclear risk No information provided.
Lazzeri 2000 
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High risk "The same procedure" used to instill resiniferatoxin or saline (placebo). During
infusion 4 in intervention group "noticed a light warm or burning sensation at
the suprapubic and/or urethral level but those who received placebo noticed
no sensation".
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk "The same procedure" used to instill resiniferatoxin or saline (placebo). During
infusion 4 in intervention group "noticed a light warm or burning sensation at

















Unclear risk Number analysed not stated.
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section.





Methods Study design: RCT
Study duration (months): 1.5
Participants Number randomised: 69
Setting: 31 sites (19 in Canada and 12 in USA)
Country: Canada, USA
Sex: female
Age, years: mean 52.1 (SD 14.9) for Group A, mean 53.1 (SD 12.9) for Group B
Diagnosis: IC/BPS
Inclusion criteria: women 18 to 75 years old with a diagnosis of IC/BPS for greater than 6 months but
15 years or less, and bladder pain for 12 months or longer, were eligible for enrolment in a screening
period of 9 to 21 days if they met inclusion criteria including baseline mean pain 5 or greater on an
11-point scale, BPIC-SS score 19 or greater, 20 baseline combined O’Leary-Sant ICSI/PI21 score 8 or
greater, at least 8 urinary voids per 24 hours and history of cystoscopy within 36 months, revealing
signs consistent with IC/BPS diagnosis including but not restricted to Hunner's lesion
Leadership 201 Trial 2016 
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Exclusion criteria: women were excluded from analysis if they had pelvic floor pain greater than 5 of
10 as assessed by the investigator, BMI less than 18 or greater than 39 kg/m2, recent cystoscopy with
therapeutic hydrodistension within 3 months or bladder surgery within 3 years
Interventions Group A (n = 37): daily 200 mg AQX-1125 capsule (oral)
Group B (n = 32): placebo
Participants in this trial were allowed to remain on stable doses of most IC/BPS medications. The 2
most common medications were pentosan polysulfate sodium and amitriptyline
Treatment category in NMA: AQX-1125 vs control
Outcomes Outcome data in analysis
Pain: numerical rating scale (range 0 to 10): at 4 weeks
ICSI: at 4 weeks
ICPI: at 4 weeks
Funding Aquinox Pharmaceuticals
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "centrally ramdomized"
Allocation concealment
(selection bias)





Low risk "double-blind, placebo controlled" study, using a single daily capsule of study
drug or "matched placebo"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind, placebo controlled" study, using a single daily capsule of study




Low risk All randomised participants were included in analysis ("missing data imputed









Low risk All randomised participants were included in analysis ("missing data imputed
using the last observation carried forward approach")
Incomplete outcome data
(attrition bias)
Low risk All randomised participants were included in analysis ("missing data imputed
using the last observation carried forward approach")
Leadership 201 Trial 2016  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section
Other bias Low risk None detected




Methods Study design: RCT
Study duration (months): 2




Age, years: mean 46.5 (SD 10.2) for Group A, mean 49.5 (SD 11.8) for Group B
Diagnosis: IC/BPS
Inclusion criteria: BPS/IC patients
Exclusion criteria: not reported
Interventions Group A (n = 40): e-health system (Internet intervention to change habitual behaviour; no treatment,
with questionnaires, SMS question/answer service for symptom relief)
Group B (n = 40): control (unclear what this entails - includes treatment)
Treatment category in NMA: behavioural therapy vs control
Outcomes Outcome data in analysis
Pain: VAS (assumed range 0 to 10): at 8 weeks
ICSI: at 8 weeks
ICPI: at 8 weeks
Funding Supported in part by Taichung Hospital and National Science Council of Taiwan
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly assigned"
Lee 2014 
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Allocation concealment
(selection bias)





High risk Probably not done. E-health system vs control treatment
Quote: "treatment was only given to the patients in the control group"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Probably not done. E-health system vs control treatment




Low risk 33/40 (83%) included in intervention group; 32/40 (80%) included in control
group. 7 and 8 from each group excluded for not filling out the questionnaire





Low risk 33/40 (83%) included in intervention group; 32/40 (80%) included in control
group. 7 and 8 from each group excluded for not filling out the questionnaire





Low risk 33/40 (83%) included in intervention group; 32/40 (80%) included in control
group. 7 and 8 from each group excluded for not filling out the questionnaire
before or after testing
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 2




Age, years: not reported
Diagnosis: IC/BPS
Inclusion criteria: IC/BPS patients
Exclusion criteria: not reported
Interventions Group A (n = 29): self-management telecare system (patient video education, mobile phone app,
lifestyles)
Group B (n = 27): control (no detail)
Lee 2016 
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Treatment category in NMA: behavioural therapy vs control
Outcomes Outcome data in analysis
Pain: VAS (assumed 0 to 10): at 8 weeks
ICSI: at 8 weeks
ICPI: at 8 weeks
Funding None
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Video education system vs control
Blinding of outcome as-
sessment (detection bias)
Subjective outcome














Unclear risk Number analysed not stated
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Lu 2015 
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Study duration (months): 12




Age, years: mean 44.1 (SD 6.7, range 34 to 54) for Group A, mean 45.0 (SD 8.8, range 30 to 60) for Group
B
Diagnosis: IC
Inclusion criteria: patients with IC
Exclusion criteria: not reported
Interventions Group A (n = 11): heparin-lidocaine instillation
Group B (n = 13): intravesical hyaluronic acid instillation
Treatment category in NMA: anticoagulants + local anaesthetics vs hyaluronic acid
Outcomes Outcome data in analysis
Cure: complete remission: at 12 months
Pain: VAS (range 0 to 6): at 12 months
Frequency, daily: at 12 months
Adverse events: at 12 months (assumed from reports)
Funding Not reported
Notes Publication status: full text
Publication in Chinese language with English abstract. Information was extracted mainly from the ab-
stract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly divided"
Comment: no further information available (paper in Chinese)
Allocation concealment
(selection bias)





Unclear risk No information available (paper in Chinese). Intravesical instillation of he-
parin-lidocaine vs hyaluronic acid
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk No information available (paper in Chinese). Intravesical instillation of he-
parin-lidocaine vs hyaluronic acid
Incomplete outcome data
(attrition bias)
Low risk All randomised participants were included in analysis
Lu 2015  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Unclear risk No information available (paper in Chinese)





Methods Study design: RCT
Study duration (months): 3




Age, years: mean 54 for Group A, mean 53 for Group B
Diagnosis: IC/PBS (NIDDK criteria)
Inclusion criteria: female patients with long-standing refractory IC/PBS. Being refractory was defined
as having failed 2 or more recognised treatments
Exclusion criteria: known history of recurrent urinary tract infection (UTI), current pregnancy, bladder
malignancy, steroid use, voiding difficulty
Interventions Group A (n = 26): botox + hydrodistension. Trigone avoided
Group B (n = 27): saline + hydrodistension
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Cure or improvement: clinically significant improvement defined as reduction in baseline score ≥ 50%
in O'Leary-Sant symptom scores: at 3 months
Frequency: at 3 months
Nocturia: at 3 months
ICSI: at 3 months
ICPI: at 3 months
Manning 2014 
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Functional bladder capacity: at 3 months
Adverse events: at 3 months
Funding Not reported. One of the study authors is on Advisory Board for Allergan
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "a series of three separate computer-generated randomisation num-
bers for each centre"
Allocation concealment
(selection bias)
Low risk Randomisation numbers were "provided by the mathematics department and






Low risk "double-blind". Sub-urothelial injection of saline or AboBTXA in de-identified
syringe with hydrodistension under general anaesthesia. "Patients and treat-
ing doctors were blinded to initial treatment allocation"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind". Sub-urothelial injection of saline or AboBTXA in de-identified
syringe with hydrodistension under general anaesthesia. "Patients and treat-
ing doctors were blinded to initial treatment allocation"
Blinding of outcome as-
sessment (detection bias)
Objective outcome








Low risk 25/26 included in intervention group; 26/27 included in control group. 1 in




Low risk 25/26 included in intervention group; 26/27 included in control group. 1 in















Low risk 25/26 included in intervention group; 26/27 included in control group. 1 in
each group missing due to incomplete bladder diary
Manning 2014  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 2
Participants Number randomised: 30
Setting: not reported
Country: Japan
Sex: 27 females and 1 male (participants in analysis only)
Age, years: mean 65.2 (SD 7.9) for Group A, mean 64.5 (SD 4.5) for Group B (participants in analysis on-
ly)
Diagnosis: IC/PBS (clinical diagnosis)
Inclusion criteria: patients aged > 50 years with IC/PBS, who fulfilled the diagnostic criteria for IC pro-
posed by the clinical guideline for IC. Stable history of IC/PBS symptoms ≥ 12 weeks after bladder hy-
drodistension, total ICSI score ≥ 7 and bladder pain (question 4 on ICSI) ≥ 4
Exclusion criteria > 200 mL of average voided volume; urinary tract infection and vaginitis; urolithia-
sis; significant hepatic, renal, cardiac or cerebrospinal disease; neurological bladder (e.g. spinal cord
injury, Parkinson’s disease); surgery and/or radiotherapy to the pelvis; use of any dietary and/or antiox-
idant supplement; initiation of bladder training in the 12 weeks before the start of the study; initiation
or discontinuation or change of the dose of the following drugs within 4 weeks after registration: anti-
depressant, anticholinergic drug, antihistaminergic drug, any drugs for lower urinary tract symptoms
and steroids
Interventions Group A (n = not reported): hydrogen-rich water 3 packs/d (1 pack, 200 mL)
Group B (n = not reported): placebo water 3 packs/d (1 pack, 200 mL)
Regimen: 8 weeks
18 analysed in Group A, 10 analysed in Group B
Treatment category in NMA: hydrogen-rich water vs control
Outcomes Outcome data in analysis
Pain: VAS (range 0 to 10): at 8 weeks
ICSI: at 8 weeks
ICPI: at 8 weeks
Adverse events: at 8 weeks
Matsumoto 2013 
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Funding Public Health Research Foundation Comprehensive Support Project for Clinical Research Office on
lifestyle-related disease
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the randomization was performed by an independent statistician and




Low risk Quote: "the randomization was performed by an independent statistician and






Unclear risk "double-blind, placebo-controlled" trial, using hydrogen-rich water and
"placebo water". Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Unclear risk Number randomised per group not stated. 30 randomised; 28 analysed (18 in





Unclear risk Number randomised per group not stated. 30 randomised; 28 analysed (18 in





Unclear risk Number randomised per group not stated. 30 randomised; 28 analysed (18 in




Unclear risk Number analysed or number randomised per group not stated
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Mayer 2005 
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Study duration (months): 17 (for the purpose of this review, data at 8.5 months' follow-up were used
in analysis)
Participants Number randomised: 265
Setting: multi-centre
Country: USA
Sex: 217 females and 48 males
Age, years: mean 46.1 for 217 women
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: eligible participants were at least 18 years old and received a diagnosis of IC, con-
firmed by cystoscopy and hydrodistension, according to National Institutes of Health-NIDDK criteria.
All patients were required to have urinary frequency (self-reported 11 or more daily) and pain/discom-
fort (4 or more on a 0 to 9 Likert scale) for at least 24 weeks before study entry. Minimum of 12 weeks of
treatment with any standard form of therapy or combination of therapies for IC must have failed; pa-
tients could not have been previously treated with BCG
Exclusion criteria 1 (medical history, comorbid conditions and tests): any history of bladder calcu-
lus, tuberculous cystitis; neurological disease affecting bladder function; bladder cancer, urethral can-
cer, prostate cancer (men only); other neoplasms requiring systemic therapy. Prior 12 weeks: genital
herpes. Prior 6 weeks: positive urine culture (100,000 colony count). Concurrent: active tuberculosis re-
quiring ongoing therapy; immunocompromised or known positive for HIV; vesicoureteral reflux; unable
to void spontaneously; active urethral calculus, ureteral calculus, urethral diverticulum; documented
chronic bacterial prostatitis (men only); active vaginitis, pregnancy, breastfeeding (women only); se-
vere debilitating medical conditions; at least 1 voided volume 75 cc in a 24-hour period; residual urine
volume 150 cc by ultrasound or catheter (men only)
Exclusion criteria 2 (prior and concurrent treatment): any history of: intravesical BCG, known aller-
gy to or intolerance of BCG; cyclophosphamide; pelvic radiation; augmentation cystoplasty, cystecto-
my or cystolysis; neurectomy, implanted peripheral nerve stimulator. Prior 24 weeks: botulinum toxin
injections for voiding dysfunction; urinary incontinence surgery; other bladder or urethral surgery that
could interfere with bladder function; TURP, TUIP, TUIBN, TUMT, TUNA, balloon dilation of the prostate,
open prostatectomy or any other prostate treatment such as cryotherapy or thermal therapy (men on-
ly); transvaginal surgery, hysterectomy, prolapse surgery, vaginal delivery or C-section (women only).
Prior 12 weeks: hydrodistension, any intravesical treatment. Prior 6 weeks: urethral dilation, urody-
namics, cystoscopy, bladder biopsy. Prior 4 weeks: initiation of any new medications for IC; any use of
pentosan polysulfate; participation in another intervention study. Concurrent: isoniazid, rifampin, oth-
er antituberculosis therapies; anticoagulant therapy with the exception of low-dose aspirin
Interventions Group A (n = 131): 1 mL of live TICE bacillus Calmette-Guérin (BCG) dissolved in 49 mL of normal saline
Group B (n = 134): 50 mL of normal saline
Up to six 50 mL instillations, each lasting up to 2 hours. Interval of 6 days to 3 weeks between instilla-
tions, and all completed within 10 weeks
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Cure or improvement: response to instillation at week 34 (from start of treatment). This is defined as re-
port of moderate or marked improvement on GRA, as well as recording no new IC treatments, no addi-
tional narcotic analgesia and no increase in IC medication dosage during weeks 31 to 34
Pain: VAS (range 0 to 9): at 34 weeks
ICSI: at 34 weeks
ICPI: at 34 weeks
Mayer 2005  (Continued)
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Functional bladder capacity: at 34 weeks
Adverse events: at 34 weeks
Funding Co-operative agreements from NIDDK, University of Maryland General Clinical Research Centre Grant,
General Clinical Research Centres Program, National Centre for Research Resources, NIH (National In-
stitutes of Health)
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk "double-blind, placebo-controlled". Placebo not described. Intravesical BCG
vs intravesical placebo
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk "double-blind, placebo-controlled". Placebo not described. For improvement
outcome, "a blinded, centralised review of the GRA [global response assess-
ment) and medication diaries was performed". Unclear for other outcomes
Blinding of outcome as-
sessment (detection bias)
Objective outcome




























Low risk 109/131 (83%) included in intervention group; 113/134 (84%) included in
placebo group
Mayer 2005  (Continued)
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Low risk Results included all outcomes specified in the methods section





Methods Study design: RCTStudy duration (month): 0.2




Age, years: mean 38, SD 11
Diagnosis: PBS
Inclusion criteria: women with PBS
Exclusion criteria: not reported
Interventions Group A (n = 15): incobotulinumtoxin A 200IU with 20 ml distilled water with 200 mcl 0.1 N HCl and 2
ml DMSO (dimethyl sulfoxide)
Group B (n = 8): NaCl 25 ml
Treatment category in NMA: neuromuscular blockade + DMSO versus control
Outcomes Outcome data in analysis
Pain: VAS (assumed range 0 to 10) at 5 days
Frequency: at 5 days
Adverse events: at 5 days
Funding NMTC International
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Mirkin 2012 
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Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Intravesical electromotive incobotulinumtoxinA and
DMSO (20 ml) versus saline (25 ml).
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Blinding not mentioned. Intravesical electromotive incobotulinumtoxinA and












Unclear risk Number analysed not stated.
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section.





Methods Study design: RCT
Study duration (months): 1




Age, years: not reported
Diagnosis: BPS
Inclusion criteria: women with BPS
Exclusion criteria: not reported
Interventions Group A (n = 38): hyaluronic acid (HA) 40 mg/50 mL plus 15 mg of tacrolimus (anticytokine substance).
Tacrolimus was preliminarily dissolved in dimethyl sulfoxide (DMSO) 15 mg/5 mL and was mixed with
HA before instillation
Group B (n = 30): HA 40 mg/50 mL (BioCyst) twice a week for 3 months
Treatment category in NMA: anticytokines vs control
Mirkin 2015 
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Outcomes Outcome data in analysis
Pain: VAS (assumed range 0 to 10): at 1 month
Frequency: at 1 month
Funding Not reported
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Intravesical instillation of hyaluronic acid (HA) vs HA +
anticytokine substances (tacrolimus)
Blinding of outcome as-
sessment (detection bias)
Subjective outcome





Unclear risk Number analysed not stated. 2/19 (11%) dropped out from HA group; 3/19
(16%) dropped out from HA + tacrolimus group, all due to pain after instilla-




Unclear risk Number analysed not stated. 2/19 (11%) dropped out from HA group; 3/19
(16%) dropped out from HA + tacrolimus group, all due to pain after instilla-
tion. Unclear how missing data were handled
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 1




Age, years: not reported
Moldwin 2015 
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Diagnosis: IC/BPS with moderate to severe pain
Inclusion criteria: women with IC/BPS with moderate to severe pain
Exclusion criteria: not reported
Interventions Group A (n = 36): AF-219
Group B (n = 38): placebo
Regimen: AF-219 was started at 50 mg BID and was titrated up by 50 mg BID every day until 300 mg or
until the highest tolerable dose
Treatment category in NMA: P2X3 antagonist vs control
Outcomes Outcome data in analysis
Adverse events: at 1 month
Funding Afferent Pharmaceuticals, Inc
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk "double-blind, placebo controlled study". Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Unclear risk Number analysed not reported
Selective reporting (re-
porting bias)
Unclear risk Outcomes not specified in methods (abstract only)





Methods Study design: RCTStudy duration (months): 3
Participants Number randomised: 110
Mulholland 1990 
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Setting: 5 centres
Country: USA
Sex: 98 females and 12 males
Age, years: mean 43.3 for Group A, mean 45.3 for Group B
Diagnosis: IC
Inclusion criteria: patients with the following examination requirement and symptom complex: ur-
gency expressed as moderate on a 5-point analog scale; frequency of at least 10 voids per day; noc-
turia of at least 2 voids per night; pain as recorded on a 5-point analog scale; continuous duration of
symptom for at least 1 year; failed previous conventional therapy such as Clorpactin, hydrodilation or
DMSO; average voided volume of 200 mL measured over 3-day period; negative urine culture and cytol-
ogy; cystoscopic examination under anaesthesia showing petechial haemorrhages or ulcers with gross
blood in the fluid return and bladder capacity of 800 mL or less
Exclusion criteria: patients with any of the following conditions: younger than 18 years; pregnancy;
premenopausal and not practicing effective means of birth control; evidence of active bleeding peptic
ulcer disease; bleeding diathesis; anticoagulant therapy; long-term use of narcotics; known allergy to
pentosan polysulfate sodium; lack of availability for the duration of the study or inability to follow in-
structions; use of artificial sweeteners; lactating mothers; signs of recurrent bacteriuria; obvious neu-
rological impairment; previous treatment with known bladder irritants; bladder carcinoma; urinary tu-
berculosis; schistosomiasis; treatment with Elmiron within 6 weeks of study
Interventions Group A (n = 54): pentosan polysulfate (PPS, oral)
Group B (n = 56): placebo
Treatment category in NMA: PPS vs control
Outcomes Outcome data in analysis
Cure or improvement: patient self-evaluation: overall improved: at 3 months
Pain: VAS (range 0 to 5): at 12 weeks
Adverse events: at 12 weeks
Funding PPS and placebo supplied by Medical Market Specialities, Inc., Boonton, New Jersey, USA
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomly assigned … with a computer-generated random code"
Allocation concealment
(selection bias)
Low risk Quote: "all investigators were blinded during the study with the code estab-





Low risk "double blind"; "identically-appearing placebo capsules were given in the
same manner" as study drug
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double blind"; "identically-appearing placebo capsules were given in the
same manner" as study drug
Mulholland 1990  (Continued)
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Low risk 51/54 (94%) included in intervention group; 47/56 (84%) included in control
group. "It is likely that lack of efficacy was responsible for patients dropping









Unclear risk Number analysed not reported
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: cross-over randomised trial
Study duration (months): 5




Age, years: not reported
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients with IC
Exclusion criteria: not reported
Interventions Group A (n = 13): acidic-buFered solution with pH of 5.0
Group B (n = 13): neutral buFered solution (H2PO4) with pH of 7.5
Single instillation via catheter of 100 mL solution, lasting for 30 minutes. Bladder then drained and
washed twice with sterile de-ionised water; a second 100 mL solution then instilled
Treatment category in NMA: buFer solutions vs control
Outcomes Outcome data in analysis
Pain: 10-point numerical rating scale (assumed range 0 to 9): at 5 minutes after instillation
Funding Interstitial Association, USA
Notes Publication status: full text
Cross-over trial. Data for the first phase only were sought for this review
Nguan 2005 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk Blinding not mentioned. Bladder instillation with acidic vs neutral buFered so-
lution
Blinding of outcome as-
sessment (detection bias)
Subjective outcome





Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCTStudy duration (months): 0.5
Participants Number randomised: 102
Setting: 19 centres
Country: USA and Canada
Sex: 99 female and 3 male
Age, years: median 42.5 (range 20 to 70) for Group A, median 49.0 (range 21 to 74) for Group B
Diagnosis: IC/PBS (clinical diagnosis)
Inclusion criteria: men and women aged 18 to 75 years with a history of symptoms of bladder pain/
discomfort ≥ 4 on a 10-point Likert scale, described as suprapubic pain related to bladder filling, ac-
companied by other symptoms including increased daytime and nighttime frequency (≥ 8 and ≥ 2, re-
spectively) in the absence of infection or other pathology, with or without the typical cystoscopic ap-
pearance of IC. Symptoms of abnormal urinary frequency and bladder pain/discomfort must have been
present for ≥ 3 months before study entry, as well as anterior vaginal wall/bladder wall pain on bimanu-
al examination
Exclusion criteria: patients were excluded from the study if any of the following criteria were present:
(1) currently receiving local anaesthetic analogue therapy or had received treatment for IC/PBS within
4 weeks before baseline visit; (2) unable to void spontaneously; (3) history of cardiac arrhythmias, other
cardiac conduction disturbances and/or significant cardiovascular disease; (4) liver disease; (5) pelvic
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radiotherapy; (6) tuberculous cystitis; (7) neurological disease affecting bladder function; (8) bladder
cancer, or carcinoma in situ, or urethral cancer; (9) bladder, urethral or ureteric calculi or clinical ev-
idence of urethritis; (10) severely debilitating or urgent concurrent medical condition; (11) men with
history of prostate cancer or an unevaluated suspicious prostate examination, or who were receiving
treatment for chronic bacterial prostatitis, as documented by a positive urine culture; or previous his-
tory of recurrent bacterial UTI; (12) women who were pregnant or breastfeeding or had symptoms of
bladder pain/discomfort and urinary frequency present only during menstruation; (13) women of child-
bearing potential, or men with partners of child-bearing potential, who were not prepared to commit
to use of a reliable form of contraception during the course of the study
Interventions Group A (n = 50): PSD597 (200 mg lidocaine + 8.4% sodium bicarbonate solution to a final volume of 10
mL) (PSD597 = intravesical alkalinised lidocaine)
Group B (n = 52): saline
Treatment category in NMA: local anaesthetics vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately’ or ‘markedly’ improved on GRA: at 15 days
Pain: 10-point Likert scale (assumed range 0 to 9 as reported in Nickel 2010 but could be 1 to 10): at 15
days
ICSI: at 15 days
ICPI: at 15 days
Adverse events: at 15 days
Funding Plethora Solutions Plc
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly allocated"
Allocation concealment
(selection bias)





Unclear risk "double-blind, placebo-controlled" trial. Blinding methods not described.
Bladder instillation of 10 mL of local anaesthestic or 10 mL of saline (placebo)
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk "double-blind, placebo-controlled" trial. Blinding methods not described.









Low risk 45/50 (90%) included in intervention group; 50/52 (96%) included in control
group
Nickel 2009  (Continued)
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)





























Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 65
Setting: multi-centre
Country: Canada, USA
Sex: 64 females and 1 male
Age, years: mean 45.5 (SD 16.07) for Group A, mean 44.4 (SD 14.87) for Group B
Diagnosis: IC/PBS. Clinical diagnosis consistent with the IC Database Study (Hanno 1999), and defini-
tion of IC/PBS described at the NIH Urologic Chronic Pelvic Pain Consensus Symposium (Baltimore, De-
cember 2007)
Inclusion criteria: females and males at least 18 years of age with clinical diagnosis of IC/PBS and no
medical condition or therapy that would exclude safe concomitant use of chondroitin sulfate were
evaluated in this clinical trial. Patients met all of the following inclusion criteria for this study: female
or male patient 18 years or older; negative bacterial urine culture from urine collected aseptically dur-
ing the screening period; patient-reported average urinary frequency at least 11 times per 24-hour peri-
od during the screening period, as captured by a 2-day diary; average pain/discomfort score of at least
4 on a 0 to 9 Likert pain scale during the screening period. In addition, all female patients of child-bear-
ing age had a negative urine pregnancy test at baseline, or assurance of previous surgery, condition or
state rendering conception impossible
Exclusion criteria: patients who met any of the following criteria: lactating females; currently receiv-
ing or having previously received investigational drugs within 30 days of screening; received any intrav-
esical therapy for IC/PBS within 4 months of first study instillation; received any oral therapy for IC/PBS
within 2 months of first study instillation (an exception is permitted for oral tricyclic antidepressants).
Patients were excluded if they were prescribed antihistamines, hormonal agonists or antagonist thera-
pies within the last 2 months (they could be included if doses of these therapies had been stable during
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the last 2 months and did not change during the duration of the study); had neurological disease that
is known to or may affect bladder function; had previous surgeries or procedures that affected bladder
function; had a current diagnosis of chemical tuberculosis or radiation cystitis; had a history of bladder
or lower ureteral calculi; had a history of cancer within the last 5 years other than adequately treated
non-melanoma skin cancer; were known to have an active sexually transmitted disease; were known to
have current vaginitis; or had current endometriosis confirmed by laparoscopy or biopsy. Patients re-
ceiving allowable pre-study therapies for IC/PBS were asked not to change these regimens throughout
the course of treatment and follow-up periods. Instead, to manage any episodes of increased pain as-
sociated with IC/PBS, the following analgesic therapies were allowed: narcotic analgesics, urinary anal-
gesics, non-steroidal anti-inflammatory drugs, salicylate and other non-narcotic analgesics
Interventions Group A (n = 33): 20 mL of 2% sodium chondroitin sulfate
Group B (n = 32): 20 mL NaCl
Treatment category in NMA: chondroitin sulfate vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately’ or ‘markedly’ improved on GRA: at 12 weeks
Pain: 10-point Likert scale (range 0 to 9): at 7 weeks
Frequency: at 7 weeks
ICSI: at 12 weeks
ICPI: at 12 weeks
Adverse events: at 12 weeks
Funding Watson Pharmaceuticals, Inc.
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized … after a predetermined randomization schedule"
Allocation concealment
(selection bias)





Low risk Quote: "double-blind". Intravesical instillation of study drug or vehicle control.
"Blinding … was maintained throughout the study by use of identical patient
kits containing identically appearing active or vehicle control vials and pack-
aging"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk Quote: "double-blind". Intravesical instillation of study drug or vehicle control.
"Blinding … was maintained throughout the study by use of identical patient





Low risk 29/33 (88%) included in intervention group (2 discontinued due to consent
withdrawal, 1 due to lack of efficacy, 1 lost to follow-up); 29/33 (88%) included
in control group (1 discontinued due to adverse event, 1 due to consent with-
drawal); LOCF also used
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Low risk 29/33 (88%) included in intervention group (2 discontinued due to consent
withdrawal, 1 due to lack of efficacy, 1 lost to follow-up); 29/33 (88%) included
in control group (1 discontinued due to adverse event, 1 due to consent with-




Low risk 29/33 (88%) included in intervention group (2 discontinued due to consent
withdrawal, 1 due to lack of efficacy, 1 lost to follow-up); 29/33 (88%) included
in control group (1 discontinued due to adverse event, 1 due to consent with-





Low risk 29/33 (88%) included in intervention group (2 discontinued due to consent
withdrawal, 1 due to lack of efficacy, 1 lost to follow-up); 29/33 (88%) included
in control group (1 discontinued due to adverse event, 1 due to consent with-





Low risk 29/33 (88%) included in intervention group (2 discontinued due to consent
withdrawal, 1 due to lack of efficacy, 1 lost to follow-up); 29/33 (88%) included
in control group (1 discontinued due to adverse event, 1 due to consent with-




Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 2.8




Age, years: mean 44.4 (SD 14.59) for Group A, mean 46.8 (SD 14.06) for Group B. 8 women (8.2%) were
aged 65 and above
Diagnosis: IC/BPS
Inclusion criteria: women were considered for inclusion in the present study if they had been diag-
nosed or re-diagnosed with IC/BPS within the previous 2 years; had a subject-reported average urinary
frequency of 8 times/24 hours during the screening period, as captured by a 3-day diary; had a pain/
pressure/discomfort score of 40 to 80 mm on a pain visual analog scale (VAS) during the screening pe-
riod; and had an inadequate clinical response after 6 months of conservative treatment. Conservative
treatment could have included ≥ 1 of the following: patient education, timed voiding and behaviour-
al modification therapy, dietary restrictions, stress reduction and/or oral therapy with tricyclic anti-
depressants, antihistamines, antimuscaranic (anticholinergic) agents, α-adrenergic blockers or anal-
gesics. Subjects were also required to have had a negative urine pregnancy test at screening and had to
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agree to use an acceptable form of birth control, as agreed to by the investigator, during the study peri-
od, if of child-bearing potential
Exclusion criteria: subjects were excluded from participation if they were lactating; had previously re-
ceived investigational products or devices within 30 days of screening; had previously received Ura-
cyst; had had symptoms of IC/BPS for > 8 years; or had received any intravesical therapy (including hy-
drodistension), oral pentosan polysulfate or oral chondroitin within 12 weeks of screening. They were
also excluded if they had received any of the following medications within 4 weeks of screening, unless
such medications had been administered at a stable dose during that month and no changes had been
made to these medications during the study: tricyclic antidepressants, antihistamines (use of antihis-
tamines as needed for allergies were allowed), anticonvulsants, adrenergic blockers, hormonal ago-
nists or antagonists or anticholinergic agents. Also, women were excluded if they had used ≥ 70 mg of
morphine equivalents of opioids weekly within 4 weeks of screening; were currently receiving therapy
with invasive neuromodulation; had any current condition that could be confused with IC/BPS or could
confuse the presentation of IC/BPS; had a screening period postvoid residual urine volume > 100 mL;
or had a history of bladder or lower ureteral calculi or previous surgery or procedures that could have
affected bladder function or any cancer within 5 years before screening, other than adequately treated
non-melanoma skin cancer
Interventions Group A (n = 49): 20 mL of 2% sodium chondroitin sulfate
Group B (n = 49): 20 mL of NaCl
Weekly for 8 weeks
Treatment category in NMA: chondroitin sulfate vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately’ or ‘markedly’ improved at 15 days: at 11 weeks
Pain: VAS (assumed range 0 to 100): at 11 weeks
Frequency: at 11 weeks
ICSI: at 11 weeks
ICPI: at 11 weeks
Adverse events: at 11 weeks
Funding Watson Pharmaceuticals, Inc.
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the treatment assignment was made according to a randomization
schedule generated using a permuted block by a randomisation statistician




Low risk Quote: "the treatment assignment was made according to a randomization
schedule generated using a permuted block by a randomisation statistician
(independent from the project statistician)"
Comment: probably done
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Low risk Quote: "double-blind". Bladder instillation of study drug or inactive control
("the identical phosphate-buFered saline vehicle used")
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk Quote: "double-blind". Bladder instillation of study drug or inactive control




Low risk 41/49 included in intervention group (discontinued due to 1 adverse event, 1
consent withdrawal, 5 lack of efficacy, 1 lost to follow-up); 40/49 included in
control group (discontinued due to 1 consent withdrawal, 5 lack of efficacy, 2




Low risk All randomised participants were included in analysis (assumption made - in-




Low risk All randomised participants were included in analysis (assumption made - in-





Low risk All randomised participants were included in analysis (assumption made - in-





Low risk All randomised participants were included in analysis (assumption made - in-




Low risk All randomised participants were included in analysis (assumption made - in-
consistent reporting of denominators)
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCTStudy duration (months): 3
Participants Number randomised: 161
Setting: 35 centres
Country: USA, Canada, Denmark, Finland, France, Germany
Sex: 147 females and 14 males
Age, years: mean 49.9 (SD 13.6, range 19 to 76) for Group A (30 mg/d, n = 54), mean 49.6 (SD 14.6, range
21 to 80) for Group A (60 mg/d, n = 55), mean 52.1 (SD 14.0, range 22 to 79) for Group B (n = 52)
Diagnosis: IC, moderate to severe
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Inclusion criteria: participants had moderate to severe IC based on scores of 13 or more on the Pelvic
Pain and Urgency/Frequency Questionnaire and 7 or greater on the O’Leary-Sant ICSI. Study inclusion
also required evidence of cystoscopy within 2 years of screening to confirm the absence of other sig-
nificant lower urinary tract pathology and the presence or absence of cystoscopic features of IC. Study
continuation required completion of 4 or more daily worst pain severity scores during the 7 days before
randomisation, with a mean daily worst pain severity score of 4 or more on an 11-point numerical rat-
ing scale (range 0 (no IC pain) to 10 (IC pain as bad as you can imagine)). Mean severity score was the av-
erage of 24-hour worst pain severity scores recorded for the 7 days before randomisation. Mean mic-
turition frequency per 24 hours of 8 or more (derived from the symptom diary before randomisation)
was also required
Exclusion criteria: IC symptoms less than 6 months; PVR urine volume greater than 200 mL at screen-
ing; history, diagnosis, signs or symptoms of any clinically significant psychiatric disorder; MVV less
than 50 mL or greater than 350 mL during 3 consecutive days; total volume voided greater than 3000
mL on average per 24 hours; greater than 1 haematuria on dipstick test at screening, unless fully inves-
tigated to rule out significant urological disease; and/or microbiologically proven urinary tract infection
at screening or randomisation
Interventions Group A (n = 109): PD-0299685 (Ca2 Channel 2 Ligand)
Group B (n = 52): placebo
Regimen: after the run-in, patients received placebo, 30 mg PD-0299685 daily (administered as 15 mg
BID) or 60 mg PD-0299685 daily (administered as 30 mg BID) for 12 weeks
Treatment category in NMA: calcium channel agonists vs control
Outcomes Outcome data in analysis
Cure or improvement: based on GRA (assumed from reports): at 12 weeks
Pain: 11-point numerical rating scale (range 0 to 10): at 12 weeks
Frequency per 24 hours: at 12 weeks
ICSI: at 12 weeks
Adverse events: at 12 weeks
Funding Pfizer
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "the randomization list was created with computer-generated pseu-
do-random code using the method of random permuted blocks"
Allocation concealment
(selection bias)





Unclear risk "double-blind, placebo-controlled" trial. Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk "double-blind, placebo-controlled" trial. Placebo not described
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design RCTStudy duration (months): 6
Participants Number randomised: 369
Setting: 67 sites
Country: USA and Canada
Sex: 332 females and 36 males
Age, years: median 44.0 (range 18 to 87) for Group A (100 mg QD, n = 128), median 42.0 (range 19 to 85)
for Group A (100 mg TID, n = 122), median 44.0 (range 18 to 78) for Group B (n = 118)
Diagnosis: IC/PBS (NIDDK criteria)
Inclusion criteria: study participants were men and women 18 years of age or older with IC/BPS based
on a total score of 8 or greater on ICSI and a score of greater than 0 on each component item (bladder
pain, urinary urgency, frequency and nocturia) that was unrelated to urinary tract infection for at least
6 months before screening: eligible patients experienced an average of at least 10 voids per day (i.e. 30
or more voids during 3 consecutive days), of which 1 or more occurred during the night (i.e. score of 1
or greater on ICSI item 3)
Exclusion criteria: key eligibility criteria also required that patients had not received intravesical
therapy (e.g. bladder distension, dimethyl sulfoxide) or undergone cystoscopy during the 4 weeks be-
fore screening. They had no evidence of microscopic haematuria or evaluation positive for significant
urological disease within the prior year. In addition, they had not received drugs known to affect IC/
BPS symptoms (i.e. antidepressants, antihistamines, antispasmodics or anticholinergics) within the 4
weeks before screening
Interventions Group A (n = 251): pentosan polysulfate (PPS, oral)
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Group B (n = 118): placebo
Regimen: PPS 100 mg QD (i.e. once a day) or PPS 100 mg TID (i.e. 3 times a day) for 24 weeks
Treatment category in NMA: PPS vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 24 weeks
Pain: 11-point numerical rating scale (range 0 to 10): at 24 weeks
Frequency: at 24 weeks
Adverse events: at 24 weeks
Funding Janssen Research & Development
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk "double-blind, placebo-controlled" trial, using "matching placebo"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Low risk For missing data, "the last observed data were carried forward to the end
point for analysis" (despite large number discontinuing trial: 106/251 from in-














Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section
Other bias Low risk None detected
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Methods Study design: RCT
Study duration (months): 2
Participants Number randomised: 82
Setting: not reported
Country: not reported
Sex: 70 females and 12 males
Age, years: mean 45.3 (range 22 to 74) for Group A, mean 51.4 (range 24 to 77) for Group B
Diagnosis: IC/BPS
Inclusion criteria: male and female patients aged ≥ 18 years. Female patients had to meet 1 of the fol-
lowing criteria: non-child-bearing potential: postmenopausal, defined as women who aged ≥ 45 years
with amenorrhoea for 24 consecutive months; child-bearing potential: were not pregnant or lactating
and abstinent, or using adequate contraception. Inclusion criteria also required evidence of cystoscopy
within 2 years of screening confirming the absence of significant lower urinary tract pathology and the
presence or absence of cystoscopic features of interstitial cystitis/bladder pain syndrome (IC/BPS). Pa-
tients were randomised if at visit 2 (randomisation), they met the continuation criteria of completed 4
or more average bladder pain scores within any of the 7 days before randomisation with a mean aver-
age bladder pain intensity score of 4 or greater (on an 11-point NRS) and a mean micturition frequency
of 8 or greater per 24 hours during any 3 consecutive days in the previous 7 days
Exclusion criteria key exclusion criteria were patients with body mass index > 39 kg/m2; pregnant
women, lactating women, women suspected of being pregnant and women wishing to become preg-
nant during the course of the study; patients with symptoms of IC/BPS for < 6 months before screen-
ing; patients with postvoid residual volume > 200 mL at screening; patients with mean voided volume
< 40 and > 400 mL per micturition as measured over 1 day of the 7-day e-diary period completed before
randomisation (visit 2); patients with total daily volume voided > 3500 mL, as confirmed by the e-diary
completed before randomisation
Interventions Group A (n = 40): 20 mg subcutaneous tanezumab
Group B (n = 42): placebo
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Pain: 11-point numerical rating scale (range 0 to 10): at 8 weeks
Adverse events: at 8 weeks
Funding Pfizer
Notes Publication status: full text
This paper reports multiple trials. Data for this review were extracted only from "Study A4091035"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
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Allocation concealment
(selection bias)





Unclear risk "double-blind, placebo-controlled" trial using subcutaneous dosing. Placebo
not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome









Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 1
Participants Number randomised: 20
Setting: not reported
Country: Japan
Sex: 19 females and 1 male
Age, years: mean 66.9 (SD 17.0) for Group A, mean 72.5 (SD 8.8) for Group B
Diagnosis: IC
Inclusion criteria: patients with refractory IC, defined as persisting symptom of O’Leary and Sant In-
terstitial Cystitis Symptom Index/Problem Index (OSSI/OSPI) score greater than 6 points, respectively,
and numerical rating scale for pain (NRS) more than 3 out of 10 points, despite multiple conventional
therapies such as lifestyle modification, hydrodistension and oral medication
Exclusion criteria: not reported
Interventions Group A (n = 10): 6-week weekly 20,000 U heparin and 5 mL 4% lidocaine in phosphate-buFered saline
at pH 7.5 (intravesical instillation)
Group B (n = 10): 6-week weekly 20,000 U heparin in 30 mL physiological saline
Treatment category in NMA: local anaesthetics vs control
Outcomes Outcome data in analysis
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Cure or improvement: 'markedly or moderately improved' on GRA: at 4 weeks
Pain: 10-point numerical rating scale (unclear minimum/maximum score): at 4 weeks
Frequency: at 4 weeks
Nocturia: at 4 weeks
ICSI: at 4 weeks
ICPI: at 4 weeks
Adverse events: at 4 weeks
Funding Iida Grant of Mitsui Memorial Hospital
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Quote: "double-blind"
Comment: blinding methods not described. Intravesical instillation of heparin
+ lidocaine vs heparin
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Quote: "double-blind"
Comment: blinding methods not described. Intravesical instillation of heparin








High risk 7/10 included in intervention group (3 withdrew because of symptom worsen-




High risk 7/10 included in intervention group (3 withdrew because of symptom worsen-




High risk 7/10 included in intervention group (3 withdrew because of symptom worsen-





High risk 7/10 included in intervention group (3 withdrew because of symptom worsen-
ing); 10/10 included in control group
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High risk 7/10 included in intervention group (3 withdrew because of symptom worsen-




Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design RCT
Study duration (months): 2.8




Age, years: not reported
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients with interstitial cystitis who fulfilled the National Institutes of Health Na-
tional Institute for Diabetes and Digestive and Kidney Diseases criteria were prospectively recruited
from our urogynaecology clinics. They were well-motivated patients in whom interstitial cystitis had
failed to respond to various oral and intravesical therapies. Inclusion criteria consisted of ability to give
informed consent, ability to perform treatment during 84 days and attend for follow-up, pain on blad-
der filling relieved by emptying; suprapubic, urethral, vaginal or perineal pain; glomerulations at cys-
toscopy and decreased bladder capacity or compliance at urodynamics
Exclusion criteria: younger than 18 years of age, duration of symptoms less than 12 months, daytime
frequency less than 7 times in 12 hours and nocturia less than 2 times, detrusor overactivity on urody-
namics, bladder tumour or calculus, urinary tract infection, radiation-induced cystitis and any cause of
peripheral neuropathy or degenerative conditions of the spinal cord
Interventions Group A (n = 29): transdermal posterior tibial nerve stimulation using active device (laser on for 30 sec-
onds over SP6/Sanyinjiao acupuncture point, once daily for 12 weeks): at home
Group B (n = 27): placebo device
Treatment category in NMA: behavioural therapy vs control
Outcomes Outcome data in analysis
Pain: SF-36 bodily pain score (range 100 to 0, with higher scores indicating less pain): at 12 weeks
ICSI: at 12 weeks
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ICPI: at 12 weeks
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly allocated"
Allocation concealment
(selection bias)





Low risk Trandermal laser therapy using an active or placebo device
"The sham devices were identical but inactivated so that neither patient nor
recruiter were aware of device type"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk Trandermal laser therapy using an active or placebo device
"The sham devices were identical but inactivated so that neither patient nor




Low risk 29/29 included in intervention group; 27/27 included in control group. "Inter-









Low risk 27/29 included in intervention group; 26/27 included in control group. "Inter-





Low risk 27/29 included in intervention group; 26/27 included in control group. "Inter-
mittent missing data" were imputed with "horizontal mean imputation"
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
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Participants Number randomised: 10
Setting: not reported
Country: USA
Sex: 8 females and 2 males
Age, years: average 68
Diagnosis: IC (Hunner's ulcer-type)
Inclusion criteria: patients presenting with Hunner’s ulcer-type IC were recruited for the study begin-
ning in January 2012. The study included patients with urgency, frequency and chronic pelvic pain con-
sistent with IC as well as cystoscopy and biopsy confirming the presence of Hunner’s ulcers
Exclusion criteria: patients were excluded if they had an active urinary tract infection, history of blad-
der malignancy, recent bladder surgery, allergy to triamcinolone or were pregnant or unable to under-
go anaesthesia
Interventions Group A (n = 5): triamcinolone injection (10 mL of triamcinolone acetonide, 40 mg/mL) of Hunner’s ul-
cers
Group B (n = 5): fulguration (using Bugbee electrocautery)
Once-only treatment
Treatment category in NMA: immune modulator vs fulguration
Outcomes Outcome data in analysis - no usable data
Funding None
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)
Unclear risk Concealment methods not described. Stated only as "Patients were blinded to
the type of procedure they received. The surgeon was blinded … until just pri-





High risk Probably not done (fulguration vs triamcinolone injection). Surgeons could
not be blinded
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Stated as "patients were blinded to the type of procedure they received", even




Low risk Results included all outcomes specified in the methods section
Other bias Low risk None detected
Oliver 2013  (Continued)
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Study characteristics
Methods Study design: cross-over randomised trial
Study duration (months): 0.001 (1 hour)




Age, years: not reported
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: IC patients meeting all of the clinical criteria of the NIDDK, with the exception that
cystoscopy under anaesthesia was not required. In addition, they had to have a score of at least 15 on
the Pelvic Pain and Urgency/Frequency Patient Symptom Scale
Exclusion criteria: patients taking tricyclic antidepressants, neurontin or narcotics were excluded. Pa-
tients taking any other medications had to have been on them for a minimum of 3 months
Interventions Group A (n = not reported): 50,000 units heparin + 200 mg lidocaine HCL (hydrochloride) + 420 mg
sodium bicarbonate in 15 mL water
Group B (n = not reported): 420 mg sodium bicarbonate in 15 mL water
Treatment category in NMA: anticoagulants + local anaesthetics vs control
Outcomes Outcome data in analysis - no usable data
Funding Urigen Pharmaceuticals
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized". "All subjects received both drug and control... in a blind-
ed and random order"
Allocation concealment
(selection bias)
Low risk Quote: "The blind was provided by the statistician for all treatments such that





Low risk Quote: "double-blind, placebo-controlled, crossover trial ... control was an ex-
cipient, sodium bicarbonate"; "the blinded kits containing the medications or
control were supplied to each site's pharmacy"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk Quote: "double-blind, placebo-controlled, crossover trial ... control was an ex-
cipient, sodium bicarbonate"; "the blinded kits containing the medications or
control were supplied to each site's pharmacy"
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section
Parsons 2012 
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Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 163
Setting: 30 centres
Country: USA
Sex: 140 females and 23 males
Age, years: mean 47, range 20 to 77
Diagnosis: IC (diagnosis made on clinical and cystoscopic grounds)
Inclusion criteria: patients at least 18 years of age with a diagnosis of IC confirmed by visualisation
of glomerulations at cystoscopy/hydrodistension, symptoms of bladder pain and urinary urgency for
at least 6 months; urinary frequency while awake at least 8 times a day; nocturia at least twice a night;
a pain score of at least 4 (on a 0 to 9 Likert scale) on average over the 30 days before study drug treat-
ment; and at least 1 voided volume of 75 cc or greater in 24 hours during the screening period
Exclusion criteria: patients with Hunner's ulcers. Other exclusion criteria were as follows: (1) current-
ly pregnant or breastfeeding; (2) presence of ulcers on pre-treatment cystoscopy; (3) intravesical ther-
apy or bladder hydrodistension within the previous 60 days; (4) initiation of pentosan polysulfate sodi-
um (Elmiron) within previous 16 weeks; (5) use of fentanyl patches, morphine sulfate, methadone or
B&O Supprettes within the previous 30 days; (6) prior augmentation cystoplasty, cystectomy or cys-
tolysis, neurectomy (i.e. hypogastric nerve plexus ablation) or implanted peripheral nerve stimula-
tor that has affected bladder function; (7) history of ureteral reflux; patients with a history of child-
hood urinary tract infections, recurrent urinary tract infections as an adult (defined as more than 3 cul-
ture-documented episodes within the previous 12 months) or pyelonephritis at any time must have a
cystourethogram to rule out ureteral reflux; (8) evidence of renal impairment, hepatic impairment or
clinically significant cardiovascular, respiratory or psychiatric disease; (9) urinary tract infection or pro-
static infection within 3 months before study entry; (10) active genital herpes or vaginitis; (11) urethral
diverticulum; (12) uterine, cervical, vaginal or urethral cancer within 5 years before study entry (13) his-
tory of cyclophosphamide or chemical cystitis, urinary tuberculosis or radiation cystitis; (14) history of
bladder tumours (benign or malignant)
Interventions Group A (n = 119): 3 arms combined for this review: A: resiniferatoxin (RTX) 0.01 microMol/L solution
in 10% ethanol in saline. Arm B: RTX 0.05 microMol/L solution in 10% ethanol in saline. Arm C: RTX 0.10
microMol/L solution in 10% ethanol in saline
Group B (n = 44): 10% ethanol in saline (placebo)
Group A & B: bladder then drained and rinsed with normal saline. Pre-treatment instillation with lido-
caine solution (initially 50 mL of 2% lidocaine for 10 minutes, increased later in study to 100 mL of 4%
lidocaine for 30 minutes). Single instillation treatment of 50 mL of RTX solution or placebo retained for
30 minutes
Treatment category in NMA: calcium channel agonists (3 arms) vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 4 weeks
Payne 2005 
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Pain: numerical rating scale (pain score from diary) (range 0 to 9): at 12 weeks
Adverse events: at 4 weeks
Funding ICOS Corporation (American biotechnology company)
Notes Publication status: full text
Notes from previous versions of the review: attempted study author contact regarding data for pain,
void volume and frequency. No response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomization was centrally performed and stratified by center in
blocks according to a computer-generated random number table"
Allocation concealment
(selection bias)
Low risk Quote: "randomization was centrally performed and stratified by center in





Low risk Quote: "'double-blind, placebo-controlled" trial. "All patients and site person-
nel were blinded to treatment assignment except for study pharmacists re-
sponsible for preparing study drug"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk Quote: "'double-blind, placebo-controlled" trial. "All patients and site person-
nel were blinded to treatment assignment except for study pharmacists re-




Low risk Review authors chose to use available case analysis. 116/119 (97%) included in




Low risk 119/119 included in intervention group; 43/44 included in control group (1





Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 16
Payne 2014 
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Setting: single institution
Country: USA
Sex: 14 females and 2 males
Age, years: mean 53.7, range 24 to 88
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: adults diagnosed by investigators with IC/BPS as the primary cause of their lower
urinary tract symptoms. Symptoms were present for > 6 months and were refractory to standard thera-
pies; current pain and urgency scores were ≥ 4/10 on a visual analogue scale. Cystoscopy with bladder
distension under anaesthesia was required at some point in the diagnostic evaluation
Exclusion criteria: NIDDK exclusion criteria were employed and residual urine > 100 cc was exclusion-
ary. Prior botox injection and neurostimulators were not allowed
Interventions Group A (n = 14): varying dose of botox injection into trigone and detrusor
Group B (n = 2): saline injection
Once-only treatment
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 6 months (assumed from re-
ports)
Adverse events: at 6 months (assumed from reports)
Funding Investigator-initiated grant from Allergan
Notes Publication status: abstract
"… the study was stopped due to futility without reaching the target recruitment goal after eight
months with no enrollment"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "randomized … by drawing presealed envelopes"
Allocation concealment
(selection bias)
Unclear risk Quote: "randomized … by drawing presealed envelopes"





Unclear risk "double-blind" trial. Injections in the trigone (sub-epithelial level) of botu-
linum toxin or "placebo" (not described). Participants "were pretreated with
… lidocaine in the bladder … prior to injection along with an oral narcotic and
anxiolytic"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk "double-blind" trial. Injections in the trigone (sub-epithelial level) of botu-
linum toxin or "placebo" (not described). Participants "were pretreated with





Low risk All randomised participants were included in analysis ("only two subjects were
randomized to placebo")
Payne 2014  (Continued)
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)

















High risk Pain, ICSI, ICPI and "24 hour bladder dairy variables" were mentioned in the
methods but were not reported in the results





Methods Study design: cross-over randomised trial
Study duration (months): 3
Participants Number randomised: 21
Setting: not reported
Country: USA
Sex: 20 females and 1 male
Age, years: mean 59 (range 36 to 79) for 11 women with ulcerative (classic) disease; mean 43 (range 24
to 61) for 9 women and 1 man with non-ulcerative disease
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients with IC who had non-ulcer disease
Exclusion criteria: not reported
Interventions Group A (n = not reported): 6 × weekly instillations via catheter with bacillus Calmette-Guérin (BCG).
Dose of 5 × 108 colony-forming units, reconstituted with 1 mL of saline and diluted with 50 mL of saline.
Each instillation for duration of up to 2 hours
Group B (n = not reported): 6 × weekly instillations of dimethyl sulfoxide (DMSO). 50 mL of solution at
concentration of 500 mg/mL
Treatment category in NMA: immune modulators vs DMSO
Outcomes Outcome data in analysis - no usable data
Funding BCG ampules were provided by OncoTICE, Organon Teknika, Askim, Sweden
Notes Publication status: full text
Notes from previous versions of the review: very poor data available. Numbers in each treatment group
are missing. Study author contacted, no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "the randomizaton procedure was performed"
Peeker 2000 
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Allocation concealment
(selection bias)
Low risk Quote: "the randomizaton procedure was performed by 1 of us … who subse-





High risk Stated as "double-blind", cross-over study; "evaluation was performed blind-
ly"; "data concerning given substance were concealed until evaluation". How-
ever, "the given substance could not be blinded due to the distinctive breath
odor of dimethyl sufoxide"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Stated as "double-blind", cross-over study; "evaluation was performed blind-
ly"; "data concerning given substance were concealed until evaluation". How-
ever, "the given substance could not be blinded due to the distinctive breath
odor of dimethyl sufoxide"
Selective reporting (re-
porting bias)
High risk Outcomes reported in the results were not specified in the methods, except
the primary outcome ("subjective improvement")
Other bias High risk Some patients may have received both treatments. "Patients randomly under-
went [treatment] and, if not improved, were treated with the other substance






Methods Study design: cross-over randomised trial
Study duration (months): 1.5
Participants Number randomised: 33
Setting: single centre
Country: Canada
Sex: 30 females and 3 males
Age, years: mean 48
Diagnosis: IC (diagnosis made clinically and with cystoscopy/biopsy)
Inclusion criteria: patients with IC
Exclusion criteria: not reported
Interventions Group A (n = 15): 50 mL of 50% dimethyl sulfoxide (DMSO)
Group B (n = 18): 50 mL of normal saline
Four treatments, each 2 weeks apart, involving outpatient bladder instillations given via catheter and
lasting at least 15 minutes. After a 4-week 'rest' period, the 2 groups crossed over, to complete instilla-
tions with the 'other' treatment (i.e. placebo for Group A and DMSO for Group B). Timing of assessment
is unclear, but it looks to have occurred soon after each phase of treatment was given
Treatment category in NMA: DMSO vs control
Outcomes Outcome data in analysis
Cure or improvement: response to treatment rated as moderate or marked improvement: at 6 weeks
(assumed from reports) (at end of first period, which was "4 treatments … at 2-week intervals")
Perez-Marrero 1988 
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Funding Not reported
Notes Publication status: full text
Cross-over trial. Data for the first phase only were sought for this review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





High risk "an evaluator blinded, complete crossover study". Review authors assumed
that patients and carers were not blinded, given breath odor caused by DMSO
bladder instillation mentioned in another trial (Peeker 2000), along with NICE
guidance. "All instillations were performed by a nurse … who had no other in-
volvement"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk "an evaluator blinded, complete crossover study". Review authors assumed




Low risk 15/15 included in intervention group; 17/18 (94%) included in control group (1
excluded as she was "found to be pregnant after the first instillation")
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 27 (for the purpose of this review, data for 8 months were used in the analy-
sis)




Age, years: median 44 (range 30 to 71) for Group A, median 40 (range 23 to 56) for Group B
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: women with IC
Exclusion criteria: immunocompromised patients, concomitant steroid medications, chemotherapy
for other carcinomas, warfarin sodium anticoagulation therapy, pregnancy or unwillingness to practice
Peters 1997 
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protected intercourse, intravesical therapy for IC within 3 months before the study, grade III or greater
vesicoureteral reflux
Interventions Group A (n = not reported): 50 mg Tice strain bacillus Calmette-Guérin (BCG)
Group B (n = not reported): 50 mL of sterile saline
Weekly instillations × 6, each comprising 50 mL volume instilled via Foley catheter. Fluid retained for 2
hours, although temporary drainage and re-instillation permitted if discomfort during 2 hours
Numbers analysed: Group A: 17; Group B: 15
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Cure or improvement: 'responders' to treatment, defined as moderate improvement, greatly improved
or cured in subjective rating of overall symptoms at 6 months
Pain: RAND-36 question pain score (assumed range 100 to 0, with higher scores indicating less pain) at 6
months
Adverse events: at 6 months
Funding Supported in part by grant from the William Beaumont Hospital Research Institute [author affiliated]
and by PerImmune, Inc., Rockville, Maryland
Notes Publication status: full text
Notes from previous versions of the review: attempted to contact study author regarding outcome data
in terms of treatment group, rather than just responder/non-responder. Replied 11/06 "looking for da-
ta"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)
Unclear risk Quote: "randomized in a double-blind fashion"





Low risk "double-blind, placebo controlled". Intravesical treatments of study drug or
"placebo (sterile saline)". "The subjects and investigators remained blinded
to experimental group assignments until all subjects had completed at least 6
months of followup"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind, placebo controlled". Intravesical treatments of study drug or
"placebo (sterile saline)". "The subjects and investigators remained blinded





Unclear risk 33 randomised, 15 included in intervention group; 15 included in control
group. Group assignment of "the 3 unevaluable subjects" unclear
Incomplete outcome data
(attrition bias)
Unclear risk 33 randomised, 15 included in intervention group; 15 included in control
group. Group assignment of "the 3 unevaluable subjects" unclear
Peters 1997  (Continued)
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Unclear risk 33 randomised, 17 included in intervention group; 15 included in control
group. Group assignment of 1 missing subject unclear
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3




Age, years: mean 47 (SD 8, range 35 to 60 for Group A; mean 49 (SD 10, range 31 to 61) for Group B
Diagnosis: BPS/IC
Inclusion criteria: women with refractory BPS/IC and a minimum pain score of 4 on a 0 to 10 visual
analogue scale (VAS)
Exclusion criteria: not reported
Interventions Group A (n = 10): 100 U of OnaBotA in 10 mL saline (intratrigonal injection)
Group B (n = 9): 10 mL saline
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Pain: VAS (assumed range 0 to 10): at 3 months
Frequency: at 3 months
Adverse events: at 3 months
Funding Allergan
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Pinto 2016 
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Allocation concealment
(selection bias)





Unclear risk Quote: "double-blind, placebo-controlled trial"
Comment: intratrigonal injection of OnaBotA or saline. Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Quote: "double-blind, placebo-controlled trial"












Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 64
Setting: 7 urological units
Country: Finland
Sex: 53 females and 11 males
Age, years: mean 56.2 (SD 14.7) for Group A, mean 59.7 (SD 13.0) for Group B
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients meeting NIDDK criteria for IC. Serum transaminase, bilirubin and serum
cholesterol had to be within normal range
Exclusion criteria: history of cancer in the last 10 years; untreated hypertension or renal insufficiency
Interventions Group A (n = 32): cyclosporin A (CyA)
Group B (n = 32): pentosan polysulfate (PPS)
Regimen: 1.5 mg/kg CyA twice daily or 100 mg PPS 3 times daily for a period of 6 months
Sairanen 2005 
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Treatment category in NMA: immune modulators vs PPS
Outcomes Outcome data in analysis
Cure or improvement: based on GRA (assumed from reports): at 6 months
Pain: VAS (0 to 10 centimetres): at 6 months
Frequency: at 6 months
Nocturia: at 6 months
ICSI: at 6 months
ICPI: at 6 months
Adverse events: at 6 months
Funding Finnish Urological Association
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)
Low risk Quote: "randomization was centralized. Closed envelopes were divided into 2
identical blocks, and a nurse not otherwise involved in the study opened the





High risk Quote: "open-label"
Comment: probably not done
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Quote: "open-label"




Low risk Review authors chose to use number who completed trial: 29/32 included in
PPS group (1 missing due to gross haematuria, 2 discontinued as not benefit-





Low risk Review authors chose to use number who completed trial: 29/32 included in
PPS group (1 missing due to gross haematuria, 2 discontinued as not benefit-





Low risk Review authors chose to use number who completed trial: 29/32 included in
PPS group (1 missing due to gross haematuria, 2 discontinued as not benefit-





Low risk Review authors chose to use number who completed trial: 29/32 included in
PPS group (1 missing due to gross haematuria, 2 discontinued as not benefit-
Sairanen 2005  (Continued)
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Low risk Review authors chose to use number who completed trial: 29/32 included in
PPS group (1 missing due to gross haematuria, 2 discontinued as not benefit-






Low risk Review authors chose to use number who completed trial: 29/32 included in
PPS group (1 missing due to gross haematuria, 2 discontinued as not benefit-





Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 75
Setting: not reported
Country: not reported
Sex: 71 females and 4 males
Age, years: mean 57.9 (SD 14.7) for Group A, mean 61.4 (SD 11.3) for Group B
Diagnosis: PBS/IC
Inclusion criteria: patients with PBS/IC
Exclusion criteria: not specified
Interventions Group A (n = 38): 50 mL Tice strain BCG (bacillus Calmette-Guérin)
Group B (n = 37): 50 mL 50% dimethyl sulfoxide (DMSO)
Treatment category in NMA: immune modulator vs DMSO
Outcomes Outcome data in analysis
Cure or improvement: GRA (global assessment to treatment response), much better or completely
cured
Funding Not reported
Notes Publication status: full text
Sairanen 2009 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
This paper reports multiple trials. Data for this review were extracted from only 1 study comparing
DMSO and BCG
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk No information provided
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Unclear risk 31/37 (84%) included in DMSO group; 31/38 (84%) included in BCG group
Selective reporting (re-
porting bias)
Unclear risk Insufficient information (RCT is part of a paper reporting multiple trials)





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 121
Setting: 7 institutions
Country: USA
Sex: 108 females and 13 males
Age, years: mean 47.8 (SD 13.9) for Group A, mean 48.7 (SD 15.1) for Group B, mean 43.7 (SD 15.1) for
Group C, mean 41.0 (SD 15.5) for Group D
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: eligible participants had to be at least 18 years old, receive a diagnosis of IC con-
firmed by cystoscopy and hydrodistension, according to NIH NIDDK criteria. Moderate symptoms of
urinary frequency (at least 11 times daily) and pain/discomfort (at least 4 on a 0 to 9 Likert scale) for at
least 24 weeks before study entry
Exclusion criteria: not reported
Interventions Group A (n = 31): hydroxyzine alone
Sant 2003 
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Group B (n = 29): pentosan polysulfate (PPS) alone
Group C (n = 30): hydroxyzine and PPS combination therapy
Group D (n = 31): placebo
Regimen: the dose of PPS was one 100 mg capsule 3 times daily. The target dose of hydroxyzine was 50
mg daily taken at bedtime titrated from 10 to 25 to 50 mg daily during 3 weeks
Treatment category in NMA: antihistamines vs PPS vs PPS + antihistamines vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 24 weeks
Pain: pain score (score range 0 to 9): at 24 weeks
ICSI: at 24 weeks
ICPI: at 24 weeks
Adverse events: at 24 weeks
Funding NIDDK, NIH (individual study authors have relationships with pharmaceutical companies)
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)










Unclear risk "double masked". Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




High risk Review authors chose to use number who completed trial: 24/31 (63%) in hy-
droxyzine group; 26/29 (90%) in PPS group; 23/30 (77%) in PPS + hydroxyzine









Unclear risk Number analysed not stated
Sant 2003  (Continued)
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Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 1




Age, years: not reported
Diagnosis: PBS
Inclusion criteria: known female patients with PBS, who were treated according to therapeutic recom-
mendations by American Urological Association Guideline with no success
Exclusion criteria: not reported
Interventions Group A (n = 20): hydrodistension with 400 mg SinaCurcumin in 500 cc normal saline
Group B (n = 20): hydrodistension with 500 cc normal saline only
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis; no usable data
Funding Not reported
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Shirvan 2015 
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Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Hydrodistension (HD) with 500 cc saline vs HD with
curcumin in 500 cc saline
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Blinding not mentioned. Hydrodistention (HD) with 500 cc saline vs HD with
curcumin in 500 cc saline
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6




Age, years: not reported
Diagnosis: IC (NIH criteria)
Inclusion criteria: patients who met NIH modified diagnostic and exclusion criteria for IC. All patients
also had to undergo cystoscopy to confirm the presence of Hunner's ulcers or glomerulations
Exclusion criteria: not reported
Interventions Group A (n = 15): 40 mg/50 mL sodium hyaluronate (Cystostat)
Group B (n = 15): DMSO (dimethyl sulfoxide, 5.4%) 27 g in 50 mL (RIMSO-50)
Regimen: Group A: weekly for 4 weeks, then monthly for 2 months; Group B: 2 weekly for 3 months
Treatment category in NMA: hyaluronic acid vs DMSO
Outcomes Outcome data in analysis; no usable data
Funding Not reported
Notes Publication status: abstract
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk No information provided
Selective reporting (re-
porting bias)
Unclear risk This abstract presented no outcome data. "We present the rest of the data
when all patients should have had a six months' follow-up"





Methods Study design: RCT
Study duration (months): 0.7
Participants Number randomised: 22
Setting: single centre
Country: Brazil
Sex: 18 females and 4 males
Age, years: mean 54.9 (SD 5.1) for Group A, mean 55.3 (SD 5.8) for Group B
Diagnosis: IC/PBS (diagnostic criteria according to the 'IC Data Base Study'; referenced as Hanno 1999)
Inclusion criteria: females and males with clinical diagnosis of IC/PBS and no medical condition or
therapy that would exclude safe concomitant use of Cystex; negative bacterial urine culture; patient-re-
ported average urinary frequency of at least 11 times per 24 hour period during the screening period
Exclusion criteria: to be included, urine must have been sterile at time of diagnosis and assessment
and urinary cytology negative; all other diseases that could cause pelvic symptoms were excluded
Interventions Group A (n = 11): Cystex for 3 weeks with a self-titration protocol. Cystex defined as "acriflavin hy-
drochloride 15.00 mg; methenamine 250.00 mg; methylene blue 20.00 mg; beladona extract 15.00 mg"
Group B (n = 11): placebo for 3 weeks
Treatment category in NMA: parasympathomimetic (+ urinary antiseptics) vs control
Outcomes Outcome data in analysis
Pain: VAS (assumed 0 to 100): at 21 days
Functional bladder capacity: at 21 days
Adverse events: at 21 days
Souza 2012 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk "placebo-controlled and double blind design". Study drug "capsule" vs "place-
bo capsules, identical in form, colour and taste to the ones of the active formu-
lation"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "placebo-controlled and double blind design". Study drug "capsule" vs "place-
bo capsules, identical in form, colour and taste to the ones of the active formu-
lation"
Blinding of outcome as-
sessment (detection bias)
Objective outcome

















Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Taha 2007 
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Study duration (months): 24




Age, years: not reported
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients who met NIH NIDDK criteria for IC and reported at least moderate pain and
frequency for a minimum of 6 months
Exclusion criteria: not reported
Interventions Group A (n = 36): bacillus Calmette-Guerin (BCG) instillation
Group B (n = 36): 300 IU botulinum toxin A injection
Regimen: Group A: once-only treatment; Group B: 6 weekly instillations
Treatment category in NMA: immune modulators vs neuromuscular blockade
Outcomes Outcome data in analysis
Cure or improvement: positive clinical response with no additional treatment for intractable interstitial
cystitis (no further definition provided)
Funding Faculty of Medicine, Tanta University
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quote: "'randomly divided into two groups (cases 1, 3, 5 & 2, 4, 6)"
Comment: this is likely to be alternate allocation
Allocation concealment
(selection bias)
High risk Quote: "'randomly divided into two groups (cases 1, 3, 5 & 2, 4, 6)"





High risk Probably not done. Intravesical instillation of BCG vs intravesical injection of
botulinum toxin A (BTX-A)
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
High risk Probably not done. Intravesical instillation of BCG vs intravesical injection of




Low risk 16/18 (89%) included in BCG group; 16/18 (89%) included in BTX-A group
Selective reporting (re-
porting bias)
Unclear risk Outcomes not specified in methods (abstract only)
Taha 2007  (Continued)
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Methods Study design: RCT
Study duration (months): 3
Participants Number randomised: 36
Setting: not reported
Country: UK
Sex: 33 females and 1 male (participants who completed study)
Age, years: median 42, range 23 to 73
Diagnosis: PBD (painful bladder disease)
Inclusion criteria: patients with a diagnosis of PBD, based on the following criteria: (1) clinical history
of suprapubic pain, frequency and occasionally urgency, nocturia and dysuria, lasting for < 3 months
despite repeatedly negative urine culture; (2) petechial haemorrhages apparent on cystoscopy af-
ter distension; (3) histological examination of bladder biopsies taken from patients, which showed a
chronic inflammatory infiltrate with submucosal angiogenesis and increased collagen deposition in the
muscle. The basement membrane also appeared discontinuous; (4) urodynamic studies were deemed
unnecessary for a diagnosis of PBD as, in keeping with previous studies, results obtained in this group
of patients are too variable to be valid
Exclusion criteria: patients were excluded from the study if they had taken antibiotics or NSAIDs or
had undergone intravesical therapy in the preceding month; in women, if there was any possibility of
pregnancy, as there is a theoretical risk of teratogenic effects in the fetus under H2-antagonist treat-
ment; if there was a history of renal/hepatic impairment or blood dyscrasias, as these may worsen or
become apparent during treatment with cimetidine; if there was concomitant treatment with drugs
metabolised within the liver using the P450 cytochrome family of enzymes (warfarin, phenytoin, quini-
dine, theophylline and tricyclic antidepressants), as cimetidine can inhibit these enzymes
Interventions Group A (n = 18): cimetidine
Group B (n = 18): placebo
Regimen: oral cimetidine 400 mg or placebo (both twice daily)
Treatment category in NMA: antihistamines vs control
Outcomes Outcome data in analysis; no usable data
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Thilagarajah 2001 
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Allocation concealment
(selection bias)
Unclear risk Quote: "blindly allocated"





Low risk "double blind"; "at the end of the study, the allocation of groups was revealed"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double blind"; "at the end of the study, the allocation of groups was revealed"
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Setting: single centre
Study duration (months): 4
Participants Number randomised: 50
Setting: single centre
Country: Germany
Sex: 44 females and 6 males
Age, years: mean 50.5 (SD 14.4) for Group A, mean 60.2 (SD 17.5) for Group B
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: women and men who met symptom criteria of the NIDDK for IC. All patients had re-
ceived previous conservative medical treatment, including hydrostatic distension, intravesical instilla-
tions (e.g. dimethyl sulfoxide, hyaluronic acid) or oral medication (e.g. antiallergics, sodium pentosan
polysulfate), which at best achieved short symptomatic relief
Exclusion criteria: previous or current intake of amitriptyline
Interventions Group A (n = 25): amitriptyline
Group B (n = 25): placebo
Regimen: 4 months with a self-titration protocol that allowed them to escalate drug dosage in 25 mg
increments at 1 week intervals (maximum dosage 100 mg)
Treatment category in NMA: antidepressants vs control
Outcomes Outcome data in analysis
Cure or improvement: subjective cure at 4 months
Pain: VAS (0 to 100 mm) on pain intensity: at 4 months
van Ophoven 2004 
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Functional bladder capacity: at 4 months
Adverse events: at 4 months
Funding Study drug supplied by Bayer Pharmaceutical, Germany
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation "using a block randomization design". Probably done
Allocation concealment
(selection bias)





Low risk "double blind"; "placebo-controlled". The drug was supplied by manufacturer;
placebo was supplied by the university hospital pharmacy, "which packed and
blinded placebo and drug tablets"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double blind"; "placebo-controlled". The drug was supplied by manufacturer;
placebo was supplied by the university hospital pharmacy, "which packed and
blinded placebo and drug tablets"
Blinding of outcome as-
sessment (detection bias)
Objective outcome




Low risk 24/25 (1 dropped out due to AE) included in intervention group; 24/25 (1




Low risk 24/25 (1 dropped out due to AE) included in intervention group; 24/25 (1









Low risk 24/25 (1 dropped out due to AE) included in intervention group; 24/25 (1




Low risk 24/25 (1 dropped out due to AE) included in intervention group; 24/25 (1
dropped out due to AE) included in control group
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section
Other bias Low risk None detected
van Ophoven 2004  (Continued)
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Study characteristics
Methods Study design: RCT
Study duration (months): 3




Age, years: mean 65.5, SD 8.8, range 42.2 to 78.0
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: patients 18 years of age or older who met diagnostic criteria of the NIDDK for IC
Exclusion criteria: not stated
Interventions Group A (n = 14): hyperbaric oxygen (HBO)
Group B (n = 7): placebo
Regimen: 90 minutes treatment in a hyperbaric chamber pressurised with 100% O2 to 2.4 atmosphere
absolute for 30 treatment sessions or 1.3 atmosphere absolute, breathing normal air in the control
group. Treatment was given in daily sessions, 6 times a week during treatment
Treatment category in NMA: hyperbaric oxygen vs control
Outcomes Outcome data in analysis
Cure or improvement: 'moderately' or 'markedly' improved on GRA: at 3 months
Pain: pain VAS (mm): at 3 months
Functional bladder capacity: at 3 months
Adverse events: at 3 months
Funding Fishbein Family Foundation
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk "randomly assigned" using "code"; "the code was broken after evaluation at 3





Low risk "double-blind", "sham-controlled". Treatment given via facial mask at cham-
ber pressure of 2.4 ata. Sham treatment "was conducted identically" except
for a facial mask used at a faintly increased pressure of 1.3 to 1.4 ata
van Ophoven 2006 
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Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind", "sham-controlled". Treatment given via facial mask at cham-
ber pressure of 2.4 ata. Sham treatment "was conducted identically" except
for a facial mask used at a faintly increased pressure of 1.3 to 1.4 ata
Blinding of outcome as-
sessment (detection bias)
Objective outcome




High risk 12/14 (85%; 1 dropped out due to a mild oxygen intoxication, 1 due to poor




















Unclear risk Number analysed not reported
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6.5
Participants Number randomised: 31
Setting: 12 sites
Country: USA and Canada
Sex: 26 females and 5 males
Age, years: mean 50.6 (SD 10.68, range 38 to 78) for Group A, mean 46.2 (SD 13.56, range 25 to 69) for
Group B
Diagnosis: IC/PBS
Inclusion criteria: adult (≥ 18 to 80 years, inclusive) men and women with IC/BPS based on a total
score ≥ 8 on the validated O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and chronic bladder
pain for at least 6 months before screening, accompanied by urinary urgency, urinary frequency (≥ 8
voids daily) and/ or nocturia. On the basis of patient self-assessment of pain using a 11-point numeri-
Wang 2017a 
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cal rating scale (NRS) (0 = “no pain”, 10 = “worst pain imaginable”), the mean of average pain intensity
scores for the last 7 days of screening had to be ≥ 5 based on at least 6 of 7 days. Other key eligibility cri-
teria required that patients had no evidence of a urinary tract infection or significant urological disease,
including neurogenic bladder and diabetic cystopathy, and had not received intravesical therapy or un-
dergone cystoscopy during the 6 weeks before screening
Exclusion criteria: patients were excluded if they had received opioid analgesic at a dosage of oral
morphine equivalent ≥ 40 mg/d or had changed drugs known to affect IC/BPS-associated pain (i.e. anti-
depressants, antihistamines, antispasmodics, anticholinergics, anticonvulsants) within the 4 weeks be-
fore screening
Interventions Group A (n = 14): subcutaneous fulranumab 9 mg every 4 weeks
Group B (n = 17): matching placebo
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Cure or improvement: ≥ 50% improvement in average pain intensity score. Time of measurement un-
clear
Pain: numerical rating scale (range 0 to 10) at 12 weeks
Frequency: at 12 weeks
Nocturia: at 12 weeks
ICSI: at 12 weeks
Adverse events: at 26 weeks
Funding Janssen Research & Development
Notes Publication status: full text
Study was terminated prematurely. The FDA placed ongoing studies on study drug 'on clinical hold' be-
cause of safety concern. "As a result, the sponsor discontinued this study prematurely, after having en-
rolled only 31 of the targeted 70 patients"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk "double-blind, placebo-controlled" study using subcutaneous injection of
study drug or "matching placebo"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Low risk "double-blind, placebo-controlled" study using subcutaneous injection of
study drug or "matching placebo"
Incomplete outcome data
(attrition bias)
Low risk All randomised participants were included in analysis (4/14 and 3/17 withdrew
from study; "the last observed data were carried forward")
Wang 2017a  (Continued)
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Low risk All randomised participants were included in analysis (4/14 and 3/17 withdrew




Low risk All randomised participants were included in analysis (4/14 and 3/17 withdrew




Low risk All randomised participants were included in analysis (4/14 and 3/17 withdrew





Low risk All randomised participants were included in analysis (4/14 and 3/17 withdrew




Low risk All randomised participants were included in analysis (4/14 and 3/17 withdrew
from study; "the last observed data were carried forward")
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 4.5
Participants Number randomised: 50
Setting: 6 centres
Country: USA
Sex: 45 females and 5 males
Age, years: mean 49.7 (SD 16.0) for Group A, mean 54.8 (SD 8.9) for Group B
Diagnosis: IC (NIDDK criteria)
Inclusion criteria: those who met published NIDDK criteria. When cystoscopy was performed by oth-
ers, we obtained reports of past procedures and confirmed Hunner’s ulcers or glomerulations. Se-
mi-quantitative assessment of bladder pain on a scale of mild, discomforting, distressing, horrible and
excruciating, and urgency on a scale of never, rarely, sometimes, frequently and always was obtained
from each patient. For study inclusion, at least 2 of 3 criteria were required, including interstitial cystitis
pain that was distressing or worse, urinary urgency sometimes or more often and/or urinary frequency
for 8 or more waking hours. Patients on pentosan polysulfate were required to withdraw from the med-
ication during the study because of anecdotal reports of improvement months after initiation. Other in-
terstitial cystitis therapy was continued if it had been administered for 2 months or longer
Exclusion criteria: patients were excluded from the study when they were pregnant or breastfeeding,
could not swallow or absorb oral medications, could not follow instructions or participate for 18 weeks
Warren 2000 
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or had known renal or liver disease. Those with a clean midstream voided urine sample that yielded 1 3
105/mL or greater bacteria of any species were also excluded from the study. In addition, patients with
allergy or intolerance to a study antibiotic participated but did not receive that antibiotic, and those
who could not receive 2 or more study antibiotics were excluded from the study
Interventions Group A (n = 25): antibiotic regimen
Group B (n = 25): placebo
Regimen: 18 weeks of placebo or antibiotics, including rifampin 300 mg OD plus a sequence of doxy-
cycline 100 mg BD, erythromycin 250 mg QDS, metronidazole 500 mg QDS, clindamycin 300 mg QDS,
amoxicillin 500 mg TDS and ciprofloxacin 250 mg BD for 3 weeks each
Treatment category in NMA: antibiotics vs control
Outcomes Outcome data in analysis
Cure or improvement: subjective cure: at 18 weeks (assumed from reports)
Adverse events: at 18 weeks.
Funding Interstititial Association; Bayer, Hoechst Marion Roussel, Pharmacia and Upjohn and Roerig Pfizer
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized"
Allocation concealment
(selection bias)





Unclear risk Quote: "double-blind, placebo controlled". Placebo not described
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Low risk 18/25 (72%; 7 withdrew due to perceived AE or unrelieved IC symptom or both)
included in intervention group; 19/25 (2 withdrew before treatment, 4 with-
drew due to diarrhoea, unrelieved symptoms, stress or constitutional symp-




Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section
Other bias Low risk None detected
Warren 2000  (Continued)
 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
 
Study characteristics
Methods Study design: RCT
Study duration (months): 4
Participants Number randomised: 58
Setting: 11 clinics
Country: USA and Canada
Sex: 48 females and 10 males
Age, years: mean 51.3 (SD 10.3) for Group A, mean 51.8 (SD 11.6) for Group B
Diagnosis: IC/PBS (clinical criteria)
Inclusion criteria: men and women older than 18 years. Eligibility required fulfilment of all of certain
criteria, including (1) persistent symptoms of urinary frequency and pain rated at least 4 on a scale of 0
to 10, (2) failure of at least 24 weeks of active treatment with a minimum of 3 standard forms of therapy
or combination of therapies for IC/PBS, (3) cystoscopic diagnosis of IC/PBS in the past with findings of
glomerulations and/or ulcerations and (4) screening cystoscopy within the 24 weeks before study entry
to evaluate for an unevaluated pathological condition
Exclusion criteria: "there were additional exclusion criteria" [exclusion criteria not reported]. Except
for medications listed in the exclusion criteria, subjects were allowed to continue on the current med-
ication regimen
Interventions Group A (n = 39): an immunosuppressant 1 gram daily, mycophenolate mofetil (MMF) for 14 days, then
1 gram BID for 10 weeks
Group B (n = 19): placebo
Treatment category in NMA: immune modulators vs control
Outcomes Outcome data in analysis
Cure or improvement: ‘moderately' or 'markedly’ improved on GRA: at 16 weeks
Pain: defined as ratings on a '10-point scale' with score range 0 to 10 (but 0 to 10 is actually an 11-point
scale) at 16 weeks
ICSI: at 16 weeks
ICPI: at 16 weeks
Adverse events: at 16 weeks
Funding NIDDK Cooperative Agreements
Notes Publication status full text
The trial was "prematurely halted". "A black box warning for MMF [mycophenolate mofetil] was issued"
by manufacturer. Early termination recommended by monitoring committee due to lack of efficacy,
increased safety concerns and slow recruitment. 19/39 in intervention group were not receiving study
drug at the primary end point (14 due to study suspension and 5 due to drug tolerability)
Risk of bias
Bias Authors' judgement Support for judgement
Yang 2011 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomized … in a 2:1 ratio"
Allocation concealment
(selection bias)





Low risk "Placebo-controlled" trial, using "matching placebo"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome






















Low risk All randomised participants were included in analysis
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section





Methods Study design: RCT
Study duration (months): 6
Participants Number randomised: 28
Setting: not reported
Country: Egypt
Sex: 23 females and 5 males
Age, years: not reported
Yassin 2011 
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Diagnosis: PBS/IC
Inclusion criteria: patients with PBS/IC who did not respond to any of the conventional treatment
modalities
Exclusion criteria: not reported
Interventions Group A (n = 18): 200 IU of botulinum toxin A into 20 mL of normal saline + hydrodistension
Group B (n = 10): NaCl + hydrodistension
Treatment category in NMA: neuromuscular blockade vs control
Outcomes Outcome data in analysis
Cure or improvement: subjective Improvement (no definition) at 6 months (assumed from reports)
Adverse events: at 6 months
Funding None
Notes Publication status: abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly divided"
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned. Submucosal injection of botuinum toxin A or normal
saline "under general anaesthetics … with video recording of the injection
sites in a similar mapping in both groups"
Blinding of outcome as-
sessment (detection bias)
Subjective outcome
Unclear risk Blinding not mentioned. Submucosal injection of botuinum toxin A or normal
saline "under general anaesthetics … with video recording of the injection




Unclear risk Appeared that all randomised participants were included in analysis, but no




Unclear risk Appeared that all randomised participants were included in analysis, but no
description of missing data was provided
Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section
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Study characteristics
Methods Study design: RCT
Study duration (months): 4




Age, years: range 30 to 50
Diagnosis: IC/PBS
Inclusion criteria: male patients who had interstitial cystitis/painful bladder syndrome
Exclusion criteria: not reported
Interventions Group A (n = 15): transcutaneous electrical nerve stimulation (TENS) for 15 minutes, once daily, 3×/
week for 4 months. 2 suprapubic electrodes and 2 under the lower back (T10-L1). Square wave form,
80 to 100 Hz frequency, 10 to 30 mA amplitude, pulse width 50 to 60 us. Traditional physical therapy
(PFMT) and medical care (clomipramine, a tricyclic antidepressant) also received
Group B (n = 15): sham TENS, traditional physical therapy (PFMT) and medical care (clomipramine, a
tricyclic antidepressant)
Treatment category in NMA: physical therapy vs control
Outcomes Outcome data in analysis
Pain: VAS (range 0 to 10) at 4 months
Funding Not reported
Notes Publication status: full text
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomly divided"
Allocation concealment
(selection bias)





Low risk TENS vs sham TENS (with physical therapy)
Blinding of outcome as-
sessment (detection bias)
Subjective outcome




Low risk All randomised participants were included in analysis
Zakaria 2016 
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Selective reporting (re-
porting bias)
Low risk Results included all outcomes specified in the methods section






BMI: body mass index.
BoNT-A: botulinum toxin type A.
BPS: bladder pain syndrome.
BT: bladder training.
CP: chronic prostatitis.
CPPS: chronic pelvic pain syndrome.
CPSI-F: female modification of Chronic Prostitis Symptom Index.
CS: chondroitin sulfate.
DMSO: dimethyl sulfoxide.
EBMP: educational and behavioural modification programme.




ICPI: Interstitial Cystitis Problem Index.
ICSI: Interstitial Cystitis Symptom Index.
IgG: immunoglobulin G.
IQR: interquartile ratio.
LOCF: last observation carried forward.
mAbs: monoclonal antibodies.
NGF: nerve growth factor.
NIDDK: National Institute of Diabetes and Digestive and Kidney Disease.
NIH: National Institutes of Health.
NMA: network meta-analysis.
NSAID: non-steroidal anti-inflammatory drug.
OSPI: O’Leary and Sant Interstitial Cystitis Problem Index.
OSSI: O’Leary and Sant Interstitial Cystitis Symptom Index.
PBD: painful bladder disease.
PBS: painful bladder syndrome.
PDE5: phosphodiesterase-5 inhibitor.
PORIS: Patient Overall Rating of Improvement in Symptoms.
PPS: pentosan polysulfate.
PUF: Pelvic Pain and Urgency/Frequency Questionnaire.
PVR: postvoid residual.
RCT: randomised controlled trial.
RTX: resiniferatoxin.
SD: standard deviation.
SHN: superior hypogastric plexus neurolysis.
TENS: transcutaneous electrical nerve stimulation.
TUIBN: transurethral incision of the bladder neck.
TUIP: transurethral incision of the prostate.
TUMT: transurethral microwave therapy.
TUNA: transurethral needle ablation.
TURP: transurethral resection of the prostate.
UTI: urinary tract infection.
VAS: visual analogue scale.
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Study Reason for exclusion
Akiyama 2014 Not a relevant study design. Treatments are not the same for all participants
Baert 1975 Not a relevant population (includes mixed diagnoses, e.g. cystitis, prostatitis, urethritis, as well as
"spasm following diagnostic or therapeutic procedures of the genitourinary tract (cystoscopies,
urethral dilatation, pyelography, catheterisation)")
Choa 1983 Not a relevant population. Includes "urethral syndrome", which is an old term for symptoms simi-
lar to BPS, but it is not BPS in its current definition
Costantini 2003 Not a relevant population. Includes "urethral syndrome", which is an old term for symptoms simi-
lar to BPS, but it is not BPS in its current definition
Gallego-Vilar 2013 Not a relevant population. A very particular group of participants (DMSO (dimethyl sulfoxide) re-
sponders) that are not consistent with other participants in the network meta-analysis
Keay 2007 Not a relevant intervention. RCT of biomarker
Ko 2016 Not a relevant study design. High suspicion that randomisation was not done by participants. Re-
ports data by number of procedure rather than by number of participants. Data are reported by
number of procedures, not by number of participants. Compares transurethral resection (TUR) vs
transurethral coagulation (TUC). Possibly linked to the Lee 2015 study. Available as meeting ab-
stract only with no contact details for study authors
Lai 2013 Not a relevant comparison. Compares different regimens of interstitial hyaluronic acid instillation
Lee 2015 Not a relevant study design. High suspicion that randomisation was not done by participant, as
participants received more than 1 procedure. Reports data by number of procedures, not by num-
ber of participants. Compares transurethral resection (TUR) vs transurethral coagulation (TUC).
Possibly linked to the Ko 2016 study. Available as meeting abstract only with no contact details for
study authors
Li 2016 Not a relevant population. Includes cystitis induced by ketamine misuse
Lubeck 2001 Not a relevant comparison. Compares 3 doses of pentosan polysulfate (PPS) and no other interven-
tion
Netto 1980 Not a relevant population. Active infection among participants is mentioned
Nickel 2005 Not a relevant comparison. Compares 3 doses of pentosan polysulfate (PPS) and no other interven-
tion
Peters 2007 Not a relevant comparison. Compares 2 types of neuromodulation (sacral nerve stimulation vs pu-
dendal nerve stimulation)
BPS: bladder pain syndrome.
DMSO: dimethyl sulfoxide.
PPS: pentosan polysulfate.




Characteristics of studies awaiting classification [ordered by study ID]
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Participants Sex: not specified
Age (mean): Group A: 57.1 years; Group B: 58.63 years
Condition: BPS/IC
Target sample size: 37 reported, original target not stated
Interventions Group A (n = 19): intravesical hyaluronic acid alone
Group B (n = 18): intravesical hyaluronic acid in combination with oral chondroitin
Outcomes Time point/follow-up unclear: "visual analogue pain scale (VAS), interstitial cystitis symptom index
(ICSI), interstitial cystitis problem index (ICPI), voiding diary for frequency/nocturia"
Notes Funding: not stated
Trial registration number: none reported
Publication type: conference abstract




Methods Study design: RCT
Participants Sex: female
Age: 18 years or over
Condition: BPS (VAS score of 4)
Target sample size: 62
Interventions Group A: intravesical heparin instillation with conservative treatment
Group B: conservative treatment alone (no description of ‘conservative treatment’)
Outcomes Follow-up: 12 weeks after treatment, when these outcomes will be measured: pain (VAS); daytime
frequency; QoL; adverse effects
Notes Funding: not reported
Trial registration number: TCTR20180912004
Publication type: trial registration
Status in relation to this review: new ongoing study
Recruitment started: 1 October 2018 (anticipated)




Methods Study design: RCT
Bosch 2018 
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Participants Sex: female
Age: 18 to 65 years
Condition: IC/BPS - participants with "moderate to severe IC/BPS as defined with scores of 7 on
the O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI)"
Target sample size: 42
Interventions Group A (n = 28): subcutaneous certolizumab pegol 400 mg
Group B (n = 14): placebo (sterile saline)
Certolizumab pegol is an anti-tumour necrosis factor-alpha agent (i.e. an anti-TNF-alpha agent)
Outcomes Follow-up: 18 weeks: GRA; ICSI; ICPI; pain (pain intensity numerical rating scale (MCID used as 30%
reduction from baseline))
Notes Funding: UCB (Union Chimique Belge), Brussels, Belgium (biopharmaceutical company)
Trial registration number: NCT02497976
Publication type: full journal article




Methods Study design: RCT
Participants Sex: female
Age: 18 to 80 years
Condition: "chronic urogenital pain"
Number randomised: 70
Interventions Group A: 90-minute life stress interview (stress and emotion interview)
Group B: wait-list control (no interview)
Outcomes Follow-up: 6 weeks
Outcomes: pain severity and pain Interference (using Brief Pain Inventory); pelvic floor symptoms
(using Pelvic Floor Distress Inventory – Short Form–20; depression and anxiety (using Brief Symp-
tom Inventory - 18)
Notes Funding: "Student Award from the Blue Cross Blue Shield of Michigan Foundation and grants from
the National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR057808 and AR057047"
Trial registration number: NCT02286115
Publication type: full journal article
Status in relation to this review: additional report of the already included Carty 2017 (already
with a PhD thesis, a conference abstract and a trial registration)
Treatment category in NMA: behavioural therapy vs control
Carty 2019 
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Methods Study design: cross-over RCT
Participants Sex: female (no males recruited)
Age: mean 52.6 years (SD ± 12.6)
Condition: BPS/IC (ESSIC criteria)
Target sample size: 15 (of which 2 dropouts)
Interventions Group A: transcranial magnetic stimulation
Group B: sham stimulation
Outcomes Two weeks' treatment followed by 6 weeks' washout period followed by 2 weeks on alternative
treatment. 6 weeks' follow-up at the end of the final treatment session
Outcomes include pain (VAS); Overactive Bladder Questionnaire (OABq); O'Leary-Saint Question-
naire; QoL (36-Item Short Form Health Survey - SF-36)
Notes Funding: Associazione Italiana Cistite Interstiziale (AICI)
Trial registration number: not reported
Publication type: full journal article




Methods Study design: RCT
Participants Sex: female
Age: 25 to 40 years
Condition: interstitial cystitis
Target sample size: 40
Interventions Group A (n = 20): interferential current (lower abdomen) + anticholinergic (propiverine hydrochlo-
ride)
Group B (n = 20): anticholinergic (propiverine hydrochloride)
Outcomes Treatment period: 8 weeks
Outcomes measured at the end of the treatment period: pain (VAS); ICSI
Notes Funding: unclear
Trial registration number: NCT03844581
Publication type: trial registration
Status in relation to this review: new ongoing study
Recruitment started: 1 January 2019
El Refaye 2019 
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Methods Study design: RCT
Participants Sex: any
Age: 20 years and over
Condition: IC/BPS; "patients with symptoms of unpleasant sensation (pain, pressure, discomfort)
perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of
more than six months duration, in the absence of infection or other identifiable causes"
Target sample size: 96
Interventions Group A: low-energy shock wave (LESW) (transcutaneous applied to the suprapubic bladder region
with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25
millijoule/mm2)
Group B: sham LESW treatment (same condition but with no energy)
Outcomes Outcomes measured at "one month after the treatment day": GRA; VAS; daytime voiding fre-
quency; nighttime voiding frequency; ICSI; ICPI; functional bladder capacity
Notes Funding: unclear
Trial registration number: NCT03619486
Publication type: trial registration
Status in relation to this review: new ongoing study
Recruitment started: 4 July 2018




Methods Study design: RCT
Participants Sex: female
Age: 18 to 60 years
Condition: chronic pelvic pain - study authors included BPS/IC due to the difficulties of excluding
from chronic pelvic pain
Target sample size: 79
Interventions Group A: manual therapy
Group B: trigger point dry needling
Outcomes Outcomes at each treatment session for up to 10 weeks: 1 treatment session per week: pain (on
0 to 10 Pain Rating Scale); Pelvic Pain Questionnaire; Pain Treatment Satisfaction Scale
Kenny 2016 
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Notes Funding: not reported
Trial registration number: NCT02795026
Publication type: trial registration
Status in relation to this review: new ongoing study
Recruitment started: April 2016




Methods Study design: CCT




Interventions Group I: self-management telecare system (patient video education, mobile phone app, lifestyles)
Group II: control (no detail - "only regular treatments")
Outcomes Outcomes measured at 8 weeks: O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI); pain and
urgency (both using VAS); QoL (SF-36)
Notes Funding: "partly funded by Feng Yuan Hospital, Ministry of Health and Welfare (Grant no.
FYH1030709-2) and Ministry of Science and Technology (Grant no. MOST106-2410-H-166-004)
Trial registration number: not reported
Publication type: full journal article
Status in relation to this review: additional report of the already included Lee 2016 (currently on-
ly 2 conference abstracts are included in the full review)




Methods Study design: RCT
Participants Target sample size: 433
Sex: any
Age: 18 to 80 years
Condition: IC/BPS
Interventions Group I: AQX-1125 100 mg
Group II: AQX-1125 200 mg
Moldwin 2018 
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Group III: placebo
Oral administration
Outcomes Outcomes to be measured at 12 weeks: "average bladder pain based on an 11-point numeri-
cal rating scale (NRS); voiding over a 24-hour period; and symptom scores based on the following
questionnaires: Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS), O’Leary-Sant Intersti-
tial Cystitis Symptom Index (ICSI) and O’Leary-Sant Interstitial Cystitis Problem Index (ICPI)"
Notes Funding: "Aquinox Pharmaceuticals Inc sponsored this clinical trial"
Trial registration number: NCT02858453; EUCTR2016-000906-12
Publication type: conference abstract
Status in relation to this review: additional report of the already included ongoing study Leader-




Methods Study design: RCT
Participants Sex: any
Age: 45 years or over
Condition: interstitial cystitis with an IPSS total score of 8 or higher
Target sample size: 80
Interventions Group A (target n = 40): pentosan polysulphate + alpha blocker
Group B (target n = 40): alpha blocker alone
Outcomes At end of 12 week treatment period, these outcomes will be measured: ICSI; ICPI; Pelvic Pain and
Urgency/Frequency Patient Symptom Scale; functional bladder capacity
Notes Funding: Chong Kun Dang (a pharmaceutical company)
Trial registration number: KCT0003772
Publication type: trial registration
Status in relation to this review: new ongoing study
Recruitment started: 1 May 2019




Methods Study design: RCT
Participants Sex: female
Age: 20 years or over
Condition: IC/BPS
Oh-Oka 2017 
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Target sample size: 40
Interventions Group A (n = 30): intensive systematic dietary manipulation
Group B (n = 10): did not receive intensive dietary manipulation
Outcomes Outcomes measured at 3 months and 1 year from baseline: pain; urinary urgency; ICSI; ICPI; QoL
Notes Funding: not reported
Trial registration number: none given
Publication type: 2 reports (1 full journal article and 1 conference abstract)




Methods Study design: RCT
Participants Sex: female
Age: over 18 years
Condition: interstitial cystitis
Target sample size: 24
Interventions Group A (n = 12): hydrodistension + hyaluronic acid
Group B (n = 12): hydrodistension alone
Outcomes At 3 months' follow-up, the following outcomes were measured using the O'Leary-Sant question-
naire: frequency; urgency; nocturia; dysuria
Notes Funding: Mashhad University of Medical Sciences (states: public funding)
Trial registration number: IRCT20130811014330N5
Publication type: trial registration
Status in relation to this review: new ongoing study
Recruitment started: 22 April 2017




Methods Study design: RCT
Participants Sex: any
Age: over 18 years to 80 years
Condition: interstitial cystitis
Yusefi 2018 
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Target sample size: 50
Interventions Group A: topical use of chamomile oil “in the bladder area”
Group B: topical use of placebo oil “in the bladder area”
Outcomes Outcomes measured at the end of the treatment period (2 months): ICSI
Notes Funding: The Qom University of Medical Science (states: public funding)
Trial registration number: IRCT20170112031893N2
Publication type: trial registration
Status in relation to this review: new ongoing study
Recruitment started: 6 December 2018
Recruitment due to end: 6 December 2019
Yusefi 2018  (Continued)
BPIC-SS: Bladder Pain/Interstitial Cystitis Symptom Score.
BPS: bladder pain syndrome.
CCT: controlled clinical trial.
ESSIC: International Society for the Study of Bladder Pain Syndrome (BPS).
GRA: Global Response Assessment.
IC: interstitial cystitis.
ICPI: Interstitial Cystitis Problem Index.
ICSI: Interstitial Cystitis Symptom Index.
IPSS: International Prostate Symptom Score.
LESW: low-energy shock wave.
MCID: minimal clinically important diFerence.
NMA: network meta-analysis.
QoL: quality of life.
RCT: randomised controlled trial.
SD: standard deviation.
SF-36: 36-Item Short Form Health Survey.
TNF: tumour necrosis factor.
VAS: visual analogue scale.&&
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Tadalafil for painful bladder
Methods Study design: parallel-group RCT
Blinding: participant and investigator
Participants Target sample size: 100
Country: India
Sex: any
Age: 15 to 85 years
Condition: "painful bladder syndrome"
Exclusion criteria: "those with co-morbidities such as Diabetes Mellitus, Hypertension, IHD, Asth-
ma, immune compromised status and proved urinary bladder diseases shall be excluded."
Bhat 2018 
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Interventions Group A: tadalafil 5 mg
Group B: placebo
Outcomes At 3 months
Primary outcomes: pain score (O'Leary-Sant and numerical rating scale); bladder capacity (USG)
Secondary outcomes: dropout rate "due to adverse events or worsening of symptoms"
Starting date 1 April 2018
Contact information Dr Gajanan Bhat
Consultant Urologist and Andrologist






End date "Not yet recruiting"
Notes Funding: "nil"




Study name A pilot study investigating the use of a therapeutic wand in addition to physiotherapy for bladder
pain syndrome
Methods Study design: parallel-group RCT
Blinding: none
Participants Target sample size: 10
Country: United Kingdom
Sex: female
Age: 18 to 65 years
Condition: "diagnosis of Bladder Pain Syndrome or interstitial Cystitis as per the definition of the
International Society for the Study of Bladder Pain Syndrome"
Interventions Group A: therapeutic wand plus physiotherapy (PFMT, lifestyle and bladder training)
Group B: physiotherapy
Outcomes At 6 weeks and 12 weeks
Bond 2016 
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Primary outcomes: O'Leary-Sant IC Symptom Index Score and Problem Index Score
At 12 weeks
Secondary outcomes: Genitourinary Pain Index; Pelvic Pain and Urinary Urgency Frequency Pa-
tient Symptom Scale; patient-reported urinary urgency; overall pain; ease of use of wand; adverse
effects
Starting date "April 2016"
Contact information Jilly Bond, Clinical Specialist Physiotherapist, University of Bradford
End date "October 2016"
Notes Funding: not reported
ClinicalTrials.gov registration number: NCT02743962





Study name Randomized controlled trial of PTNS versus sham efficacy in treatment of bladder pain syndrome
Methods Study design: parallel-group RCT
Blinding: participant and investigator
Participants Target sample size: 100
Country: USA
Sex: female
Age: 18 years or older
Condition: "Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC)"... "with visual analog scale > 5"
Interventions Group A: percutaneous tibial nerve stimulation
Group B: sham
Outcomes At 12 weeks
Primary outcomes: Patient Global Impression of Improvement (PGI-I)
Secondary outcomes: quality of life scores (VAS); O'Leary-Sant Pain Scores ("pain intensity, lo-
cation of pain and associated symptoms"); Overactive Bladder-Questionnaire; Short Form SF-12
Health Scale
Starting date June 2016
Contact information Dominique Malacarne
New York University School of Medicine
New York, New York, USA 10016
Brucker 2016 
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Email: malacd01@nyumc.org
End date March 2020
Notes Funding: unclear




Study name Randomized controlled trial comparing two different bladder instillation treatments for interstitial
cystitis/bladder pain syndrome
Methods Study design: parallel-group RCT
Blinding: participant and care provider
Participants Target sample size: 80
Country: USA
Sex: female
Age: 18 years or older
Condition: "with IC/BPS who have a score of ≥ 6 on either index (problem or symptom index) of the
O'Leary-Sant questionnaire who have selected bladder instillations as part of their IC/BPS treat-
ment"
Interventions Group A: intravesical instillation of "standard cocktail" plus triamcinolone acetonide (40 mg/1 mL)
Group B: intravesical instillation of "standard cocktail" alone.
Standard cocktail = "heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbon-
ate (15 mL of 1 mEq/mL) and 0.5% bupivacaine (10 mL of 5 mg/mL)"
Outcomes At 3 weeks and 6 weeks
Primary outcomes: O'Leary-Sant Questionnaire
Secondary outcomes: Pelvic Pain and Urgency/Frequency Questionnaire; Overactive Bladder
Questionnaire; Pelvic Floor Distress Inventory; Pelvic Organ Prolapse Incontinence Sexual Ques-
tionnaire; VAS for pain; adverse effects
Starting date 25 January 2019
Contact information Alyce Goodman-Abraham
University of Louisville Urogynecology at Springs Medical Center
Louisville, Kentucky, United States, 40205
Email: contactus@ulp.org
End date December 2020
Notes Funding: not reported
ClinicalTrials.gov registration number: NCT03463915
Cardenas-Trowers 2018 
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Study name Efficacy of Clorpactin(R) in bladder pain syndrome/interstitial cystitis: a randomised placebo-con-
trolled trial
Methods Study design: parallel-group RCT
Blinding: "blinded (masking used)". No further details
Participants Target sample size: 54
Final sample size: 50
Country: Australia
Sex: female
Age: 18 to 70 years
Condition: "diagnosed with bladder pain syndrome/interstitial cystitis". No further details
Interventions Group A: intravesical: Clorpactin (sodium oxychlorosene)
Group B: placebo (cystodistension)
Outcomes At 3 months
Primary outcomes: "subject improvement as reflected in the Global Response Assessment"
Secondary outcomes: "nil"
Starting date Actual recruitment start date: 1 March 2012
Contact information Dr Kristina Cvach
Mercy Hospital for Women
163 Studley Rd Heidelberg VIC 3084
Australia
Email: kcvach@mercy.com.au
End date Actual recruitment end date: 31 December 2016
Notes Funding: "self-funded/unfunded"




Study name A phase 2, randomized, double-blind, placebo-controlled study of YM672 in the treatment of
painful bladder syndrome/interstitial cystitis
Methods Study design: parallel-group RCT
Blinding: double blind - no other details
Participants Target sample size: 150
Drug Company 2005 
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Country: multi-national
Sex: any
Age: 18 years or older
Condition: "diagnosis of PBS/IC defined as suprapubic pain related to bladder filling, accompa-
nied by other symptoms, such as increased daytime and nighttime frequency, in the absence of
proven urinary infection or other obvious pathology, with symptoms for at least 12 consecutive
weeks prior to the screening visit." A score of a least 1 on the PBS/IC Problem Index Question #4.
PBS/IC Symptom Index Score of at least 7 (total score) at baseline
Interventions Group A: oral: YM672 (IPD(R)) ("suplatast tosilate" on trial registration)
Group B: placebo
Outcomes At 12 weeks and/or at "end of treatment"
Primary outcome: "...success, defined as "moderately improved" or "markedly improved" PBS/IC
on the subject-rated 7-point Global Response Assessment (GRA)"
Secondary outcomes: including GRA at weeks 4 and 8; IC Symptom Index; IC Problem Index; mean
number of micturitions per day; mean number of micturitions per night; severity of urinary urgency
on VAS; severity of bladder pain, pelvic pain and pain (including discomfort) accompanied by uri-
nary urgency on VAS; adverse events, etc.
Starting date Not reported (ethics committee opinion 05/01/2005)
Contact information Astellas Pharma Europe B.V. No further details
End date 23 April 2007
Notes Funding: Astellas Pharma Europe B.V.
Trials registration number: EUCTR2005-003367-23-DE




Study name Exploratory, randomized, double-blind, placebo-controlled evaluation of efficacy, tolerability, and
safety of intravesical instillation of GRT6010 compared to placebo in subjects with bladder pain
syndrome
Methods Study design: parallel-group RCT
Blinding: double blind - no other details
Participants Target sample size: 120 (of which 15 will be 65 years of age or older)
Country: multi-national
Sex: female
Age: 18 to 75 years
Condition: "pain perceived to be related to the urinary bladder and consistent presence of at least
1 other urinary symptom such as persistent urge to void or frequency for at least 12 months. Princi-
Drug Company 2017a 
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pal exclusion criteria: presence of Hunner’s lesion as demonstrated by a cystoscopy with hydrodis-
tention"
Interventions Group A: intravesical: GRT6010
Group B: placebo
Outcomes Treatment period/time points/length of follow-up: unclear, total length of study in all countries
reported as 1 year
Primary outcome: average daily paIn scores on a 0 to 100 VAS
Secondary outcomes: including O’Leary/Sant Questionnaire (Symptom and Problem Index) score;
Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS); mean number of micturitions per day;
adverse events, etc.
Starting date Not reported (ethics committee opinion 22/05/2017)
Contact information Grünenthal GmbH
Email: Clinical-Trials@grunenthal.com
End date Date of the global end of the trial: 2 May 2018
Notes Funding: Grünenthal GmbH
Trial registration number: EUCTR2016-003940-35
WHO Trial Reference Number (UTRN): U1111-1188-0214




Study name A Phase III, multicenter, randomized, double-blind, placebo controlled, parallel group study to as-
sess the efficacy and safety of KRP-116D in Japanese patients with interstitial cystitis
Methods Study design: parallel-group RCT
Blinding: double blind - no other details
Participants Target sample size: 90
Country: Japan
Sex: any
Age: 20 years or older
Condition: "diagnosed with IC"
Interventions Group A: intravesical: KRP-116D ("dimethyl sulfoxide" according to the trial registration)
Group B: placebo
Outcomes Treatment period/time points/length of follow-up: not reported
Primary outcome: O'Leary and Sant's IC Symptom Index
Drug Company 2017b 
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Secondary outcomes: "O'Leary and Sant's IC Problem Index; Urinary Symptom, Bladder Pain
Score, etc.; Safety Questionnaire; Symptom Diary; adverse event and adverse drug reaction"
Starting date 25 May 2017
Contact information Kyorin Pharmaceutical Co., Ltd
Email: develop@mb.kyorin-pharm.co.jp
End date Not reported (expected end date: 30 June 2019)
Notes Funding: Kyorin Pharmaceutical Co., Ltd




Study name A study to investigate efficacy, safety, pharmacodynamics and pharmacokinetics of ASP6294 in the
treatment of female subjects with bladder pain syndrome/interstitial cystitis
Methods Study design: parallel-group RCT
Blinding: participant and investigator
Participants Target sample size: 117
Country: multi-national
Sex: female
Age: 18 years of age or older
Condition: used the ESSIC definition for BPS/IC with document proof of at least 2 months' dura-
tion. In addition: "a score of ≥ 4 and ≤ 9 for pain as assessed by scoring the average pain of the week
preceding Visit 1/Screening, using an 11-point NRS (0-10)"; "subject has an estimated voiding fre-
quency of ≥ 8 and ≤ 30 voids per 24 hours"; "subject has a score of ≥ 7 on the Interstitial Cystitis
Symptom Index (ICSI) Questionnaire"
Interventions Group A: ASP6294 (administration: subcutaneous injection)
Group B: placebo
Outcomes At 12 weeks
Primary outcome: average mean daily pain (MDP)
Secondary outcomes: 13 listed, including Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-
SS); average worst daily pain; GRA; adverse effects, etc.
Starting date 28 September 2017
Contact information Astellas Pharma Europe B.V. No further details
End date 21 March 2019
Notes Funding: Astellas Pharma Europe B.V.
ClinicalTrials.gov registration number: NCT03282318
Drug Company 2017c 
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Study name The LEADERSHIP 301 Trial: a 12-week, randomized, multi-center, double-blind, placebo-controlled,
3-arm, parallel-group, phase 3 trial to evaluate the efficacy and safety of 2 doses of AQX-1125 tar-
geting the Src homology 2-containing inositol-5'-phosphatase 1 (SHIP1) pathway in subjects with
interstitial cystitis/bladder pain syndrome followed by 14- or 40-week extension periods
Methods Study design: parallel-group RCT
Blinding: "quadruple (participant, care provider, investigator, outcomes assessor)"
Participants Target sample size: 433
Country: multi-national
Sex: any
Age: 18 to 80 years
Condition: "symptoms of bladder pain in addition to urinary urgency and/or urinary frequency for
more than 6 months"; "clinical diagnosis, or history consistent with the diagnosis, of interstitial
cystitis/bladder pain syndrome for > 3 months but ≤ 20 years". Must have undergone a cystoscopy
within the last 36 months before baseline
Interventions Group A: AQX-1125 100 mg
Group B: AQX-1125 200 mg
Group C: placebo
Oral administration
Outcomes At 12 weeks
Primary outcome: maximum daily bladder pain score "based on a standardized 11-point numeri-
cal rating scale (NRS) recorded by electronic diary (e-diary)"
Secondary outcomes: IC Symptom Index Score; Bladder Pain/IC Symptom Score; GRA; voiding fre-
quency over 24 hours; adverse effects
Starting date July 2016
Contact information Aquinox Pharmaceuticals (Canada), Inc.
End date February 2020
Notes Funding: Aquinox Pharmaceuticals (Canada), Inc.
ClinicalTrials.gov registration number: NCT02858453
Other trial registration number: EUCTR2016-000906-12
Other study ID numbers: AQX-1125-301
Leadership 301 Trial 2016 
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Study name A phase 2a, randomized, double-blind, placebo-controlled multi-center single dose study to eval-
uate the safety and effectiveness of URG101 compared with the individual components lidocaine
and heparin in subjects with interstitial cystitis/bladder pain syndrome
Methods Study design: parallel-group RCT
Blinding: triple (participant, care provider, investigator)
Participants Target sample size: 92
Country: USA
Sex: any
Age: 18 years of age or older
Condition: diagnosed with BPS/IC and have "moderate-to-severe symptoms of bladder pain of
bladder origin for at least 9 months prior to the study; may or may not have received a cystoscopy
in association with their diagnosis of interstitial cystitis/bladder pain syndrome prior to or at time
of screening; Have a score of ≥ 15 and < 30 on the PUF questionnaire, completed at screening; a
minimum score of 5 is required on the VAS"
Interventions Group A: lidocaine
Group B: heparin
Group C: lidocaine plus heparin
Group D: placebo
Intravesical administration
Outcomes At 12 or 24 hours after administration
Primary outcome: change in bladder pain on VAS
Secondary outcomes: change in urgency on VAS; adverse effects
Starting date September 2015
Contact information Urigen
End date 18 June 2018
Notes Funding: Urigen
ClinicalTrials.gov registration number: NCT02591199
On trial registration states: "terminated (prematurely terminated based on interim study analy-
sis)"




Study name Comparison of bladder directed and pelvic floor therapy in women with interstitial cystitis/bladder
pain syndrome
Peters 2016 
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Methods Study design: parallel-group RCT
Blinding: single (outcome assessor)
Participants Target sample size: 128
Country: USA
Sex: female
Age: 18 to 85 years of age
Condition: "history of patient self-reported IC/BPS symptoms for at least 6 months"
Interventions Group A: physical therapy (pelvic floor)
Group B: intravesical (heparin sulphate, lidocaine, sodium bicarbonate and Kenalog)
Other names: Xylocaine, triamcinolone
Outcomes At week 9 (1 week after last treatment)
Primary outcome: GRA
Secondary outcomes: change in pelvic floor examination findings and symptoms as measured by
questionnaires
Starting date 21 April 2017
Contact information KM Peters, William Beaumont Hospitals. Baylor College of Medicine
Email: kmpeters@beaumont.edu
End date August 2020
Notes Funding: unclear
ClinicalTrials.gov registration number: NCT02870738




Study name A pilot study of the effects of mirabegron on symptoms in patients with interstitial cystitis
Methods Study design: parallel-group RCT
Blinding: single (participant)
Participants Target sample size: 60
Country: USA
Sex: female
Age: 18 to 95 years of age
Condition: "participants must be diagnosed with BPS/IC with a minimum O'Leary-Sant score of
8 on the ICSI, as well as 8 on the ICPI. Participants should be stable on their regimen (no increase
or change in medications, behavioral treatments or physical therapy in previous 4 weeks prior to
Shah 2016 
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starting the study) and be willing to remain on this regimen during the duration of the study. Par-
ticipant must be stable on current IC/BPS regimen. Participant must have subjective complaints of
i. urinary urgency, relieved with voiding; ii. urinary frequency, ≥ 8 voids per day; or iii. pelvic pain,
pressure, hypersensitivity or discomfort"
Interventions Group A: mirabegron (beta-3-adrenergic agonist; tablets; presumably oral administration)
Group B: placebo
Outcomes At 12 weeks
Primary outcome: IC symptom improvement on O'Leary Sant Questionnaire
Secondary outcomes: incontinence episodes via bladder diary and UDI-6 Questionnaire; QoL via
PFIQ-7 Questionnaire; participant satisfaction via GRA; sexual function via FSFI Questionnaire; ad-
verse effects
Starting date August 2016
Contact information Philadelphia Urosurgical Associates
Email: drexelurogyn@gmail.com
End date December 2018
Notes Funding: unclear. Sponsors and collaborators: Philadelphia Urosurgical Associates; Astellas Phar-
ma Global Development, Inc.
ClinicalTrials.gov registration number: NCT02787083
Other study ID numbers: MYRB-15G02
Shah 2016  (Continued)
BPS: bladder pain syndrome.
BPIC-SS: Bladder Pain/Interstitial Cystitis Symptom Score.
ESSIC: International Society for the Study of Bladder Pain Syndrome (BPS).
FSFI: Female Sexual Function Index.
GRA: Global Response Assessment.
IC: interstitial cystitis.
ICPI: Interstitial Cystitis Problem Index.
ICSI: Interstitial Cystitis Symptom Index.
IHD: ischaemic heart disease.
MDP: mean daily pain.
NRS: numerical rating scale.
PBS: painful bladder syndrome.
PFIQ-7: Pelvic Floor Impact Questionnaire-7.
PFMT: pelvic floor muscle training.
PGI-I: Patient Global Impression of Improvement.
PTNS: percutaneous tibial nerve stimulation.
PUF: Pelvic Pain and Urgency/Frequency Patient Symptom Scale.
QoL: quality of life.
RCT: randomised controlled trial.
UDI-6: Urinary Distress Inventory-6.
USG: ultrasonography.
VAS: visual analogue scale.
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Treatment category Example of intervention
Conservative therapies
Behavioural, psychological and complemen-
tary therapies
· Bladder training
· Stress management techniques
· Complementary therapy (e.g. acupuncture)
Physical therapy · Pelvic floor muscle training (PFMT)
· Non-invasive electrical stimulation (e.g. transcutaneous electrical nerve stimula-
tion (TENS))
Pharmacological treatments (by mode of action, irrespective of route of administration)
Amino acid · L-Arginine
Analgesics  
Analgesics, local (local anaesthetics) · Lidocaine













Calcium channel agonists · Capsaicin
· PD-0299685
· Resiniferatoxin (RTX)
(Sodium) chondroitin sulfate  
Dimethyl sulfoxide (DMSO)  
Table 1.   Interventions for the treatment of BPS 
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· Bacillus Calmette-Guerin (BCG)
· Curcumin
· Fulranumab
· Mycophenolate mofetil (MMF)
· Tanezumab
· Nerve growth factors (NGFs)




P2X3 antagonist · AF-219
Parasympathomimetic (+ urinary antiseptics) · Cystex
Phosphodiesterase-5 (PDE5) inhibitor · Sildenafil




Neuromuscular blockade · Botulinum toxin
· Lipotoxin (liposomal formulated onabotulinumtoxinA (onaBoNTA))
Fulguration  
Transurethral resection  
Table 1.   Interventions for the treatment of BPS  (Continued)
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Neuromodulation (implanted)  
Denervation · Neurolysis
· Superior hypogastric plexus neurolysis
· Surgical denervation
· Cystolysis – peripheral denervation
· Sympathetic denervation
· Parasympathetic denervation
Bowel surgery · Bladder augmentation - cystoplasty
· Cystoplasty with supratrigonal resection
· Cystoplasty with subtrigonal cystectomy - orthotopic continent bladder augmen-
tation
· Urinary diversion with or without total cystectomy and urethrectomy
Table 1.   Interventions for the treatment of BPS  (Continued)










Study name Intervention A Intervention B
Conservative vs control
Carrico 2008 Guided imagery Control (rest)
Carty 2017 Life-stress interview Usual care
Hsieh 2012 Hydrodistension + bladder training Hydrodistension
Kanter 2016 Mindfulness-based stress reduction + usual
care
Usual care
Lee 2014 E-health system Control (include treat-
ment)
Lee 2016 Self-management telecare system (patient





O'Reilly 2004 Transdermal laser stimulation of the posteri-
or tibial nerve
Sham
FitzGerald 2009 Myofascial physical therapy Global therapeutic mas-
sage
Physical therapy Control
FitzGerald 2012 Pelvic floor myofascial physical therapy Global therapeutic mas-
sage
Table 2.   Treatment category (by mode of action) for active interventions in the included studies 
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Zakaria 2016 TENS +
physical therapy + medical care
Sham TENS + physical
therapy + medical care
Pharmacological vs control
Cartledge 2000 L-Arginine PlaceboAmino acid Control
Korting 1999 L-Arginine Placebo
Antibiotics Control Warren 2000 Antibiotic regimen Placebo








Anticytokines Control Mirkin 2015 Hyaluronic acid + anticytokine substance Hyaluronic acid
Foster 2010 Amitriptyline + EBMP Placebo + EBMPAntidepressants Control
van Ophoven 2004 Amitriptyline Placebo
Antihistamines Control Thilagarajah 2001 Cimetidine Placebo
AQX-1125 Control Leadership 201 Trial
2016
AQX-1125 Placebo
BuFer solutions Control Nguan 2005 Acidic buFered solution Neutral buFered solu-
tion
Caffeine Control Herati 2011 Caffeine Placebo
Chen 2005 RTX, 2 arms with varying dose Placebo
Ham 2012 RTX + hydrodistension Hydrodistension
Kim 2012 RTX + hydrodistension Hydrodistension
Lazzeri 1996 Capsaicin NaCl
Lazzeri 2000 RTX NaCl




Payne 2005 RTX, 3 arms with varying dose Placebo
Gulpinar 2013 Sodium chondroitin sulfate + hyaluronic acid Hyaluronic acid




Nickel 2012a Sodium chondroitin sulfate NaCl
DMSO Control Perez-Marrero 1988 DMSO Saline
Table 2.   Treatment category (by mode of action) for active interventions in the included studies  (Continued)
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Hyperbaric oxy-
gen
Control van Ophoven 2006 Hyperbaric oxygen Placebo
Hydrogen-rich wa-
ter
Control Matsumoto 2013 Hydrogen-rich water Placebo
Bosch 2014 Adalimumab Placebo
Dimitrakov 2001 Recombinant human nerve growth factor Placebo
Evans 2011 Tanezumab Placebo
Irani 2004 BCG NaCl
Mayer 2005 Live Tice BCG Saline
Nickel 2016 Tanezumab Placebo
Peters 1997 Tice strain BCG Saline
Shirvan 2015 Hydrodistension + curcumin Hydrodistension in nor-
mal saline




Yang 2011 Mycophenolate mofetil Placebo
Nickel 2009 PSD597 SalineLocal anaesthetic Control
Nomiya 2017 Heparin + lidocaine Heparin
Hanno 2015 AF-219 PlaceboP2X3 antagonist Control





Control Souza 2012 Cystex Placebo
PDE5 inhibitor Control Chen 2014 Sildenafil Placebo
Bade 1997 PPS Placebo
Davis 2008 Intravesical PPS + oral PPS Intravesical placebo +
oral PPS
Mulholland 1990 PPS Placebo
PPS Control




Control Ahmadnia 2011 Botulinum toxin A NaCl
Table 2.   Treatment category (by mode of action) for active interventions in the included studies  (Continued)
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Chuang 2017 2 arms: onabotulinumtoxinA (i) with lipo-
somes (lipotoxin) and (ii) in normal saline
Saline
Gottsch 2011 Botulinum toxin A Saline
Ismail 2016 Botulinum toxin A Saline
Kuo 2009 Botulinum toxin A + hydrodistension Hydrodistension
Kuo 2016 Botulinum toxin A + hydrodistension NaCl + Hydrodistension
Manning 2014 Botulinum toxin A + hydrodistension Saline + hydrodisten-
sion
Payne 2014 Botulinum toxin A Saline
Pinto 2016 Botulinum toxin A Saline




Control Mirkin 2012 Incobotulinumtoxin A + DMSO NaCl






Geirsson 1993 Acupuncture TENS
(Sodium) chon-
droitin sulfate
DMSO De Ridder 2013 Sodium chondroitin sulfate DMSO
Hyaluronic acid DMSO Singh 2003 Hyaluronic acid DMSO
Peeker 2000 BCG DMSOImmune modula-
tors
DMSO















Gulpinar 2015 Sodium chondroitin sulfate Hyaluronic acid
Immune modula-
tors





Taha 2007 BCG Botulinum toxin A
Table 2.   Treatment category (by mode of action) for active interventions in the included studies  (Continued)
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vs PPS + antihistamines
vs control
Sant 2003 Hydroxyzine PPS PPS + hy-
droxyzine
Placebo
Table 2.   Treatment category (by mode of action) for active interventions in the included studies  (Continued)
BCG: bacillus Calmette-Guérin.
DMSO: dimethyl sulfoxide.





TENS: transcutaneous electrical nerve stimulation.
 
 
Treatment category Example of intervention









Table 3.   List of interventions for which no studies were identified in the review 
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Denervation · Surgical denervation
· Cystolysis – peripheral denervation
· Sympathetic denervation
· Parasympathetic denervation
Bowel surgery · Bladder augmentation - cystoplasty
· Cystoplasty with supratrigonal resection
· Cystoplasty with subtrigonal cystectomy - orthotopic continent bladder augmentation
· Urinary diversion with or without total cystectomy and urethrectomy
Table 3.   List of interventions for which no studies were identified in the review  (Continued)
 
 






















Behavioural therapy Con 2 9.64 (1.13 to 99.38) 2 7.04 (1.57 to 31.61) Very low
Physical therapy Con 2 6.78 (1.08 to 46.85) 2 4.77 (2.00 to 11.38) Very low
Amino acid Pharm 1 3.36 (0.24 to 53.09) 1 3.07 (0.66 to 14.18) Low
Local anaesthetics Pharm 2 1.94 (0.28 to 13.78) 2 2.20 (0.84 to 5.80) Very low
Antibiotics Pharm 1 4.71 (0.36 to 63.5) 1 4.33 (1.09 to 17.17) Very low
Antidepressants Pharm 2 5.91 (1.12 to 37.56) 2 7.02 (0.35 to 141.48) Very low
Antihistamines Pharm 1 1.43 (0.15 to 14.01) 1 1.96 (0.49 to 7.87) Very low
Calcium channel agonists Pharm 3 1.51 (0.38 to 6.22) 3 1.40 (0.57 to 3.43) Very low
Chondroitin sulfate Pharm 3 3.82 (0.86 to 19.18) 2 1.70 (0.85 to 3.41) Very low
DMSO Pharm 4 3.05 (0.55 to 16.58) 1 4.55 (0.77 to 26.84) Very low
Table 4.   Results of the meta-analyses for proportion cured or improved 
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Hyaluronic acid Pharm 2 2.10 (0.12 to 44.26) 0 N/A Very low
Hyperbaric oxygen Pharm 1 11.73 (0.27 to 8324.85) 1 5.53 (0.25 to 124.4) Very low
Immune modulators Pharm 10 2.74 (1.16 to 6.57) 7 2.19 (1.24 to 3.89) Very low
PDE5 inhibitor Pharm 1 24.53 (1.21 to 1255.14) 1 16.43 (1.89, 142.50) Very low
PPS Pharm 6 1.14 (0.40 to 3.35) 5 1.41 (0.95 to 2.08) Very low
Neuromuscular blockade Surg 6 5.80 (2.08 to 18.30) 6 4.19 (1.44 to 12.25) Very low
Anticoagulants + local
anaesthetics
Comb 1 0.93 (0.01 to 65.89) 0 N/A Very low
PPS + antihistamines Comb 1 3.94 (0.42 to 37.37) 1 5.18 (1.34 to 20.06) Very low
Chondroitin sulfate +
hyaluronic acid
Comb 1 7.04 (0.37 to 128.77) 0 N/A Very low
Table 4.   Results of the meta-analyses for proportion cured or improved  (Continued)























Mean difference vs control
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Behavioural therapy Con 6 -0.60 (-1.79 to 0.62) 6 -1.50 (-2.93 to -0.06) Very low
Physical therapy Con 2 -3.92 (-5.80 to -1.94) 2 -3.69 (-9.90 to 2.52) Moder-
ate
Local anaesthetics Pharm 2 -0.31 (-2.58 to 2.00) 2 -0.51 (-1.93 to 0.91) Very low
Calcium channel agonists Pharm 6 -0.53 (-1.72 to 0.68) 6 -0.68 (-0.94 to -0.42) Very low
Chondroitin sulfate Pharm 4 0.36 (-1.31 to 2.05) 3 0.30 (-0.40 to 1.00) Very low
Hyperbaric oxygen Pharm 1 -2.45 (-5.95 to 1.04) 1 -2.45 (-4.76 to -0.15) Low
Table 5.   Results of the meta-analyses for pain 
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Hydrogen-rich water Pharm 1 -0.20 (-3.50 to 3.12) 1 -0.20 (-2.17 to 1.77) Very low
Immune modulators Pharm 8 -0.77 (-1.81 to 0.24) 7 -0.54 (-1.27 to 0.20) Low
PDE5 inhibitor Pharm 1 -0.60 (-3.77 to 2.56) 1 -0.60 (-2.30 to 1.10) Very low
Neuromuscular blockade Surg 6 -0.33 (-1.71 to 1.03) 5 -0.21 (-1.01 to 0.60) Very low
Hydrodistension Surg 3 -0.01 (-3.48 to 3.44) 0 N/A Very low
Fulguration Surg 1 -1.93 (-6.53 to 2.70) 0 N/A Very low
Anticytokines Pharm 1 -1.20 (-3.92 to 1.51) 1 -1.20 (-1.85 to -0.55) Very low
Denervation Surg 1 1.97 (-2.44 to 6.44) 0 N/A Very low
AQX-1125 Pharm 1 -1.01 (-3.83 to 1.82) 1 -1.00 (-2.03 to 0.03) Very low
Neuromuscular blockade +
DMSO
Comb 1 -2.81 (-5.87 to 0.24) 1 -2.80 (-4.36 to -1.24) Low
Antidepressants Pharm 2 -1.27 (-3.25 to 0.71) 2 -1.28 (-3.31 to 0.76) Low
Antihistamines Pharm 1 0.65 (-1.96 to 3.27) 1 0.56 (-0.44 to 1.55) Very low
BuFer solutions Pharm 1 0.23 (-3.89 to 4.33) 1 0.21 (-2.94 to 3.36) Very low
DMSO Pharm 2 1.46 (-1.22 to 4.13) 0 N/A Very low
P2X3 antagonist Pharm 1 -1.20 (-4.13 to 1.73) 1 -1.20 (-2.54 to 0.14) Very low
Parasympathomimetic (+
urinary antiseptics)
Pharm 1 -2.75 (-5.83 to 0.34) 1 -2.76 (-4.36 to -1.16) Low
PPS Pharm 4 0.42 (-1.04 to 1.91) 3 -0.03 (-0.65 to 0.60) Very low
PPS + antihistamines Comb 1 -0.58 (-3.20 to 2.04) 1 -0.67 (-1.70 to 0.37) Very low
Chondroitin sulfate +
hyaluronic acid
Comb 1 -0.05 (-197.8 to 195.2) 0 N/A Very low
Treatments not part of the connected network
Hyaluronic acid Pharm 1 N/A 0 N/A N/A
Anticoagulants + local
anaesthetics
Comb 1 N/A 0 N/A N/A
Table 5.   Results of the meta-analyses for pain  (Continued)
Pain is measured on a 0 to 10 scale where 0 is no pain and 10 is maximum pain.
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Behavioural therapy Con 1 -2.01 (-6.44 to 2.47) 1 -2.00 (-3.41 to -0.59) Very low
Amino acid Pharm 1 4.14 (-2.47 to 10.80) 1 4.10 (-1.18 to 9.38) Low
Local anaesthetics Pharm 1 0.35 (-6.12 to 6.69) 1 0.30 (-4.67 to 5.27) Very low
Anticholinergics Pharm 1 -0.73 (-6.34 to 4.95) 1 -0.75 (-4.62 to 3.13) Very low
Anticytokines Pharm 1 -4.69 (-9.70 to 0.29) 1 -4.70 (-7.38 to -2.02) Very low
Calcium channel agonists Pharm 4 -0.79 (-3.61 to 2.23) 4 -1.09 (-2.72 to 0.55) Very low
Chondroitin sulfate Pharm 2 0.05 (-3.35 to 3.46) 2 0.03 (-1.44 to 1.49) Very low
Immune modulators Pharm 4 -1.95 (-4.78 to 0.73) 3 -0.82 (-2.51 to 0.88) Very low
PDE5 inhibitor Pharm 1 -2.46 (-7.54 to 2.53) 1 -2.50 (-5.32 to 0.33) Very low
PPS Pharm 2 -0.37 (-5.00 to 3.44) 1 -6.00 (-10.34 to -1.66) Very low
Neuromuscular blockade Surg 5 -0.91 (-3.24 to 1.29) 5 -0.84 (-2.28 to 0.56) Very low
Neuromuscular blockade +
DMSO
Comb 1 -8.97 (-15.23 to -2.81) 1 -9.00 (-13.62 to -4.38) Moder-
ate
Antidepressants Pharm 1 -2.41 (-6.85 to 2.05) 1 -2.40 (-3.75 to -1.05) Very low
Treatments not part of the connected network
Anticoagulants + local anaes-
thetics
Comb 1 N/A 0 N/A N/A
Hydrodistension Surg 1 N/A 0 N/A N/A
Hyaluronic acid Pharm 1 N/A 0 N/A N/A
Denervation Surg 1 N/A 0 N/A N/A
DMSO Pharm 1 N/A 0 N/A N/A
Chondroitin sulfate +
hyaluronic acid
Comb 1 N/A 0 N/A N/A
Table 6.   Results of the meta-analyses for daytime frequency (number of daytime voids) 
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Behavioural therapy Con 1 -0.71 (-3.21 to 1.82) 1 -0.70 (-1.26 to -0.14) Very low
Amino acid Pharm 1 0.12 (-2.65 to 2.87) 1 0.10 (-1.29 to 1.49) Low
Local anaesthetics Pharm 1 0.29 (-3.05 to 3.67) 1 0.30 (-2.14 to 2.74) Very low
Calcium channel ago-
nists
Pharm 3 -0.24 (-2.04 to 1.52) 3 -0.30 (-0.99 to 0.38) Very low
Chondroitin sulfate Pharm 1 -0.01 (-2.63 to 2.65) 1 0.00 (-1.10 to 1.10) Very low
PDE5 inhibitor Pharm 1 -1.40 (-4.07 to 1.22) 1 -1.40 (-2.47 to -0.33) Very low
PPS Pharm 2 -1.20 (-3.62 to 1.28) 1 -2.20 (-4.03 to -0.37) Very low
Neuromuscular block-
ade
Surg 4 -0.04 (-1.35 to 1.27) 4 -0.04 (-0.84 to 0.76) Very low
Antidepressants Pharm 1 0.01 (-2.53 to 2.50) 1 0.00 (-0.69 to 0.69) Very low
Immune modulators Pharm 2 -2.65 (-5.04 to 0.20) 1 -1.00 (-3.63 to 1.63) Low
Treatments not part of the connected network
Denervation Surg 1 N/A 0 N/A N/A
Hydrodistension Surg 1 N/A 0 N/A N/A
Table 7.   Results of the meta-analyses for nocturia (number of nighttime voids) 
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Mean difference vs control
(95% CI) (random effects)
Behavioural therapy Con 5 -0.89 (-2.57 to 0.81) 5 -0.94 (-2.05 to 0.18)
Physical therapy Con 1 -0.70 (-4.07 to 2.68) 1 -0.70 (-2.61 to 1.21)
Local anaesthetics Pharm 2 -1.25 (-3.95 to 1.44) 2 -1.30 (-2.73 to 0.13)
Calcium channel ago-
nists
Pharm 2 -1.25 (-4.01 to 1.49) 2 -1.22 (-3.14 to 0.70)
Chondroitin sulfate Pharm 4 0.34 (-1.63 to 2.32) 3 0.32 (-0.84 to 1.49)
Hydrogen-rich water Pharm 1 0.16 (-4.1 to 4.45) 1 0.20 (-3.10 to 3.50)
Immune modulators Pharm 5 -1.06 (-2.87 to 0.77) 3 -0.76 (-1.65 to 0.15)
PDE5 inhibitor Pharm 1 -6.02 (-9.05 to -2.93) 1 -6.00 (-7.28 to -4.72)
Neuromuscular blockade Pharm 5 -0.65 (-2.49 to 1.10) 4 -0.58 (-1.96 to 0.80)
Hydrodistension Surg 2 -1.26 (-5.22 to 2.62) 0 N/A
Denervation Surg 1 1.64 (-3.41 to 6.56) 0 N/A
Antidepressants Surg 1 -1.51 (-4.47 to 1.48) 1 -1.50 (-2.48 to -0.52)
Antihistamines Pharm 3 1.16 (-1.95 to 4.36) 1 1.00 (-0.77 to 2.77)
AQX-1125 Pharm 1 -2.39 (-5.62 to 0.80) 1 -2.40 (-4.02 to -0.78)
DMSO Pharm 1 1.02 (-3.08 to 5.20) 0 N/A
PPS Pharm 5 1.18 (-1.10 to 3.45) 1 0.60 (-1.15 to 2.35)
PPS + antihistamines Comb 3 -1.14 (-4.31 to 2.06) 1 -1.30 (-3.09 to 0.49)
Table 8.   Results of the meta-analyses for ICSI (Interstitial Cystitis Symptom Index) score 
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Mean difference vs control
(95% CI) (random effects)
Behavioural therapy Con 4 0.31 (-1.80 to 2.38) 4 0.27 (-2.08 to 2.62)
Physical therapy Con 1 -1.40 (-5.09 to 2.33) 1 -1.40 (-2.98 to 0.18)
Local anaesthetics Pharm 2 -1.15 (-4.09 to 1.97) 2 -1.45 (-2.84 to -0.06)
Calcium channel ago-
nists
Pharm 1 -2.94 (-7.41 to 1.55) 1 -2.92 (-5.93 to 0.09)
Chondroitin sulfate Pharm 4 -0.18 (-2.41 to 2.09) 3 -0.19 (-1.30 to 0.92)
Hydrogen-rich water Pharm 1 -0.20 (-4.36 to 4.00) 1 -0.20 (-2.73 to 2.33)
Immune modulators Pharm 4 -0.59 (-2.61 to 1.54) 3 -0.07 (-1.12 to 0.98)
PDE5 inhibitor Pharm 1 -3.50 (-7.71 to 0.69) 1 -3.50 (-6.05 to -0.95)
Neuromuscular blockade Surg 6 -1.37 (-3.28 to 0.48) 5 -1.28 (-2.61 to 0.05)
Hydrodistension Surg 2 -1.87 (-6.02 to 2.25) 0 N/A
Denervation Surg 1 1.04 (-4.39 to 6.40) 0 N/A
Antidepressants Pharm 1 -1.28 (-4.83 to 2.25) 1 -1.30 (-2.32 to -0.28)
Antihistamines Pharm 1 1.63 (-1.78 to 5.31) 1 0.80 (-0.63 to 2.23)
AQX-1125 Pharm 1 -1.99 (-5.72 to 1.72) 1 -2.00 (-3.55 to -0.45)
DMSO Pharm 1 0.43 (-4.22 to 5.15) 0 N/A
PPS Pharm 2 2.66 (-0.16 to 5.59) 1 0.40 (-1.22 to 2.02)
PPS + antihistamines Comb 1 -0.27 (-3.82 to 3.50) 1 -1.10 (-2.79 to 0.59)
Table 9.   Results of the meta-analyses for ICPI (Interstitial Cystitis Problem Index) score 
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Kuo 2016 Functional bladder
capacity (mL), final value
2 219.6
(103.6)
40 189 (99.4) 20































































































































































Kuo 2009 Functional bladder
capacity (mL),
final value:
a. Botulinum toxin A
100 units;






























11 17.8 (47.6) 11

























0 (unclear) 0 9 (unclear) 0 0 8 (unclear) 0 Geirsson 1993
Pharmacological

































































































































































Control 3 12 21 57 12 25 48 Korting 1999
Antibiotics Control 4.5 20 25 80 10 25 40 AEs included nausea and/or vomiting 23 vs 6;
diarrhoea 12 vs 2; headache 5 vs 2; dizziness 2
vs 0; rash 1 vs 3; vaginal symptoms 3 vs 2; oth-










0 13 0 0 11 0 Lu 2015
3 119 135 88 98 136 72 AEs included constitutional symptoms (pri-
marily fatigue, malaise) 61 vs 42; dermatolog-
ical/skin 9 vs 10; gastrointestinal (primarily
dry mouth, constipation) 57 vs 32; infection,
fever 9 vs 14; musculoskeletal 7 vs 3; neuro-
logical (primarily dizziness, somnolence) 45
vs 29; ocular, visual 3 vs 7; pain (primarily
headache) 43 vs 48; pulmonary 15 vs 13; re-




4 22 24 92 5 24 21 AEs included mouth dryness 19 vs 2; weight
gain 15 vs 2; sedation 9 vs 3; constipation
11 vs 2; nausea/vertigo 3 vs 3; blurred vi-
sion/diplopia 4 vs 0; erectile dysfunction 1
vs 0. "A dry mouth was the most frequent
side effect in the amitriptyline group. No ad-
verse effects of grade 3 or higher were report-
ed" (van Ophoven 2004)
AQX-1125 Control 1 19 37 51 25 32 78 Any treatment-emergent adverse events.
"The most frequently reported TEAEs (greater
than 5%) and those that developed at a high-
er frequency in the AQX-1125 group were dys-
pepsia, gastroesophageal reflux disease and




Control 3 16 18 89 3 4 75 AEs included pain during instillation, abdomi-
nal pain, cystitis, dizziness, pallor and urinary
tract disorders (number per event not report-
ed) (Chen 2005)































































































































































3 N/R 8 N/A N/R 10 N/A AEs included haematuria 2 vs 0; bladder pain
0 vs 1. "These side effects disappeared within
2 days" (Ham 2012)
6 N/R 17 N/A N/R 18 N/A AEs included pain during instillation: 17 vs 15
(Lazzeri 1996)
3 N/R 9 N/A N/R 9 N/A AEs included pain during instillation: 4 vs 0
(Lazzeri 2000)
1 N/R 119 N/A N/R 44 N/A AEs included pain during instillation: 90 vs 23
(Payne 2005)
3 22 33 67 28 32 88 AEs included gastrointestinal disorders 0 vs 1;
nausea 0 vs 1; infections and infestations 0 vs
1; urethritis 0 vs 1; renal and urinary disorders
0 vs 1; urethral pain 0 vs 1; reproductive sys-
tem and breast disorders 1 vs 0; pelvic pain 1
vs 0; skin and subcutaneous tissue disorders
0 vs 1; rash macular 0 vs 1; urinary tract signs
and symptoms 1 vs 1; dysuria 1 vs 1. Most AEs












DMSO 6 11 74 15 11 36 31 Treatment-related AEs were seen in 1 partic-
ipant in the ‘chondroitin sulfate + hyaluron-
ic acid’ group and 8 participants in the DMSO
group. The most common treatment-related
AEs were related to renal and urinary disor-
ders (1 vs 8), in particular, bladder irritation (0
vs 1) or bladder pain (1 vs 1), cystitis (0 vs 2),









Control 4 23 29 79 18 20 90 AEs included UTI 1 vs 2; voiding dysfunction
(retention) 0 vs 0. "Headache was the most
frequently reported AE in the tanezumab
group (20.6% vs placebo 16.7%). Paresthe-































































































































































sia (tanezumab 17.6%, placebo 3.3%) and hy-
peresthesia (tanezumab 8.8%, placebo 0.0%)
were the most common AEs of abnormal pe-
ripheral sensation reported for tanezum-
ab. All of the abnormal peripheral sensation
AEs were mild to moderate in severity, and
most had resolved by the end of the study.
There were 3 patients on tanezumab and 2 on
placebo who had a clinically significant wors-
ening from baseline in the neurological exam-
ination" (Evans 2011)
8.5 123 129 95 126 132 95 AEs included allergy/immunology 21 vs 19;
cardiovascular, general 7 vs 15; constitution-
al symptoms 75 vs 67; fever 5 vs 13; gastroin-
testinal 70 vs 72; bladder symptoms 101 vs
101; haematuria 27 vs 45; infection, catheter
related 1 vs 1; other infection 16 vs 11; mus-
culoskeletal 29 vs 23; neurological 31 vs 25;
pain (pelvic) 18 vs 26; pain (headache) 17 vs
10; pain (arthralgias, myalgias 31 vs 16); pain
(other) 39 vs 39; pulmonary 35 vs 34; sexu-
al, reproductive 15 vs 9; skin 42 vs 38 (Mayer
2005)
2 23 40 58 24 42 57 AEs occurring in ≥ 3 patients in any treatment
included headache 4 vs 4; arthralgia 4 vs 4;
myalgia 3 vs 0; hyperaesthesia 3 vs 0; paraes-
thesia 2 vs 3; UTI 2 vs 1; pain in extremity 2 vs
2; peripheral oedema 2 vs 0; injection site re-
action 2 vs 4; back pain 1 vs 1; hypoaesthesia
1 vs 1; nausea 1 vs 0; fatigue 1 vs 1; abdomi-
nal pain 1 vs 0; bladder pain 0 vs 0; dizziness 0
vs 0; urinary retention 0 vs 0. AEs of abnormal
peripheral sensation included hyperaesthesia
3 vs 0; paraesthesia 2 vs 3; hypoaesthesia 1 vs
1; allodynia 1 vs 0; sensory disturbance 1 vs 0;
burning sensation 0 vs 0; decreased vibratory
sense 0 vs 2 (Nickel 2016)
6 N/R 17 N/A N/R 15 N/A AEs included arthralgia 3 vs 1; fatigue 2 vs
0; low back pain 3 vs 4; burning 3 vs 5; nau-
sea 1 vs 2; bronchitis 1 vs 0; diarrhoea 1 vs 2;
fever less than 38.5°C 0 vs 1; incontinence 1
vs 1; urinary tract infection 2 vs 1; rash 0 vs 1;































































































































































shoulder/neck pain 1 vs 1; abdominal disten-
sion 1 vs 0 (Peters 1997)
6.5 8 14 57 11 17 65 AEs included diarrhoea 3 vs 2; carpal tunnel
syndrome 2 vs 0; UTI 2 vs 2; pain 0 vs 2; pain in
extremity 0 vs 2; paraesthesia 0 vs 2; sinusitis
0 vs 2 (Wang 2017a)
4 34 39 87 13 19 68 AEs included blood/bone marrow 2 vs 1;
constitutional symptoms (primarily fatigue,
malaise) 14 vs 6; dermatological/skin 7 vs 3;
gastrointestinal (primarily nausea, constipa-
tion, diarrhoea) 27 vs 8; haemorrhage 2 vs
0; infectious/febrile 7 vs 2; lymphatic 0 vs 1;
metabolic/laboratory 4 vs 0; musculoskeletal
1 vs 2; neurological (primarily dizziness, anx-
iety) 8 vs 4; ocular, visual 2 vs 1; pain, primar-
ily headache 21 vs 11; pulmonary 2 vs 2; re-
nal/genitourinary 9 vs 2; sexual/reproductive
function 1 vs 1; benign viral syndromes 2 vs 1;




PPS 6 30 32 94 18 32 56 "In the immune modulator group, increased
blood pressure and serum creatinine were
considered significant AE as was gross hema-
turia in the PPS arm" (Sairanen 2005)
0.5 N/R 50 N/A N/R 52 N/A AEs included general disorders and adminis-
tration site conditions: any 8 vs 5; fatigue 4 vs
3. Infections and infestations: any 3 vs 6; UTI
1 vs 4. Musculoskeletal and connective tissue
disorders: any 2 vs 4; back pain 1 vs 3. Ner-
vous system disorders: any 6 vs 8; dizziness 4
vs 3; headache 2 vs 4. Renal and urinary disor-
ders: any 13 vs 10; bladder pain 7 vs 3; dysuria





1 0 10 0 0 10 0 Nomiya 2017
P2X3 an-
tagonist
Control 1 N/R 36 N/A N/R 38 N/A "AEs were generally mild. The P2X3 antago-
nist group reported significantly more dys-
geusia/hyoogeusia than the placebo group".
Number per event not reported (Hanno 2015)































































































































































1 N/R 36 N/A N/R 38 N/A "AEs were generally mild. The most frequent-
ly reported AE in AF-219 treated patients








Control 0.7 10 11 91 9 11 82 "Dry mouth was the most frequent side effect
in the Cystex group" (Souza 2012)
PDE5 in-
hibitor
Control 6 N/R 24 N/A N/R 24 N/A AEs included mild headache in 1 and flushing
in 4 in the sildenafil group. "The symptoms
remitted after 2-4 days" (Chen 2014)
4.5 N/R 21 N/A N/R 20 N/A AEs included UTI 2 vs 0; headache 14 vs 12;
bruise in arms due to blood draw 11 vs 11;
mild hair loss 3 vs 1 (Davis 2008)
3 3 54 6% 7 56 13 AEs included headache 1 vs 2; nausea 1 vs
0; indigestion 1 vs 0; increased perspiration
1 vs 0; severe mood swings 1 vs 0; suicidal
ideation 1 vs 0; diarrhoea 0 vs 2; explosive di-
arrhoea 0 vs 1; severe joint pain 0 vs 1; skin
rash on arms 0 vs 1; itching 0 vs 1 (Mulholland
1990)
PPS Control
6 205 251 82 96 118 81 AEs include bladder pain 82 vs 38, nausea 31
vs 9, headache 30 vs 16, nasopharyngitis 21
vs 2, diarrhoea 19 vs 7, UTI 18 vs 4, back pain
12 vs 2, sinusitis 12 vs 7, dizziness 10 vs 3, in-
fluenza 7 vs 6 (Nickel 2015)
Surgical
1 N/R 59 N/A N/R 31 N/A AEs included dysuria after treatment 3 vs 1;





3 0 9 0 0 11 0 Gottsch 2011































































































































































> 6 N/R 44 N/A N/R 23 N/A AEs included UTI 3 vs 0; voiding dysfunction
12 vs 0; haematuria 2 vs 0; dysuria 10 vs 1
(Kuo 2009)
2 20 40 50 1 20 5 AEs included UTI 2 vs 0; voiding dysfunction
(retention) 1 vs 0; dysuria 16 vs 1; haematuria
1 vs 0 (Kuo 2016)
3 N/R 26 0 N/R 27 % AEs included UTI 7 vs 5 (Manning 2014)
6 (unclear) N/R 14 0 N/R 2 % AEs included voiding dysfunction (retention)
5 vs 0 (Payne 2014)
3 N/R 10 0 N/R 9 % AEs included UTI 3 vs 2 (Pinto 2016)











3 N/R 15 N/A N/R 17 N/A AEs included upper urinary tract retention 0





1 N/R 12 N/A N/R 12 N/A AEs included self-limited transient haema-
turia 0 vs 1; leL lower limb numbness 1 vs 0;




Control 3 4 12 33 1 7 14 "Four patients in the treatment arm reported
transient problems with accommodation dur-
ing treatment that were not further report-
ed at 3-month follow-up. One woman report-
ed mild eustachian tube dysfunction during
treatment sessions, resulting in a transient
hearing impairment within the chamber. The
events were solved by intense chewing of
some candy or gum, resulting in the open-
ing of the tube with subsequent pressure bal-
ance between the middle ear and the envi-
ronment. A decongestant nasal spray was oc-
casionally administered some minutes before
start of and/or during treatment. Oral med-































































































































































ication was given to control temporary claus-
trophobia in another patient at the start of























6 51 60 85 50 61 82 4-Arm trial using factorial design (Sant 2003)







TEAE: treatment-emergent adverse event.












n1 N1 % n2 N2 % Outcome definition/Notes
Pharmacological




3 0 8 0 0 10 0 SAE (bladder puncture and sepsis; Ham 2012)































































































































































6 0 17 0 0 18 0 Significant AE (details not reported; Lazzeri
1996)
3 0 9 0 0 9 0 Important AE (details not reported; Lazzeri
2000)
3 2 108 2 0 52 0 SAE, including 1 event each of deep vein
thrombosis and a suicide attempt. Both cas-
es were deemed treatment-related SAEs and
were resolved. The patients were discontin-
ued from the study (Nickel 2012b)
1 0 119 0 1 44 2 SAEs included abdominal pain requiring hos-


















6 0 21 0 0 21 0 Severe AE (details not reported; Gulpinar
2015)
3 (unclear) 0 21 (un-
clear)
0 0 22 (un-
clear)
0 Significant AE (details not reported; Bosch
2014)
4 2 29 7 4 20 20 SAEs, including "vertigo" and "drug expo-
sure during pregnancy" for tanezumab;
"cholelithiasis", "ovarian mass", "urosep-
sis and urinary tract infection", "transient is-





8.5 64 129 50 63 132 48 Severe AE, defined as Grade 3 AE on the Com-
mon Toxicity Criteria
A total of 32 serious (rather than severe) AEs
were reported among 21 participants (num-































































































































































ber in each group unclear), with 2 ascribed
to treatment (BCG hypersensitivity reaction
in 1 patient in the BCG group; prostatitis and
UTI in 1 patient in the placebo group) (Mayer
2005)




Control 0.5 4 50 8 5 52 10 Severe AE. The most common event was
bladder pain, which usually resolved within a
day of instillation (Nickel 2009)
1 0 36 0 0 38 0 SAE (details not reported; Hanno 2015)P2X3 an-
tagonist
Control
1 0 36 0 0 38 0 SAE (details not reported; Moldwin 2015)
PDE5 in-
hibitor
Control 6 0 24 0 0 24 0 SAE (details not reported; Chen 2014)
PPS Control 6 4 251 2 4 118 3 SAEs, including 1 event each of abdominal
pain, anxiety, chest pain, gastroesophageal
reflux disease, pyrexia, renal mass and uri-
nary tract infection in the PPS group; 1 event
each of cholelithiasis, cholesterolosis, homi-
cidal ideation and urinary retention in the
placebo group (Nickel 2015)
Surgical
1 0 61 0 0 31 0 Treatment-related SAE (Chuang 2017)










1 0 12 0 0 12 0 SAE (details not reported; El-Hefnawy 2015)






































































































































































SAE: serious adverse event.
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A P P E N D I C E S
Appendix 1. Cochrane Incontinence Specialised Register - search terms




All searches were of the 'Keyword' field in EndNote 2018.
Please note: the UK Clinical Research Network Portfolio was replaced by UK Clinical Trials Gateway, which in turn has been replaced by Be
Part of Research. At 11 July 2019, the site is still in development and is available at https://bepartofresearch.nihr.ac.uk/
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Protocol first published: Issue 5, 2019
Review first published: Issue 7, 2020
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